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NADPH oxidases are a family of reactive oxygen species generating 
enzymes which are implicated in cardiovascular pathophysiology. The Nox2-
based NADPH oxidase has been reported to be involved in the development of 
cardiac hypertrophy and fibrosis. However the relevant cellular source(s) 
involved in the above effects remains unclear.  The aim of this thesis was to 
investigate the critical cell source of the Nox2 in a model of angiotensin II 
(AngII) induced left ventricular hypertrophy (LVH) and fibrosis.   
ROS production in resident cardiac fibroblasts was stimulated by AngII, 
aldosterone and TGFβ to investigate cardiac fibroblasts as a crucial cell source 
for Nox2. Only TGFβ elicited a Nox2 dependent ROS response thus placing 
Nox2 downstream of TGFβ. As AngII stimulates cardiac fibrosis and 
hypertrophy via downstream TGFβ, resident cardiac fibroblasts could be 
another critical cell source for Nox2 in the development of cardiac fibrosis and 
hypertrophy.  
The importance of Nox2 in macrophages/monocytes (peripheral 
circulating cell) migration was investigated by way of Dunn Chambers. Nox2 
was shown to be crucial in the chemotaxis of these cells towards CSF-1 
stimulation. Also the speed and persistence of their migration was significantly 
reduced following the loss of Nox2.  
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Chimeric mice (WT mice with Nox2-/- marrow and Nox2-/- mice with WT 
marrow) were generated in-house by lethal radiation and marrow rescue with 
cells from mice of different genotype. Following AngII stimulation the chimeric 
mice demonstrated a hypertensive response. The loss of Nox2 in the circulating 
cells prevented the development of left ventricular hypertrophy suggesting that 
the peripheral circulating cells were a critical cell source for Nox2 in the 
development of cardiac hypertrophy. The loss of Nox2 in the resident cardiac 
cells prevented the development of cardiac fibrosis thus suggesting that the 
resident cardiac cells were the critical cell source for Nox2 in the development of 
cardiac fibrosis.  
These results indicate that Nox2 has a cell specific role in the 
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Hypertension is a common medical condition in which a person’s blood 
pressure is chronically elevated and can be classified as either essential 
(primary) or secondary. Essential hypertension accounts for 90-95% of the cases 
of hypertension and is defined as hypertension in which no cause underlies the 
raised blood pressure (Carretero and Oparil, 2000). It is estimated that nearly 
one billion people are affected by hypertension worldwide, and this figure is 
predicted to increase to 1.5 billion by 2025 (Kearney et al., 2005). Secondary 
hypertension indicates that the hypertension is a result of (ie secondary to) 
another condition such as kidney disease, tumors or adrenal disease.  
 The British Hypertension Society recommends that drug therapy be 
started in patients with a sustained systolic blood pressures of greater than or 
equal to 160 mmHg or sustained diastolic blood pressures of greater than or 
equal to 100 mmHg despite non-pharmacological measures (Williams et al., 
2004). Treatment is recommended as persistent hypertension is a well 
established risk factor for developing end organ damage typically in the kidneys 
(Wang et al., 2009a), eyes (Wong and Mitchell, 2007), arteries (Insull, Jr., 
2009), brain (Papadopoulos and Votteas, 2006) and the heart (Murphy et al., 
2009; Papadopoulos and Papademetriou, 2010).  
Even though no direct cause is known for essential hypertension there are 
many risk factors such as sedentary lifestyle (Kyrou et al., 2006), obesity 
(Segura and Ruilope, 2007; Wofford and Hall, 2004), alcohol (Djousse and 
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Mukamal, 2009), age (Kosugi et al., 2009) and genetic mutations (Dickson and 
Sigmund, 2006; Gong and Hubner, 2006; Kotchen et al., 2000). The 
mechanism underlying essential hypertension is not well understood but what is 
known is that with time there is an increase in the total peripheral resistance 
which results in high blood pressure. One of the proposed theories for this 
increased total peripheral resistance is an overactive renin-angiotensin system 
(Figure 1.1) which leads to greater formation of AngiotensinII (AngII) resulting 
in vasoconstriction of arteries and retention of sodium and water in the kidneys,  
the net result of which is to increase blood pressure (Sowers et al., 2009). This is 
supported by genetic linkage between the angiotensinogen gene and 
hypertension in many studies in which there is the presence of increased levels 
of plasma angiotensinogen (AngII precursor) in hypertensive subjects (Naber 
and Siffert, 2004).  
1.2. RAAS 
The renin-angiotensin system (RAS) or the renin-angiotensin-
aldosterone system (RAAS) (Figure 1.1) is a hormone system that regulates 
blood pressure and water (fluid) balance. The classical view is that the RAS 
cascade exists in the circulation. The classical circulatory RAS cascade is 
initiated by production and secretion of the enzyme renin from the kidney’s 
juxtaglomerular apparatus in response to stimuli such as a reduction in 
circulating blood volume.  Renin is considered a key enzyme of RAS due to the 
rate limiting nature of its hydrolytic  activity on angiotensinogen. Recently there 
has also been the discovery of  a renin/prorenin receptor the function of which is 
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to be fully elucidated (Nguyen et al., 2002). Angiotensinogen is released into the 
circulation, predominately from the liver. AngII is formed by the enzymatic 
cleavage of angiotensinogen by renin to form the inactive peptide, Angiotensin I.  
This in turn is converted to AngII by angiotensin converting enzyme (ACE). This 
enzyme is highly expressed in the endothelial cell membrane of the pulmonary 
circulation (Weber, 2001; Zaman et al., 2002). Another action of ACE outside 
the RAS is the inactivation of the vasodilator bradykinin further strengthening 
the role of ACE and therefore the RAS as being pro-hypertensive. 
However recent discoveries have contributed to changing our 
understanding of RAS from the classical linear cascade to a cascade with 
multiple mediators, receptors and enzymes (Chappell, 2007; Santos and 
Ferreira, 2007; Simoes e Silva AC et al., 2006).  It is now appreciated that the 
RAS also exists in distinct organs such as the heart which has been termed the 
local RAS (Miyazaki and Takai, 2006; Paul et al., 2006). The local RAS has also 
been found in blood vessels, kidney, adrenal glands, pancreas adipose tissue, 
nervous system and reproductive system (Lavoie and Sigmund, 2003; Nielsen et 
al., 2000; Sernia, 2001; Spat and Hunyady, 2004). The local RAS appears to be 
regulated independently of the circulatory RAS but can interact with it. The 
effect of the local RAS can occur on the cell itself (autocrine), on adjacent cells 
(paracrine) or through the bloodstream to a specific organ or tissue (endocrine) 
(Miyazaki and Takai, 2006; Paul et al., 2006). However the main importance of 
local RAS is linked to local regulatory mechanisms that control many 

















Figure 1-1 Renin angiotensin system  
Renin can act via its own newly discovered receptor the function of which is not fully 
known. Its established role is in converting angiotensinogen to the inactive Ang I. 
Angiotensin converting enzyme (ACE) converts Ang I to Ang II which via its AT1 receptor  
mediates the hypertensive roles of Ang II. ACE2 removes Ang II by reducing the availability 
of Ang I and by converting it to Ang-(1-7).  Ang-(1-7) actions via its Mas receptor are 




Recently, an ACE homologue, ACE2 was discovered (Figure 1.1), which is 
expressed in the heart (Gembardt et al., 2005). In contrast to ACE, ACE2 does 
not metabolise bradykinins. The catalytic efficiency of ACE2 against AngII is 
400 fold higher than for AngI.  This enzyme can degrade AngII to angiotensin 
fragments called Ang(1-7), and also cleaves AngI into Ang(1-9) (Hamming et al., 
2007). The identification of Mas as a G-protein coupled receptor of Ang-(1-7) 
established this heptapeptide as a biologically active member of the RAS 
cascade.(Figure 1.1) Most evidence supports a counter regulatory role for Ang-
(1-7) by opposing many AngII-AT1 receptor mediated actions (Chappell, 2007; 
Santos and Ferreira, 2007; Simoes e Silva AC et al., 2006). Indeed in some 
tissues ACE2 is the main isoform for Ang-(1-7) generation. Therefore, ACE2 acts 
as a clearance mechanism directly removing AngII and working indirectly on 
AngI, therefore reducing the ability to produce AngII.  The RAS can be seen as a 
dual function system in which the vasoconstrictor or vasodilator actions are 
primarily driven by the ACE/ACE2 balance. Furthermore, the principle enzymes 
in the classical cascade, renin and ACE, are not the only enzymes which can 
conduct the reaction.  Production of AngII from AngI can be driven by a 
protease chymase instead of ACE (Kinoshita et al., 1991), whereas renin can be 
replaced by cathepsin D (Genest et al., 1983).  In local RAS, chymase may be the 
dominant enzyme producing AngII, therefore treatment with ACE inhibitors will 
not prevent AngII being produced locally by chymase (Wolny et al., 1997).   
Basal expression of the RAS components is low in the heart, however, during 
pathological conditions, the local RAS in the heart becomes activated (Kumar et 
al., 2009).  The significance of local versus systemic RAS system is yet to be fully 
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defined however there is evidence to suggest that in many disease settings local 
RAS may play a role (Koka et al., 2006; Kumar et al., 2008; Li et al., 2004; 
Singh et al., 2008). 
AngII acts via its receptor named AngII receptor of which there are two 
subtypes namely AT1 and AT2. The G-protein coupled AT1 receptor mediates the 
known physiological and pathological actions of AngII and undergoes rapid 
desensitisation and internalisation after agonist stimulation. It is the AT1 
receptor which mediates the hypertensive effects of Ang II (Touyz and Schiffrin, 
2000). Throughout the body, AngII is a potent vasoconstrictor and this results 
in an increase in the total peripheral resistance. Its action in the adrenal gland is 
to stimulate the release of aldosterone which acts on the kidneys to again 
increase fluid reabsorption. Physiologically the net result of this increased fluid 
retention and increase in peripheral resistance is to increase the blood pressure. 
The AT2 receptor acts through Gi and tyrosine phosphatases to exert 
predominantly inhibitory actions on cellular responses mediated by the AT1 
receptor. For example, both receptors play a role in regulating vascular smooth 
muscle cell function. While AT1 receptor is associated with vasoconstriction AT2 
receptors generally have the opposite effect of vasodilatation (Touyz and 
Schiffrin, 2000). 
Ang-(1-7) is formed from AngII by the action of endopeptidases or  by 
ACE2. Alternatively it can be formed from AngI by the action of ACE2 forming 
Ang-(1-9) in the process. ACE inhibitors elevate plasma Ang-(1-7) concentration 
by both increasing AngI, the substrate for Ang-(1-7) as well as preventing Ang-
(1-7) degradation. The recent identification of ACE2 which forms Ang-(1-7), the 
 25 
Mas receptor as an Ang-1(1-7) receptor and its counter regulatory role of AngII 
induced effects has given it more biological significance (Jin et al., 2012). In this 
regard, at least in part, some of the beneficial effects of ACE inhibitors in the 
heart and kidney may be attributed to Ang-(1-7) (Santos and Ferreira, 2007; 
Simoes e Silva AC et al., 2006). Thus the RAS may act through two opposite 
arms. The major one responsible for systemic actions is constituted by ACE-
AngII-AT1  receptor axis and the counter regulatory arm formed by ACE2-Ang-
(1-7)-Mas axis (Santos and Ferreira, 2007; Simoes e Silva AC et al., 2006). 
 
1.3. EFFECT OF HYPERTENSION ON THE HEART 
1.3.1  STRUCTURE OF THE EXTRACELLULAR MATRIX OF THE HEART 
The normal myocardium is composed of a variety of cells. Cardiac 
myocytes occupy a major portion of tissue space however represent only one 
third of all cells.  The remaining two thirds and include endothelial and vascular 
smooth muscle cells of the intramural coronary vasculature and fibroblasts 
located in both interstitial and perivascular spaces. The cells are tethered within 
an extracellular scaffolding of fibrillar collagen termed the extra cellular matrix 
(ECM). 
The extra cellular matrix (ECM) is made up of a complex lattice of 
structural proteins e.g. collagen and elastin, as well as adhesive proteins e.g. 
laminin and fibronectin, which surround the cardiomyocytes.  Collagens are the 
major constituent of the ECM, with the fibrillar collagen types I and III being the 
most abundant in normal hearts, and their diverse structural properties play an 
important part in the structure and function of the heart (Graham et al., 2008).  
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Collagen I has a high tensile strength, which therefore, determines cardiac 
stiffness, while the distensible property of collagen type III  maintains cardiac 
structure (Weber, 1989). Associated with the collagens are elastic fibers, which 
are responsible for passive recoil; these fibers are made from an elastin core 
covered in fibrillin microfibrils. Adhesive proteins including fibronectin, laminin 
and collagen typeIV bind ECM structural proteins to the cardiomyocytes 
providing structural support. 
The ECM is the structural component that maintains the alignment of the 
myocytes preventing slippage during contraction. As a passive functional 
component it is the main determinant of diastolic stiffness. However the ECM is 
not an inert component and plays an essential role in the transmembrane 
signaling via integrins leading to MAP kinase activation and cytoskeletal 
rearrangement of the cells tethered to the ECM.  
1.3.2  HYPERTROPHY 
 An increase in peripheral resistance imposes a greater workload on the 
heart  which the heart compensates by developing a muscular hypertrophy. 
Ventricular hypertrophy (VH), defined as an increase in overall ventricular 
muscle mass, can occur naturally as a reaction to aerobic and anerobic exercise. 
In aerobic training, the stress imposed on the heart is volume overload as blood 
return to the heart increases via increased contraction of the skeletal muscle 
(skeletal-muscle pump). As a result aerobic training results in the heart being 
able to pump a larger volume of blood through an increase in the size of the 
ventricles (Pluim et al., 2000). The ventricular cardiomyocytes respond by 
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adding new sarcomeres in-series with existing sarcomeres (i.e the sarcomeres 
lengthen rather than thicken). This results in ventricular dilatation while 
maintaining normal sarcomere length. The wall thickness normally increases in 
proportion to the increase in chamber radius. This type of hypertrophy is termed 
eccentric hypertrophy.  
 Anaerobic training results in the thickening of the myocardial wall in 
order to push blood through arteries compressed by muscular contraction. 
Therefore the stress imposed on the heart in anerobic training is pressure 
overload. Wall thickness is increased as new sarcomeres are added in-parallel to 
existing sarcomeres in the ventricular cardiomyocytes. However the chamber 
radius may not change. This type of hypertrophy is termed concentric 
hypertrophy (Pluim et al., 2000). The ventricles are capable of generating 
greater forces and higher pressures, while the increased wall thickness 
maintains normal wall stress. 
Pathological hypertrophy can be caused by an increase in the afterload as 
a result of, for example aortic stenosis and hypertension. The stress imposed on 
the heart is chronic pressure overload and the left ventricle responds by 
developing concentric hypertrophy. Pathological cardiac hypertrophy is 
associated with changes in gene expression in the cardiomyocytes and re-
expression of “foetal” genes such as atrial natriuretic factor (ANF), β-myosin 
heavy chain (β-MHC) and skeletal α-actin is seen (Sadoshima and Izumo, 1997). 
Such cardiac hypertrophy can cause a rapid change in the isoform of the 
myofibril which results in a reduction in the rate of shortening. This change is 
thought to be an adaptation of the heart to conserve energy however, this may 
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also lead to a reduced force of contraction and contribute to the maladaptation 
(Gupta, 2007).  
The VH itself is not a disease but serves as an independent risk factor for 
increasing the future incidence of myocardial infarction, stroke, sudden cardiac 
death and heart failure (Boyd et al., 2012; Cicala et al., 2007; Gerdts et al., 
2012). The hypertrophied ventricle is stiff and less compliant and is therefore 
unable to relax as effectively and this reduces the diastolic filling of the heart. At 
a cellular level the cardiac myocyte hypertrophy may or may not be accompanied 
by the growth of noncardiomyocyte cells. The cardiac tissue homogeneity is 
preserved with the cardiac myocyte growth that appears in response to 
ventricular pressure or volume overload. Such adaptive hypertrophy is observed 
in athletes (Di, V et al., 1997), patients with chronic anemia (Bartosova et al., 
1969), arteriovenous fistula (Michel et al., 1986),  atrial septal defect, or 
hyperthyroidism (Bonnin et al., 1983). However this is not associated with VH 
following activation of RAS.  
Cardiac hypertrophy seen in hypertensive heart disease is associated with 
activation of the RAAS (Kim and Iwao, 2000; Mehta and Griendling, 2007; 
Weber et al., 1999).  In time fibrosis develops in the hypertrophied heart 
impairing the diastolic compliance further resulting in what is termed as 
diastolic dysfunction. The hypertrophy also negatively influences the energetics 
of the cardiomyocytes  resulting in their dysfunction (Sambandam et al., 2002). 
The impairment of cardiomyocyte function results in the impairment in the 
cardiac contraction of the heart, termed systolic dysfunction. The heart with 
both diastolic and systolic dysfunction is now said to be in total heart failure. 
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1.3.3  CARDIAC FIBROSIS 
1.3.3.1 The role of RAS 
Fibrosis is multifactorial and can result from a variety of causes including 
myocardial ischaemia, senescence, diabetes and hormones such as AngII 
amongst other causes. It is common to identify two different types of fibrosis, 
namely, reparative and reactive fibrosis. Reparative fibrosis occurs as a reaction 
to a loss of myocardial tissue due to necrosis or apoptosis, and is mainly 
interstitial. In contrast, reactive fibrosis is observed in the absence of cell loss as 
a reaction to inflammation and is primarily perivascular (Swynghedauw, 1999).  
Such adverse remodelling of the heart’s non-muscular compartment in 
hypertension is not necessarily due to the mechanical pressure overload. In 
models of infra-renal aortic banding with normal circulating levels of AngII and 
aldosterone, there is no evidence of increased cardiac fibrosis despite the 
presence of significant hypertrophy (Brilla et al., 1990). Similarly chronic 
elevation of noradrenaline levels is also not associated with increased cardiac 
fibrosis despite an elevation in blood pressure (Patel et al., 1989). Furthermore 
in human hypertension, fibrosis has been found in both the left and right 
ventricles in biopsies of myocardial tissue, despite the right heart pumping 
blood against a reduced afterload, suggesting that humoral factors are more 
important than the mechanical loading in the bringing about the fibrotic 
response (Amanuma et al., 1994). Raised levels of AngII are thought to play a 
key role in triggering the inflammatory response resulting in fibrosis. In support 
of this many studies have shown that the blockade of AngII or its action results 
in a reduction in fibrosis. For example Tokuda et al (Tokuda et al., 2004) 
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demonstrated that a sub-depressor dose of candersartan (an angiotensin II 
receptor blocker)  in mice who had had supra-renal aortic banding markedly 
ameliorated perivascular fibrosis.    
One of the ways AngII is thought to initiate fibrosis is by up-regulating 
the expression of macrophage chemoattractant protein-1 (MCP-1), which is a 
major regulator of macrophage recruitment into inflammatory tissues.  It has 
been observed that pressure overloaded hearts show an increased expression of 
MCP-1 which was accompanied by macrophage infiltration in the perivascular 
space of both small and large intramyocardial arteries (Capers et al., 1997; 
Tokuda et al., 2004). Administration of sub-depressor dose of candesartan 
significantly suppressed MCP-1 induction and macrophage accumulation 
suggesting that AngII induces reactive fibrosis through mechanisms that are 
independent of the pressor effect (Tokuda et al., 2004).  
 
1.3.3.2 Role of macrophages 
Macrophage infiltration is a key early event in the development of 
reactive myocardial fibrosis (Kuwahara et al., 2003) and Tokuda et al found the 
accumulation of macrophages to be due to MCP-1 (Tokuda et al., 2004).  The 
importance of macrophage infiltration for the development of fibrosis is 
demonstrated by the blockade of MCP-1 and ICAM-1 early in this process. The 
blockade of either prevented the  onset of myocardial fibrosis suggesting their 
coordinated role towards macrophage recruitment in pressure overloaded 
myocardium (Kuwahara et al., 2003; Kuwahara et al., 2004). 
 31 
 
1.3.3.3 Origin of fibroblast/myofibroblasts 
The origins of activated fibroblasts in the fibrotic process are diverse.  
Firstly the proliferation and activation of tissue resident fibroblasts in response 
to profibrotic cues originating from infiltrating inflammatory cells can lead to 
quiescent fibroblasts expressing a myofibroblasts phenotype (Postlethwaite et 
al., 2004). A second source is the recruitment of fibroblast precursor cells from 
the bone marrow. These cells are called fibrocytes and they possess the ability to 
migrate from the bloodstream in response to specific chemokine gradients and 
localize in tissue undergoing pathological fibrogenesis (Bellini and Mattoli, 
2007; Herzog and Bucala, 2010). A third source of myofibroblasts is by way of 
transformation of epithelial cells to myofibroblasts, a process known as 
epithelial mesenchymal transition (EMT).  Such EMT has been shown to occur 
in the course of renal fibrosis, pulmonary fibrosis and liver fibrosis (Rastaldi, 
2006; Willis et al., 2006; Willis and Borok, 2007; Zeisberg and Kalluri, 2008). 
More recently endothelial to mesenchymal transition (EndoMT) has been shown 
to contribute in the development of fibrosis (Zeisberg et al., 2007b). This is a 
complex biological process in which endothelial cells loose their specific 
endothelial cell markers such as vascular endothelial cadherin (VE cadherin) 
and initiate expression of mesenchymal cell products such as α smooth muscle 
actin and vimentin. These cells can also become motile and are capable of 
migrating into the surrounding tissue. Goumans et al (Goumans et al., 2008) 
pointed out that in cardiac fibrosis EndoMT may be the most important 
contributor towards the generation of fibrotic tissue.     
 32 
1.3.3.4 Role of fibroblasts 
The infiltrating macrophages in the perivascular space co-localise with 
fibroblasts. The macrophages are known to secrete profibrotic cytokines such as 
TGF-β1. These in turn can cause proliferation of the fibroblasts and their 
differentiation to myofibroblasts, which synthesise collagen (Kai et al., 2005). 
Kuwahara et showed that the perivascular accumulation of macrophages 
preceded  TGF-β1 expression and fibroblast proliferation (Kuwahara et al., 
2004). Activated myofibroblasts can themselves express TGF-β1 and other pro-
fibrotic substances which self-amplifies the ongoing fibrotic process 
(Desmouliere et al., 1993). Therefore macrophage infiltration is crucial as an 
upstream event of myocardial fibrosis with further downstream macrophage 
TGF-β1 expression and fibroblast activation.    
 
1.3.3.5 Disruption of the equilibrium of collagen synthesis 
The collagen synthesis and degradation in the heart is kept in 
equilibrium. This process is maintained by a variety of hormones and cytokines 
of which matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) are important (Graham et al., 2008).  The effector 
hormones of the renin-angiotensin system, inflammatory cytokines (eg TGF-β1), 
growth factors (eg insulin-like growth factor) and degradation fragments from 
increased MMP activity, have been shown to have potent profibrotic effects. By 
contrast, bradykinin, nitric oxide, natriuretic peptide, and glucocorticoids have 
been shown to promote collagenolysis. An excess of stimulators, due either to 
absolute stimulator overproduction or to their relative overabundance because 
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of a deficit in inhibitor formation, can promote fibrosis. In the setting of 
hypertensive heart disease (HHD), this equilibrium is disrupted, with activation 
of the RAS system and overproduction of AngII leading to fibrosis. 
As fibrosis progresses the existing collagenous matrix increases in 
dimension resulting in interstitial cardiac fibrosis. There is accumulation of 
thick collagen fibres around small intramyocardial coronary arteries  resulting in 
perivascular fibrosis (Jalil et al., 1988). These fibres then radiate into the 
intermuscular spaces and may merge with co-existing interstitial cardiac 
fibrosis. Later,   areas of cell necrosis are observed and lead to microscopic scar 
formation (Weber et al., 1989). 
A key mediator of the pro-fibrotic effect of AngII is oxidative stress. 
Oxidative stress is also implicated in the downstream signalling pathways of the 
RAAS in many pathological settings. 
 
1.4 OXIDATIVE STRESS AND REDOX SIGNALING 
Oxidative stress can be defined as the oxidative cellular damage resulting 
from the a pathological imbalance between the production of reactive oxygen 
species (ROS) and antioxidant defenses (Griendling and FitzGerald, 2003a; 
Mehta and Griendling, 2007; Paravicini and Touyz, 2008; Weber et al., 1999). 
Thus it can result from either excess production of ROS or alternatively 
deficiencies in antioxidant systems. 
Reactive oxygen species (ROS) are oxygen based molecules which have a 




hydrogenperoxide (H2O2), peroxynitrite (ONOO
_
 ) and hydroxyl radicals (OH
-
) 
which all aerobic organisms generate. Traditionally they have been considered 
to be deleterious since they can induce free-radical oxidative damage to DNA 
and other macromolecules. However under normal physiological conditions 
ROS is produced in quantities required for signaling. As part of this signaling 
the ROS is converted by existing antioxidant systems thus preventing the 
indiscriminate production of ROS. Clearly, perturbation of this system due to 
increased ROS production or a decrease in the antioxidant system can result in 
an increased oxidative state within the cells and tissues, termed oxidative stress.  
Recently it has been recognised that oxidative stress can play a role in the 
pathophysiology of many diseases such as diabetes, hypertension, 
atherosclerosis, cardiac hypertrophy, heart failure and cardiac fibrosis via 
modulation of a number of diverse intracellular signalling pathways such as 
MAPK, Akt, JNK,  and transcription factors such as NFkb (Ejiri et al., 2003; 
Fukui et al., 1997; Griendling and Alexander, 1997; Griendling and FitzGerald, 
2003a; Griendling and FitzGerald, 2003b; Grieve et al., 2004; Jung et al., 2004; 
Paravicini and Touyz, 2006; Sawyer et al., 2002). The modulatory effect of ROS 
in the pathophysiological signalling (Figure 1.2) of such diseases is termed 
‘redox signalling’ (Jung et al., 2004; Paravicini and Touyz, 2006; Suzuki and 
Griendling, 2003).  
The signalling properties of ROS is achieved by mechanisms such as the 
reversible oxidation of redox sensitive target proteins (e.g. tyrosine 
phosphatase) or the formation of cysteine disulfide bonds within signalling 
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proteins. Alternatively interaction of O2
-
 with the signalling free radical nitric 
oxide (NO) reduces NO availability, thus modulating NO dependant responses 
and producing the toxic free radical peroxynitrate in the process. When O2
-
 is 
produced it is rapidly dismutated to H2O2, by the superoxide dismutase (SOD) 
enzyme. H2O2 can diffuse across cell membranes and may therefore be 
responsible for redox signalling further away from the initial cellular source 
(Rao et al., 1993a; Rao et al., 1993b; Zafari et al., 1998). Extracellular ROS 
production by macrophages can activate MMPs which can degrade the collagen 





























Figure 1-2 Redox dependant signalling pathways  
Intracellular ROS modify the activity of tyrosine kinase as well as MAPK. ROS may inhibit 
protein tyrosine phosphatise activity and influence gene and protein expression by 
activating transcription factors. ROS can also stimulate plasma membrane Ca 2+ and K+ 
channels leading to changes in cation concentration. Activation of these redox sensitive 
pathways results in numerous cellular responses.  
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1.5 SOURCES OF ROS 
ROS are produced from a number of sources such as the mitochondria, 
nitric oxide synthase (NOS) and xanthine dehydrogenase. In addition, the 
enzyme complex NADPH oxidase has been demonstrated to be an important 
source of ROS. 
1.5.1  DYSFUNCTIONAL NITRIC OXIDE SYNTHASE 
Nitric oxide (NO) is an important signalling molecule with particular 
relevance for normal endothelial function. There are 3 isoforms of NOS all of 
which may be expressed in the heart. These are endothelial NOS (eNOS) and 
neuronal NOS (nNOS), which are constitutively expressed, and inducible NOS 
(iNOS).  
NOS exists as a dimer with two subunits connected via a central 
calcium/calmodulin-binding region. NO and L-citrulline are generated by NOS 
through catalysing the oxidation of L-arginine. This requires the transfer of 
electrons from NADPH and NOS cofactor tetrahydrobiopterin (H4B),  with 
water formed as a by-product (Sears et al., 2004).  However in situations where 
either L-arginine or H4B are limiting, NOS can generate superoxide radicals. 
These findings have led to the concept of “NOS uncoupling”, where the activity 
of the enzyme for NO production is decreased in association with an increase in 
NOS-dependant superoxide radical formation (Heitzer et al., 2000; Katusic, 
2001). Moreover H4B is readily oxidised so that any setting where there is a 
significant degree of oxidative stress can result in the situation where NOS is 
uncoupled secondary to H4B depletion (Laursen et al., 2001).  
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1.5.2  MITOCHONDRIAL ELECTRON TRANSPORT CHAIN 
In the Kreb’s cycle, reduced nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH) are generated by the oxidation of 
nutrients such as glucose. Electrons derived from NADH and FADH are then 
transferred along a series of electron transport carriers - Complex I (NADH 
dehydrogenase), Complex II (succinate dehydrogenase), Complex III 
(cytochrome bc1) and Complex IV (cytochrome oxidase) which are located on 
the inner mitochondrial membrane. This results in the transfer of  electrons to 
molecular oxygen to form water. The proton gradient generated by this process 
is used for the synthesis of adenosine triphosphate (ATP). During this process a 
variety of oxygen intermediates are formed such as hydrogen peroxide and 
superoxide (Sena and Chandel, 2012). Monoamine oxidase A and B are also 
found anchored to the outer mitochondrial membrane where they have an 
important role in the oxidative deamination of amines such as serotonin, 
dopamine and epinephrine using oxygen molecule as the electron acceptor 
(Edmondson et al., 2009).    Importantly high levels of antioxidant enzymes 
such as MnSOD and catalase are present which limit the total quantity of these 
reactive intermediates. Nevertheless it is estimated that under physiological 
conditions superoxide may leak from the respiratory chain. This amount may 





1.5.3  XANTHINE OXIDOREDUCTASE  
Xanthine oxidoreductase is a ubiquitous metalloflavoprotein that appears 
in two interconvertible yet functionally distinct forms. These are xanthine 
dehydrogenase (XD), which is constitutively expressed in vivo and xanthine 
oxidase (XO) (Meneshian and Bulkley, 2002). XO is generated by the 
posttranslational modification of XD, either through the reversible oxidation of 
sulfhydryl residues on XD or the irreversible proteolytic cleavage of a segment of 
XD, which occurs at low oxygen tension and in the presence of several 
proinflammatory mediators. Functionally, both XD and XO catalyse the 
oxidation of purines to urate. However, whereas XD requires NAD+ as an 
electron acceptor for these redox reactions, thereby generating the stable 
product NADH, XO is unable to use NAD+ as an electron acceptor, requiring 
instead the reduction of molecular oxygen for this purine oxidation and 
generating the highly reactive superoxide free radicals. 
Xanthine oxidase-derived ROS are known to be important in ischemia-
reperfusion injury and play a role in endothelial dysfunction (Brown et al., 1988; 
Spiekermann et al., 2003). During ischemia and exposure of XD to low oxygen 
tension, irreversible proteolytic cleavage might convert XD to XO (Battelli et al., 
1992),  thereby priming the system for the triggering of microvascular 
inflammation by the generation of ROS upon the subsequent delivery of oxygen 
at reperfusion. The ROS thereby generated from XO could therefore trigger the 
accumulation, activation and diapedesis of neutrophils, with consequent 
neutrophil-mediated microvascular inflammatory injury, leading ultimately to 
parenchymal organ dysfunction.   
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1.5.4  LIPOXYGENASE/CYCLO-OXYGENASE 
Arachidonic acid (AA) is released from glycerophospholipids in the 
nuclear envelope and from the plasma membrane via the activity of cytosolic 
phospholipase A2 and is subsequently metabolised by cyclooxygenase (COX) and 
lipoxygenase (LOX) to generate a variety of bioactive eicosanoids, including 
prostaglandins, thromboxanes and leukotrienes (Funk, 2001; Samuelsson et al., 
1987). ROS can be generated as a byproduct during the oxidation processes of 
AA by COX and LOX (Edderkaoui et al., 2005).  
1.6 ANTIOXIDANT SYSTEM  
The body has several potential endogenous antioxidant defences to 
protect against the overproduction of ROS. The defence mechanisms include 
enzymatic defences such as the superoxide dismutase (SOD) family, catalase and 
the glutathione peroxidase enzyme system (Marczin et al., 2003). Non-
enzymatic systems include ascorbic acid (vitamin C), α-tocopherol (vitamin E), 
glutathione, β-carotene and vitamin A (Gotto, 2003).  Vitamins are major 
antioxidant in humans. The vitamins act as a potent free radical scavenger that 
can react with oxygen, superoxide and the hydroxyl radical (Abudu et al., 2004). 
1.6.1  SUPEROXIDE DISMUTASE 
Superoxide radical spontaneously dismutes to O2 and hydrogen peroxide 
(H2O2) quite rapidly.  However the dismutation rate is second order with respect 
to initial superoxide concentration. Thus, the half-life of superoxide, although 
very short at high concentrations (e.g. 0.05 seconds at 0.1mM) is actually quite 
long at low concentrations (e.g. 14 hours at 0.1 nM). At the subnanomolar 
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concentrations superoxide can  inactivate the citric acid cycle enzyme aconitase, 
can poison energy metabolism and releases potentially toxic iron. Aconitase is 
one of several iron-sulfur containing dehydratases in metabolic pathways shown 
to be inactivated by superoxide (Gardner et al., 1995). Therefore SOD is required 
to actively remove superoxide quickly at all concentrations. To this end SOD has 
one of the largest reaction rate with its substrate of any known enzyme, this 
reaction being only limited by the frequency of collision between itself and 
superoxide. Hence the SOD catalysed dismutation is favoured when 
concentrations of superoxide radicals are low, which occurs under physiological 
conditions, (Figure 1.3) and even more favoured as concentrations of superoxide 
become higher. 
 There are currently three identified members of the enzyme family, 
namely cytosolic Cu/Zn SOD (SOD1), mitochondrial Mn-SOD (SOD2) and 
extracellular SOD or ec-SOD (SOD3) (Faraci and Didion, 2004).  The isoforms 
differ in their location, Cu/Zn SOD is found in the cytosol, Mn-SOD is localised 
to the mitochondria and ecSOD is found in the extracellular space. Cu/Zn SOD 
is the most widely distributed of these enzymes and comprises approximately 
90% of the total SOD pool. The physiological importance of SODs is illustrated 
by the severe pathologies evident in mice genetically engineered to lack these 
enzymes. Mice lacking SOD2 die several days after birth, amidst massive 
oxidative stress (Li et al., 1995). Mice lacking SOD1 develop a wide range of 
pathologies, including hepatocellular carcinoma (Elchuri et al., 2005), an 
acceleration of age-related muscle mass loss (Muller et al., 2006), an earlier 
incidence of cataracts and a reduced lifespan. Mice lacking SOD3 do not show 
 42 
any obvious defects and exhibit a normal lifespan, though they are more 
sensitive to hyperoxic injury (Sentman et al., 2006).  
 
1.6.2  CATALASE 
 Catalase is an intracellular enzyme located mostly in peroxisomes but 
also in the cytosol. It catalyses the conversion of hydrogen peroxide to water and 
molecular oxygen. Thus it removes superoxide indirectly by converting the 
hydrogen peroxide produced by SOD. (Figure 1.3) Catalase has one of the 
highest turnover numbers of all enzymes. One molecule of catalase can convert 
millions of molecules of hydrogen peroxide to water and oxygen per second.  
The true biological significance of catalase is not always straightforward 
to assess. Mice genetically engineered to lack catalase are phenotypically 
normal, indicating that this enzyme is dispensable in animals under some 
conditions (Ho et al., 2004). However catalase deficiency may increase the 
likelihood of developing Type II diabetes (Goth et al., 2001; Goth, 2008). Some 
human beings have very low levels of catalase (acatalasia), yet show few ill 
effects. As such it is likely that the predominant scavengers of H2O2 in normal 
mammalian cells are peroxiredoxins rather than catalase. 
1.6.3  PEROXIREDOXINS  
Peroxiredoxins are a ubiquitous family of antioxidant enzymes. They are 
divided into three classes namely typical 2-Cys, atypical 2-Cys and 1-Cys. These 
enzymes share the same basic catalytic mechanism, in which a redox-active 
cysteine (the peroxidatic cysteine) in the active site is oxidized to a sulfenic acid 
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by the peroxide substrate(Claiborne et al., 1999). The recycling of the sulfenic 
acid is what distinguishes the three enzyme classes. 2-Cys peroxiredoxins are 
reduced by thiols such as glutathione, while the 1-Cys enzymes may be reduced 
by ascorbic acid or glutathione (Monteiro et al., 2007). 
1.6.3.1 Glutathione 
Glutathione (GSH) and thioredoxin (TRX)  comprise the main 
intracellular redox buffering capacity of which glutathione is the more 
abundant. Glutathione is oxidised to glutathione disulphide (GSSG) and the 
2GSH/GSSG couple is a representative indicator of the redox enviroment of the 
cell (Droge, 2002; Schafer and Buettner, 2001). The high ratios of reduced to 
oxidised GSH and TRX are maintained by the activity of GSH reductase and 
TRX reductase, respectively.  
Glutathione has a number of mechanisms of protecting against oxidative 
stress. Glutathione is a cofactor of several detoxifying enzymes against oxidative 
stress such as glutathione peroxidase. (Figure 1.3) Thus GSH can detoxify 
hydrogen peroxide and lipid peroxides by the catalytic action of glutathione 
peroxidase. GSH can also scavenge hydroxyl radicals and singlet oxygen directly 
and is also able to regenerate important antioxidants such as vitamin C and E  
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Figure 1-3 Antioxidant system 
Superoxide radical is dismutated by the superoxide dismutase (SOD) to hydrogen 
peroxide. Hydrogen peroxide is most efficiently scavenged by the enzyme glutathione 
peroxidise (GPx) which requires GSH as an electron donor. The oxidised glutathione 
(GSSG)  is reduced back to GSH by the enzyme glutathione reductase (GRed) which uses 
NADPH as electron donor. Some transition metals such as Fe2+ and Cu+   can break 
hydrogen peroxide to the reactive hydroxyl radical. The hydroxyl radical are removed by 




1.7 NADPH OXIDASE 
1.7.1  HISTORICAL OVERVIEW 
NADPH oxidase is now thought to be the predominant source of ROS in 
vascular tissue and cardiac cells. NADPH oxidase derived ROS appears to play a 
physiological role in redox signaling and is the only one that appears to be 
specifically designed for this purpose (Cave et al., 2005; Cave et al., 2006; 
Geiszt, 2006; Griendling et al., 2000; Griendling, 2004; Griendling, 2006; 
Lambeth, 2004; Lassegue et al., 2012). 
Historically, NADPH oxidase was identified in phagocytes and proposed 
as being responsible for the superoxide generation in the respiratory burst 
(ROSSI and ZATTI, 1964). A second line of evidence came from clinical findings 
of patients suffering from recurrent pyogenic infections. These patients had a 
genetic defect in their NADPH oxidase gene and no respiratory burst in their 
phagocytes (BERENDES et al., 1957). The genetic disorder is now referred to as 
chronic granulomatous disease (CGD). 
The development of the cell free system allowed activation of the 
phagocyte NADPH oxidase to be examined using purified cytosol and membrane 
fractions (Bromberg and Pick, 1985; Heyneman and Vercauteren, 1984). This 
system provided the tool for the discovery of the cytosolic subunits p47phox, 
p40phox, p67phox and the small GTP-binding proteins Rac1 and Rac2 (Abo et al., 
1991; Knaus et al., 1991; Nunoi et al., 1988; Volpp et al., 1988; Wientjes et al., 
1993).  Progress towards understanding the phagocyte NADPH oxidase led to 
the observation that a similar enzyme was present in a variety of other cells 
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including fibroblasts, tumor cells and vascular smooth muscle cells to name a 
few (Griendling et al., 1994; Meier et al., 1991; Szatrowski and Nathan, 1991b).  
The availability of the human genome sequence resulted in the identification of 
the first homolog of the phagocyte NADPH oxidase termed as Nox1. In this 
novel Nox terminology for the enzyme the original phagocyte NADPH oxidase 
was termed Nox2.  The identification of Nox1 was quickly followed by the 
cloning of Nox3, Nox4 and Nox5 and two large members of the Nox family 
namely DUOX1 and DUOX2 (Banfi et al., 2001; Cheng et al., 2001; De, X et al., 
2000; Dupuy et al., 1999; Geiszt et al., 2000; Kikuchi et al., 2000; Shiose et al., 
2001).  
 
1.7.2  CELLULAR AND HISTOLOGICAL LOCALISATION OF NADPH OXIDASE 
It is now appreciated that the  NADPH oxidase isoforms have a varied 
tissue distribution across the body. Nox1 is highly expressed in the colon (Suh et 
al., 1999), Nox3 is found predominantly in the inner ear (Banfi et al., 2004a), 
whilst Nox4 was originally found in the kidney (Geiszt et al., 2000) but also has 
high expression in the vasculature and many other tissues. Nox5 is found in the 
lymphoid tissue and testis (Cheng et al., 2001), whereas the Duoxs have high 
expression levels in the thyroid gland (De, X et al., 2000). In cardiovascular 
tissue, expression of more than one isoform of Nox is seen in several cell types 
(see Table 1.1). It is increasingly thought that this implies specific roles for the 




Table 1-1 Expression of Nox isoform mRNA in cardiovascular cells 
 Cardiomyocytes Endothelial cells 
(EC) 
Fibroblasts Vascular smooth 
muscle cells (VSMC) 
Nox 1 - Human coronary 
artery EC (Sorescu 
et al., 2002) 
Rat aortic EC (Ago 
et al., 2004) 
Rat basilar artery 
EC (Ago et al., 2005) 
Human cardiac 
fibroblasts (Sorescu 
et al., 2002) 
Human coronary 
artery SMC (Sorescu 
et al., 2002) 
Rat aortic SMC 
(Lassegue et al., 
2001) 
Mouse aortic SMC 
(Grote et al., 2003) 
Rabbit pulmonary 
artery SMC 
(Weissmann et al., 
2000) 
Rat mesenteric 
artery SMC (Touyz et 
al., 2002) 
Nox 2 Mouse cardiomyocytes 
(Bendall et al., 2002a; 
Peng et al., 2005) 
Rat cardiomyocytes 
(Xiao et al., 2002) 
Human coronary 
artery EC(Sorescu 
et al., 2002) 
Rat aortic EC (Ago 
et al., 2004) 
Rat basilar artery 
EC (Ago et al., 2005) 
Human cardiac 
fibroblasts (Sorescu 
et al., 2002) 
Adventitia of human 
coronary artery 
(Sorescu et al., 2002)  
Adventitia of mouse 




et al., 2002) 
Rat aortic 
SMC(Lassegue et al., 
2001) 
Nox 4 Mouse cardiomyocytes 
(Peng et al., 2005) 
Human coronary 
artery EC (Sorescu 
et al., 2002) 
Rat aortic EC (Ago 
et al., 2004) 
Rat basilar artery 
EC (Ago et al., 2005) 
Human cardiac 
fibroblasts 
(Cucoranu et al., 
2005; Sorescu et al., 
2002) 
Adventitia of human 
coronary artery 
(Sorescu et al., 2002) 
Rat cardiac 
fibroblasts (Colston 
et al., 2005) 
Human coronary 
artery SMC(Sorescu 
et al., 2002) 
Rat aortic 
SMC(Lassegue et al., 
2001) 
Rat mesenteric 
artery SMC(Touyz et 
al., 2002) 
Nox 5 - Human EC ((Belaiba 
et al., 2007)) 
Human cardiac 
fibroblasts 
(Cucoranu et al., 
2005) 
Human aortic SMC 
(Pedruzzi et al., 
2004) 
SMC within human 
aortic 
atherosclerotic 




1.7.3  NADPH OXIDASE STRUCTURE 
NADPH oxidases are transmembrane proteins that transport electrons 
across biological membranes to reduce oxygen to superoxide. Nox2 is the 
prototype NADPH oxidase and has been the most extensively studied. 
The prototypical NADPH oxidase complex consists of a membrane-bound 
flavocytochrome b558, which is a heterodimer consisting of a catalytic Nox 
subunit and p22phox  (Babior, 2004). The membrane bound Nox subunit 
transfers electrons from NADPH, in the phagocyte cytoplasm, across two heme 
units, to molecular oxygen, thereby producing superoxide (Cross et al., 1995). 
Although the Nox subunit is the catalytic component of the flavocytochrome 
b558, its partner p22phox  subunit is also essential. The expression of p22phox 
subunit and the formation of the heterodimer is a prerequisite for its egress 
from the endoplasmic reticulum and proper localisation in the plasma 
membrane. Consistent with the requirement of heterodimer formation for 
stability is the observation that patients with genetic defects in either Nox or 
p22phox  subunits lack both proteins (Heyworth et al., 2003). Subunit p22phox is 
required by Noxes 1, 2, 3 and 4 for protein stabilisation and for binding of 
regulatory cytosolic  subunits.  
 There are several cytosolic subunits namely p47phox, p67phox, p40phox  and 
the small GTPase  Rac1 or Rac2 are known to be involved in the activation of 
Nox2. (Figure 1.4) Biochemical studies using broken cell system have 
demonstrated that p47phox serves as an organising adaptor protein lacking 
intrinsic catalytic activity. However p67phox  represents an essential activating 
cofactor which possesses the domain that regulates the reduction of FAD by 
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NADPH (Nisimoto et al., 1999). Similarly to Nox2, other Nox isoforms have 
associated factors. Homologues of p47phox and p67phox named NOX organising 
(NOXO1) and activating (NOXA1) proteins have been identified and each 
implicated in the activity of NOX1 and 3 (Bedard and Krause, 2007). In contrast 
to Nox2, Nox4 does not require the cytosolic subunits. Therefore p22phox  is the 
only subunit essential for Nox4 activation. This may explain why Nox4 appears 
to be constitutively active (Ambasta et al., 2004) with its activity suggested to be 
transcriptionally regulated (Serrander et al., 2007). This would therefore negate 
a requirement for control by regulatory cytosolic subunit proteins.  For Nox5 
and Duox proteins calcium serves as a regulator (Banfi et al., 2004b; Banfi et al., 


















































Figure 1-4  Structure and activation of NADPH oxidase  
 In resting cells, heterodimeric Nox and p22phox resides in the membrane, whereas the 
complex of p47phox p67phox and p40phox is cytosolic. The Nox enzyme is shown in more detail 
in the circled inset. The Nox enzyme has six transmembrane domains. Two of these contain 
two histidines (H), coordinating two hemes (purple squares). The cytoplasmic COOH 
terminus contains FAD and NADPH binding domains. The Nox family of enzymes differ in 
their mechanism of activation. For Nox2, agonists trigger the phosphorylation of the 
autoinhibitory domain of p47phox, releasing a conformational restriction allowing for its 
association at the membrane. Nox1 and 3 require NOXO1 and NOXA1  whereas Nox4 is 
constitutively active without the requirement for other subunits. Nox5 is activated by 
calcium and does not appear to require subunits.  
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1.7.4  ACTIVATION AND FUNCTION OF NADPH OXIDASES  
The activation of Nox2 happens through a complex series of protein-
protein interaction. Nox2 constitutively associates with p22phox  and its activation 
requires the translocation of cytosolic factors to the Nox2/p22phox complex. The 
phosphorylation of the autoinhibitory region in p47phox leads to a 
conformational change in the p47phox allowing for it to interact with p22phox 
(Groemping et al., 2003; Sumimoto et al., 1996). The region of p22phox 
responsible for this interaction is the COOH terminus (Leto et al., 1994; 
Sumimoto et al., 1996). Truncation of p22phox  or mutations within the COOH 
terminus domain leads to a loss of activation of Nox1, Nox2 and Nox3 
(Kawahara et al., 2005; Leusen et al., 1994).  In agreement with the concept that 
Nox4 activation does not involve cytosolic subunits, these truncations or 
mutations of p22phox  COOH terminus does not decrease Nox4 activity. 
Interestingly AA has been reported to activate NADPH oxidase directly by 
stimulating p22phox, thereby inducing ROS generation (Kim and Dinauer, 2006; 
Luchtefeld et al., 2003; Shiose and Sumimoto, 2000). LOX-and COX-generated 
AA metabolites have also been demonstrated to stimulate the production of ROS 
by NOX thus revealing the existence of an inter-connected signalling system 
between eicosanoids and NOXs (de Carvalho et al., 2008; Luchtefeld et al., 
2003). For example, a 5-LOX metabolite, leukotriene B4 (LTB4) and COX 
metabolite, PGF2α, are capable of stimulating NADPH oxidase. This LTB4 
induced ROS generation occurring via NOX has been seen to be crucial in cell 
chemotaxis (Woo et al., 2002; Woo et al., 2003).  
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The localisation of p47phox  to the membrane brings p67phox and p40phox 
into contact with Nox2. The subunits p67phox, p40phox and Rac fail to translocate 
to the membrane in neutrophils from patients lacking p47phox (Dusi et al., 1996; 
Heyworth et al., 1991; Kawahara et al., 2005).  
The protein kinase C (PKC) isoforms β, δ and ε are suggested to be the 
major kinases responsible for p47phox  phosphorylation but recent studies suggest 
that other kinases such as Akt, , p38MAPK, and p21 activated kinase (PAK) can 
also be involved. The precise role of p40phox, which has significant homology to 
p47phox, in oxidase activation is poorly understood. 
Interestingly, recent data indicate that p47phox  may have additional roles 
in nonphagocytic cells. It has been suggested that protein–protein interactions 
involving p47phox  and other nonoxidase factors may play an important role in the 
spatial confinement of NADPH oxidase. Thus this allows for locally derived ROS 
to modulate signals and thereby enabling local redox signaling. Several different 
proteins have been found including the TNF receptor-associated factor 4 
(TRAF4) and WAVE1, an important regulator of the cytoskeleton, which may act 
as a scaffold to enable the recruitment of the NADPH oxidase. Such local redox 
modulation by NADPH derived ROS has been seen to be involved with 
cytoskeletal regulation (Li et al., 2005; Xu et al., 2002) and therefore in cellular 
migration.  
Rac  also becomes activated from GDP to GTP, catalysed by guanine 
nucleotide exchange factors (GEFs) such as Tiam-1, Trio, and Vav-1 and P-Rex1, 
which appears to be of particular importance (Mizrahi et al., 2005; Price et al., 
2002; Welch et al., 2002). The GTPase Rac interacts directly with Nox2 followed 
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by a subsequent interaction with p67phox  thus enabling optimal positioning of 
Rac and completing the assembly.  Once assembled the complex is active and 
generates superoxide by transferring an electron from NADPH in the cytosol to 
oxygen on the luminal or extracellular space.  
The electrons are transferred in a series of steps. The electrons are 
transferred from the NADPH to FAD, a process that is regulated by p67phox 
(Nisimoto et al., 1999). A single electron is then transferred from the reduced 
flavin FADH2 to the iron centre of the inner heme. Since the iron of the heme 
can only accept one electron, the inner heme must donate its electron to the 
outer heme before the second electron can be accepted from the now partially 
reduced flavin FADH. Oxygen is bound to the outer heme as a final step to 
accept the electron (Cross and Segal, 2004; Doussiere et al., 1996; Vignais, 
2002). The process is electrically balanced by proton conduction in the same 
direction (Lassegue and Clempus, 2003). 
1.8 INVOLVEMENT OF NOX2 IN CARDIAC HYPERTROPHY 
Studies of hypertrophy in isolated cultured cardiomyocytes have 
identified an important role for intracellular ROS generation. As such Hirotani 
et al (Hirotani et al., 2002) showed that the GPCR agonists (AngII, endothelin-1, 
phenylephrine) induced cardiac hypertrophy was mediated through NF-κB 
activation via the generation of ROS. Nakamura et al (Nakamura et al., 1998) 
also showed in cardiac myocytes that TNF-α and AngII caused hypertrophy via 
the generation of ROS. Similarly Xiao et al (Xiao et al., 2002) provided the 
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evidence that ROS from NADPH oxidase appeared to be involved in α1-
adrenoceptor stimulated cardiomyocyte hypertrophy. 
Definitive evidence for the involvement of NADPH oxidase in 
pathological hypertrophy came from experiments involving genetically modified 
mice. Global Nox2-/- mice subjected to subpressor dose of AngII for 2 weeks 
showed significantly reduced cardiac hypertrophy compared to wild type 
(Bendall et al., 2002a). This result suggested that AngII induced cardiac 
hypertrophy, in the absence of a pressor response, requires Nox2 oxidase 
activity.  In line with this finding, AngII induced hypertrophy of isolated 
cardiomyocytes were shown to involve the activation of Nox2 oxidase (Hingtgen 
et al., 2006a). As Nox2-/- mice have a lower baseline blood pressure than wild 
type, it is  possible that this may have contributed to the difference seen by 
Bendal et al (Bendall et al., 2002a).  Hence Byrne et al (Byrne et al., 2003) 
investigated the effect of a pressor dose of AngII in inducing cardiac 
hypertrophy. These experiments again showed a reduced level of cardiac 
hypertrophy in the Nox2-/- mice again suggesting that independent of the 
mechanical effect of blood pressure, chemical stimulation by angiotensin II 
induces cardiac hypertrophy via Nox2 oxidase.  
In contrast to AngII induced hypertrophy, the hypertrophic response to 
aortic banding was found to be similar between Nox2-/- and wild type mice by 
Byrne et al (Byrne et al., 2003). They also found an increased level of NADPH 
oxidase activity which they ascribed to the increased levels of Nox4 seen in the 
Nox2-/- mice. Maytin et al have also shown that pressor effects from aortic 
banding induced similar levels of cardiac hypertrophy in both wild type and 
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Nox2-/- mice (Maytin et al., 2004). These authors also found increased levels of 
p22phox and  p47phox mRNA.  Taken together these data support the fact Nox2 
does not play an essential role in cardiac hypertrophy as induced by the 
mechanical effect of aortic banding. The data also suggests that Nox4, as the 
source of ROS, could be important in the development of observed cardiac 
hypertrophy.  
1.9 NADPH OXIDASE DERIVED ROS AND CARDIAC FIBROSIS  
A significant body of data implicates Nox2 in the development of cardiac 
fibrosis. As such, our laboratory has shown that Nox2-/- mice had a markedly 
reduced fibrosis compared to wild type animals in response to either a 
subpressor or pressor infusion of AngII (Bendall et al., 2002a; Byrne et al., 
2003; Johar et al., 2006). Furthermore the profibrotic effects of AngII  have 
been shown to be inhibited by the antioxidant N-acetyl-cysteine, consistent with 
the role of ROS in this process (Johar et al., 2006). 
Nox2 has also been implicated in aldosterone induced myocardial fibrosis 
(Johar et al., 2006). Aldosterone infusion resulted in NADPH oxidase activation 
and increased cardiac fibrosis, with these effects being inhibited in Nox2-/- mice.  
The authors also provided evidence that mineralocoticoid receptor (MR) 
activation is involved in AngII induced myocardial NADPH oxidase activation 
and subsequent interstitial cardiac fibrosis. In line with this, spironolactone 
inhibited both the increase in NADPH oxidase activity.. This finding suggested 
that MR receptor activation was important in the AngII stimulation. In a more 
recent study, apoptosis signal-regulating kinase 1 (ASK1) deficient mice 
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subjected to aldosterone/salt treatment showed a marked reduction in Nox2 
associated ROS production with a significant reduction in interstitial fibrosis 
and perivascular fibrosis (Johar et al., 2006; Nakamura et al., 2009).  
Johar et al found that interstitial cardiac fibrosis induced by AngII and 
aldosterone involved the Nox2 dependent upregulation of profibrotic cytokines 
such as CTGF and profibrotic genes such as pro-collagen-1, pro-collagen-3 and 
fibronectin. They also found that there was increased Nox2 dependent activation 
of NF-κ B and MMP2 (Johar et al., 2006; Nakamura et al., 2009). 
In contrast to the above mentioned role of Nox2, some recent studies 
suggest an important role of Nox4 in the development of cardiac fibrosis. 
Cucoranu et al in a study involving cultured human cardiac fibroblasts found 
that Nox4 and 5 mRNAs were abundantly expressed (Cucoranu et al., 2005). 
These authors reported that TGF-β1 upregulated Nox4 expression and promoted 
the conversion of fibroblasts to myofibroblasts which are the main producers of 
collagen in the extracellular matrix. In line with the role for Nox4 in fibrosis 
Byrne et al (Byrne et al., 2003) also demonstrated an increase in Nox4 protein 
expression following AngII infusion.     
The evidence for cardiac fibrosis secondary to the pressor effect of aortic 
banding is conflicting. Matyn et al (Maytin et al., 2004) published evidence that 
Nox2 oxidase did not play an important role in cardiac fibrosis in this model as 
myocardial fibrosis was increased to a similar level in both wild type and Nox2 -/- 
mice. In contrast Greive et al (Grieve et al., 2006) demonstrated a reduced level 
of fibrosis in the Nox2-/- mice implicating an important role for the Nox oxidase 
in myocardial fibrosis following aortic banding. 
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In summary the data would suggest an important role of Nox2 in AngII 
induced cardiac fibrosis independent of any pressor effect. The activation of the 
MR is also important in this AngII induced cardiac fibrosis. More recently Nox4 
has been found to be important in the development of cardiac fibrosis, the 
expression of the oxidase being upregulated by both TGF-β1 and AngII. The role 
of Nox2 is conflicting in a mechanical pressure overload model as seen after 
aortic banding.  
1.10 CELLULAR SOURCE OF NOX2 
The development of cardiac fibrosis is a complex process involving the 
interactions of multiple cells. The evidence in support for the common 
dependence on  Nox2 for the development of cardiac fibrosis in several cardiac 
pathologies has been suggested (Grieve et al., 2006; Johar et al., 2006; Looi et 
al., 2008). A key question is how Nox2 drives this cardiac fibrosis. Nox2 is 
expressed in cardiac fibroblasts, endothelial cells and in 
monocytes/macrophages, and an obvious possibility is that the  cellular 
expression of Nox2 in any of these cell types may be an important factor. 
 For example the Nox2 in circulating monocytes could be important in 
driving the conversion of the monocyte phenotype to a pro-inflammatory one 
which encourages cardiac infiltration. Conversely endothelial production of ROS 
may also be important with respect to endothelial activation and the attraction 
of pro-fibrotic inflammatory cells (Grafe et al., 1997; Li and Shah, 2003; Li and 
Shah, 2004; Pueyo et al., 2000). As such it is known that the adhesion of 
circulating monocytes  to the endothelium of the vessel wall and the subsequent 
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migration  of the cell into the heart is an essential step in the development of 
cardiac fibrosis (Kuwahara et al., 2003). Once in the heart, macrophages can 
release cytokines to stimulate the transformation of fibroblasts to 
myofibroblasts and thus increased production of collagen, a pivotal step in the 
development of cardiac fibrosis (Weber et al., 1993). Nox2 in the fibroblast could 
be critical for the transformation of the fibroblast to an activated phenotype. The 
cell-specific contribution of Nox2 remains to be established, in which  the 
activation of Nox2 is critical for the development  of the fibrotic process. 
 
1.11 AIM 
The aims of this thesis were: 
 To investigate the role of Nox2 in the redox response of cardiac 
fibroblasts. 
 To investigate the role of Nox2 in macrophage migration and their 
circulating inflammatory profile. 
 To investigate the contribution of Nox2 in circulating inflammatory cells 




2 ROLE OF NOX2 IN ANGIOTENSIN II STIMULATED 
ROS RESPONSE IN CARDIAC FIBROBLASTS 
 
2.1 INTRODUCTION 
During normal cardiac function cellular components of the heart interact 
in a dynamic fashion to respond to changes in development, homeostatic and 
pathological stimuli. The main cellular constituents of the heart include cardiac 
fibroblasts, myocytes, endothelial cells and vascular smooth muscle cells with 
the majority of the cells consisting of fibroblasts and cardiac myocytes (Camelliti 
et al., 2005). Cardiac myocytes occupy approximately 75% of normal myocardial 
tissue volume, but they account for only 30–40% of cell numbers (Baudino et 
al., 2006; Vliegen et al., 1991). The majority of the remaining non-myocyte cells 
are fibroblasts. Fibroblasts are found throughout the cardiac tissue, surrounding 
myocytes and contribute to the structural, biochemical, mechanical and 
electrical properties of the myocardium (Kohl and Noble, 1996; MacKenna et al., 
2000; Sun et al., 2002a). Moreover these cells help maintain the ECM 
homeostasis of the heart via the autocrine and paracrine action of secreted 
factors as well as via direct cell-cell interaction (Baudino et al., 2006; Camelliti 
et al., 2004; Camelliti et al., 2005; Gaudesius et al., 2003; Manabe et al., 2002; 
Sussman et al., 2002).  Alterations in these signals or biochemical input can 
cause deleterious, adaptive and/or compensatory changes in the heart. Cardiac 
fibrosis is frequently associated with myocardial remodelling as in ischemic and 
rheumatic heart disease, inflammation, hypertrophy, and infarction. The 
increase in fibrous tissue content and the synthesis of extra-cellular matrix 
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(ECM) proteins is reliant on the proliferative and secretory potential of 
fibroblasts.  
2.1.1  IDENTIFICATION OF FIBROBLASTS  
Traditionally fibroblasts are defined as cells of mesenchymal origin that 
produce interstitial collagen and have classically been viewed as a uniform cell 
type. This view has been challenged as fibroblasts have been shown to 
demonstrate extensive phenotypic heterogeneity according to the different 
tissue and the physiological condition of the tissue from which they are 
harvested (Chang et al., 2002; Fries et al., 1994; Lekic et al., 1997). 
Morphologically cultured fibroblasts are flat spindle shaped cells with multiple 
processes emanating from the main cell body. They tend to display a prominent 
Golgi apparatus and extensive rough endoplasmic reticulum especially when 
active. The lack of a truly specific marker has long been a limiting factor in 
studying fibroblasts in vivo. The intermediate filament vimentin is abundant in 
cardiac fibroblasts and has been used as a marker to identify cardiac fibroblasts 
(Camelliti et al., 2005). However this marker is also present in other cell types, 
for example vascular endothelial cells. Nevertheless given the characteristic 
cyto-morphological differences between these cell types, vimentin has been a 
suitable tool for reliable identification of cardiac fibroblasts.  
A more specific marker for cardiac fibroblasts is the collagen receptor 
Discoidin Domain Receptor 2 (DDR2) (Goldsmith et al., 2004). DDR1 and 
DDR2 represent a relatively novel family of collagen specific receptor tyrosine 
kinases involved in the conversion of extracellular stimuli into cellular 
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responses. These receptors mediate a variety of cell functions, including growth, 
migration, morphology and differentiation. The tissue distribution of DDR1 and 
DDR2 varies and can be mutually exclusive. DDR2 expression has been detected 
in both rat and mouse heart. Originally defined as a collagen receptor on 
mesenchymal cells, DDR2 has also been found on leukocytes, as well as in 
tumours, but importantly not on cardiomyocytes, cardiac endothelial or smooth 
muscle cells (Camelliti et al., 2005; Goldsmith et al., 2004). Therefore, in the 
heart, the DDR2 receptor is fibroblast specific. Another marker that has been 
proposed to be fibroblast specific is fibroblast-specific-protein-1. However 
studies in the literature have shown FSP-1 to be expressed in other cells 
including leukocytes (Mazzucchelli, 2002). 
2.1.2  MYOFIBROBLASTS AS NOX2 EXPRESSING CELLS  
 Fibroblasts are phenotypically heterogenous and under appropriate 
conditions, resting or quiescent fibroblasts can acquire an active, synthetic, 
contractile phenotype termed myofibroblast. The myofibroblasts express several 
smooth muscle cell markers that are not typically expressed in fibroblasts 
(Tomasek et al., 2002).  These myofibroblasts are more mobile than fibroblasts 
and can contract collagen gels and are therefore thought to be important in 
wound closure of healing scars (Sun and Weber, 2003). Indeed research has 
shown that myofibroblasts  play a key role in the reparative fibrosis following 
myocardial infarction (Calderone et al., 2006).  
Fibroblasts can respond to a wide range of different stimuli including 
hypoxia, hormonal (e.g AngII) and mechanical (e.g. stretch).   TGFβ1, cytokines 
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and other growth factors (Kaden et al., 2005; Serini et al., 1998; Tamaoki et al., 
2005; Walker et al., 2004) have been shown to transform fibroblasts to 
myofibroblasts.  In keeping with this, stimulation of cardiac fibroblasts by TGFβ1 
has also has been shown to increase the synthesis of collagen, fibronectin, and 
proteoglycans (Dobaczewski et al., 2010; Eghbali et al., 1991; Heimer et al., 
1995; Leask, 2007; Villarreal et al., 1996). 
In  global knockout experiments, ROS and more specifically Nox2 was 
shown to be important in the process of aldosterone or AngII induced cardiac 
fibrosis or pressor induced hypertrophy (Bendall et al., 2002a; Byrne et al., 
2003; Johar et al., 2006). However the exact cell source of the Nox2 critical in 
this process was not identified. Loss of Nox2 in a range of different cell types 
could be important including cardiac myocytes, endothelial cells, fibroblasts or 
macrophages. In particular, Nox2 in  cardiac fibroblasts could be an important 
cell source. AngII is the effector molecule of the RAS, and cardiac fibroblasts can 
express angiotensinogen, renin and ACE, allowing them to produce AngII locally 
in the heart (Sanghi et al., 2005). Also, AngII stimulation has been shown to 
increase collagen production and secretion from cardiac fibroblasts (Autelitano 
et al., 2003; Lijnen et al., 2001). As stimulation by AngII is known to be 
mediated by Nox2, cardiac fibroblasts could be a possible cell source of the 
Nox2, the loss of which in AngII stimulated mice resulted in a loss of fibrosis 
and hypertrophy. In this chapter, the ROS response mediated by Nox2 in 
cardiac fibroblasts following AngII stimulation is investigated. 
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2.1.3  AIM 
The aims of this chapter were to develop an in vitro model using murine 
primary cardiac fibroblasts to investigate the role of the Nox2 isoform of 




2.2.1 CREATION OF NOX2-/- MICE 
Experiments were conducted in WT and Nox2-/- male littermate controls 
on a C57BL/6J background. Nox2-/- mice have previously been reported as a 
model of chronic granulomatous disease by homologous recombination and 
have a neomycin resistance cassette inserted in exon 3 of the Nox3 subunit on 
the X chromosome.  Phagocytic cells from Nox2-/- mice do not exhibit an 
oxidative burst after stimulation with phorbol myrisate as compared with WT 
mice. However there is no obvious phenotype apart from an increased 
susceptibility to certain infection (Pollock et al., 1995).  
These mice were originally obtained from the Jackson Laboratory and a 
colony bred at the Comparitive Biology Unit at Kings College London. 
Subsequently, the animals were backcrossed with the C57BL/6J strain 
established in the unit to minimize possible general variability. Determining the 
phenotype to confirm the presence or absence of the Nox2 gene, in isolated 
genomic DNA from each individual mice, genotyping was performed. Ear 
punches harvested under anesthesis (2.5% isoflurane/97.5% Oxygen (2L/min)) 
were digested in a solution of Proteinase K (10mg/ml) Roche, UK) in an alkaline 
buffer (0.1M Tris EDTA, 0.1M NaEDTA, 1%SDS and 0.15M NaCl, pH 8.0) for 2-
4 hours at 55oC cDNA was precipitated in isopropanol, washed with 80% 
ethanol and resuspended in TE buffer (imMEDTA, 10mM Tris pH 8.0). 
Amplification of resultant cDNA was conducted in a thermal cycler (AB Applied 
Biosystems, (UK) involving 35 cycles of denaturing (30sec at 94oC), annealing 
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(30sec at 56oC) and synthesis (30sec at 72oC). A duplex reaction reaction on 1μL 
of DNA was achieved using primers (10μM) for Nox2 in a 25μL total reaction 
volume containing 12.5μL Red Taq Ready Mix, 0.5μL forward primer, 0.5μL 
reverse primer1, 1μL of reverse primer2 (Table) and 9.5μL nuclease free  water. 
Subsequent polymerase chain reaction (PCR) products were separated by 
electrophoresis on a 1.5% agarose gel containg Ethidium Bromide (400ng/mL) 
in 40 mM Tris-acetate, 1 mM EDTA and visualised under ultraviolet light. A 
single band at ~240basepairs (bp) confirmed WT status, a single band at ~195bp 
confirmed a Nox2-/-, whereas a double band at ~240bp and 195bp respectively 
confirmed heterozygote.  
 
2-1 Primer used in genotyping 
Primer sequence  
Forward AAG AGA AAC TCC TCT GCT GTG AA 
Reverse1 CGC ACT GGA ACC CCT AGA AAA GG 
Reverse2 GTT CTA ATT CCA TCA GAA GCT TAT CG 
     
 
2.2.2  HARVESTING  PRIMARY CARDIAC FIBROBLAST BY COLLAGENASE DIGESTION  
Mice were heparinised and terminally anaesthetised with pentobarbitone 
sodium by intraperitoneal injection. Following a midline incision of the thorax, 
hearts were excised and transferred immediately into cold, sterile-filtered Krebs 
Henseleit buffer (KHB, containing NaCl 120mM, KCl 5.7mM, NaH2PO4 
1.38mM, MgSO4 0.66mM, Glucose 10mM, HEPES 20mM, pH 7.2 – 7.4). Hearts 
were then rinsed twice in KHB and transferred to a dry petri dish. 5 drops of 
Liberase enzyme (1mL Liberase Blendzyme IV, 200l 2.5% Trypsin, 360l 
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HEPES 1M, 35l Hank’s Balanced Salt Solution) was added and heart tissue was 
finely minced before it was transferred into a 20ml glass bottle. 4-5ml of 
Liberase was added to the chopped heart tissue in the bottle and placed in a 
warm (37°C) shaking water bath for 10 minutes. The bottle was then removed 
and allowed to stand. Once the undigested tissue had settled, the supernatant 
was aspirated, added to 10mls of cold, sterile KHB and placed on ice. 2-3mls of 
fresh Liberase was added to the remaining tissue and replaced in the shaking 
water bath for a further 5 minutes of digestion. The last step was repeated until 
all the heart tissue had been digested typically taking 5-6 cycles. The tubes 
containing the tissue digest and KHB were centrifuged at 1200rpm, at 40C for 5 
minutes. The pellet was then resuspended in 10mLs of KHB and spun down 
again. The supernatant was again removed and the primary cardiac fibroblast 
(PCF) cells resuspended in 5mL of Dulbecco’s modified Eagle’s medium, 
(DMEM, with 10% foetal calf serum FCS, 5% Penicillin/Streptomycin, 5% L-
Glutamine). The PCFs were then placed into T75 tissue culture flasks that had 
been pretreated with 1% gelatin for 1 hour, and incubated  in a CO2 incubator 
for the cells to attach and grow for 12 hours. The PCFs were passaged in a 1:2 
ratio and used at passage 2. The cells were passaged by washing the flasks with 
PBS and detaching the cells with 0.25% trypsin (with EDTA). The trypsin was 
neutralised with FCS and the cells pelleted by centrifuging at 1200rpm for 5 
minutes. The pelleted cells were resuspended in fresh DMEM media and placed 
into a newly prepared T75 flask.  
 
 67 
2.2.3  IMMUNOCYTOCHEMISTRY OF PRIMARY CARDIAC FIBROBLASTS 
Five thousand passage 2 WT PCFs were plated onto glass bottomed 
LabTek chamber slides (precoated with 1% gelatin), fixed with 10% methanol, 
and blocked with 5% goat serum and 3% BSA. Cells were incubated with primary 
antibody for 90mins at room temperature. (Table 2.1) A anti-DDR2 primary 
antibody (Santa Cruz, USA) for tyrosine kinase receptor for collagen was used to 
positively identify fibroblasts. The secondary antibody was incubated for 30mins 
and the slides viewed under a Zeiss Axioskop 2 microscope and images taken 
with appropriate filters. The endothelial cell specific marker von Willebrand 
factor (vWF) was used to identify endothelial contamination. 
 
 
Table 2-2 Primary and secondary antibodies for immunocytochemistry  
 Primary Secondary 
DDR2 Rabbit anti-DDR2 
(1:10) 
Alexa 488 conjugated goat anti-rabbit IgG 
(1:200) 
vWF Rabbit anti-vWF 
(1:200) 




2.2.4  FLOW CYTOMETRY OF PRIMARY CARDIAC FIBROBLASTS 
WT PCF from passage 0 and passage 1 were used to assess the purity of 
the cell isolation with FACS. Samples of 100,000 cells were suspended in cold 
PBS and kept on ice. Cells were positively identified by incubation with an 
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antibody against the fibroblast surface antigen CD90, conjugated with 
fluorescein-isothiocyanate (FITC) (1:10 concentration, 30mins incubation). To 
identify if there were any endothelial cells present in the isolation, the cells were 
incubated with an antibody against endothelial cell-specific vWF (1:200, 
30mins). Samples were assayed in the FACSVantage machine (Becton 
Dickinson) using an excitation wavelength of 488nm and emission wavelength 
of 510nm along with the appropriate non-specific IgG controls. 10,000 events 
per sample were recorded. The counts (cell number) were plotted against 
fluorescence (Long scale) using CellQuest software. 
 
 
2.2.5  CHEMILUMINESCENCE MEASUREMENT OF  ROS PRODUCTION  
Assessment of changes in superoxide production in PCF from aldosterone 
or angiotensin stimulation were undertaken using lucigenin enhanced 
chemiluminescence (LEC). Luminometric assays, among other techniques, 




and Janiszewski, 2005). Levels of superoxide production from PCF were 
determined using the LEC with a Lucy 1 luminometer machine (Rosys Anthos, 
Austria). Lucigenin is an acridylium dinitrate compound that emits light on 
reduction by interaction with superoxide anion. The relevant reactions of the 





















LucigeninO2 → 2N-methylacridone + hν (light)  
The flux of photons (hν) emitted is measured in terms of LEC intensity 
and taken as representing superoxide anion levels, especially at low lucigenin 
concentration (5μM ). High concentrations (200 μM) of lucigenin can cause a 
large increase in LEC by itself,  partially due to redox cycling (Munzel et al., 
2002; Pagano, 2001)   NADPH (300μM)  is added to maximise O2-  production 
associated with the NADPH oxidase (Brandes and Janiszewski, 2005; Munzel et 
al., 2002).    
 
 
2.2.5.1 Homogenate Method 
PCFs from WT and Nox2-/- mice were plated onto 10cm Petri dishes 
(60cm2) in DMEM (10% FCS & 25mM glucose). The plates were pre-coated in 
1% gelatine/PBS and seeded at 300,000 cells/dish and allowed to settle 
overnight. Cells were serum starved for 24 hours with serum free DMEM (5mM 
glucose). After 24hrs of serum starvation the appropriate stimulation was added 
for a further 24hrs. The medium was removed and the plate washed with PBS 
and the cells dislodged by scraping in 400μl of buffer B (50mM monobasic 
potassium phosphate, 1mM EGTA, 150mM sucrose, pH 7.0) with 2μl of protease 
inhibitor cocktail. The cells were homogenised with a Polytron PT2100 
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homogeniser for 10 second bursts. All samples were kept on ice and their protein 
concentrations determined using the Bradford colorimetric technique.  
Ten μg of the cell homogenate sample was loaded onto a 96 well 
microplate containing buffer B to make the total volume 75μL. Arachadonic acid 
(30 μM) was added for 5 minutes as a positive control to demonstrate cellular 
ROS production  in response to physiological stimulation. Inhibitors were also 
added 5 minutes prior to the addition of NADPH. ROS production was 
stimulated by adding NADPH (300μM) to each well followed by dark-adapted 
lucigenin (5μM final conc). Readings were taken every minute for 20-30 




A standard bovine serum albumin (BSA) concentration curve was 
generated. 950μl of a 1 in 5 dilution of BioRad dye reagent from the BioRad 
assay kit (BioRad Laboratories, Germany) was added to 50μl of BSA standards 
(0 - 0.5μg/μl). Light absorbance was measured by a spectrophotometer 








Inhibition of NADPH 
The enzymatic source of NADPH-stimulated LEC in the PCF was 
determined pharmacologically using the following inhibitors in Table 2.2 with 5-
min preincubation.  
 
 
Table 2-3 Inhibitors used to determine the source of ROS production  
  INHIBITORS SITE OF ACTION 
1)      Diphenylene iodonium (DPI) (10µM) 
Inhibits all flavoprotein including NADPH 
oxidase 
2)      Rotenone(2µM) 
Mitochondrial respiratory chain complex I 
inhibitor  
3)      
Nitro-L-arginine methyl ester  
(L-Name) (100µM) Nitric oxide synthase inhibitor  
4)      
Thenoyltrifluoroacetone (TTFA) 
(10µM) 
Mitochondrial respiratory chain complex II 
inhibitor  
5)      Allopurinol(100µM) Xanthine oxidase inhibitor  





2.2.5.2 Adherent whole-cell method 
WT and Nox2-/- PCFs from passage 1 were seeded onto gelatin-coated 96 
well microplates (5000 cells/well) in DMEM with 0.5% serum and left to settle 
overnight. The cells were incubated with appropriate stimulation, namely AngII 
(10-7  M) for 24 hrs. Following stimulation the cells were washed with PBS and 
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75μL of intracellular (IC) solution (140mM KCL, 1 mM EGTA, 6 mM glucose, 
20mM K-PIPS, 1 mM MgCl2, ph 7) was placed into the wells. To enable NADPH 
and lucigenin to enter the cells, the PCFs were permeablised by adding 2μL of 
0.5% Saponin to each well. AA (30 μM) was added 5 mins prior to the addition 
of NADPH as a positive control to show the cells were viable and able to 
respond.  ROS production was stimulated by adding NADPH (300μM) to each 
well followed by dark-adapted lucigenin (5μM). Readings were taken every 








2.2.7  STATISTICAL ANALYSIS  
NADPH-stimulated LEC was measured for 20mins. LEC increased over 
the first 10-15 mins and then gradually plateaued. As such the area under the 
curve (AUC) in arbitrary units represented the cumulative LEC over 20mins. 
The values are presented as means +/- SEM. Statistical significance was 
investigated by fitting regression models to the AUC data. STATA statistical 
software package was used and a p-value of less than 0.05 was considered 
significant.   
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2.3 RESULTS 
2.3.1  CHARACTERISATION OF FIBROBLASTS 
2.3.1.1 Bright field and immunocytochemistry 
The light field image (Figure 2.1) showed no cardiac myocytes as they 
have been destroyed in the collagenase digestion process. The majority of the 
cells are cardiac fibroblasts contaminated with some endothelial cells. Cardiac 
fibroblasts appeared spindle-like in shape and spread out. (Figure 2.1A, B & C) 
In comparison the endothelial cells were smaller in size and clump together to 
form cobblestone-like patches. (Figure 2.1C) The shapes of the WT PCFs varied, 
consistent with fibroblasts being phenotypically heterogenous. 
PCFs were identified with DDR2 staining (Figure 2.2 A & B) and 
compared to that of the 3T3 fibroblast cell line (Figure 2.2 C). Both cells showed 
the speckled staining of DDR2. Assesment of several slides under low power 
showed that majority of the cells were cardiac fibroblasts.  Fibroblasts stained 
with non-specific IgG negative control showed little background staining. A 
small number of contaminating endothelial cells were identified by staining for 




Figure 2-1Primary cardiac fibroblast 
Images of WT PCFs. A) and  B) illustrates PCFs at X20 magnification and C) illustrates PCFs 







Figure 2-2 Immunocytochemistry staining  
Immunofluoresence images (X40 magnification)  for DDR2 in WT PCFs (A and B) and 3T3 
fibroblast cell line (C) while (D) shows endothelial cells stained for von Willebrand factor.  
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2.3.1.2 FACS analysis 
Flow cytometry was performed on WT PCFs passage 0 or 1 in order to 
quantify the purity of the cell isolation. The endothelial cells survive the 
collagenase digestion and comprise the main contaminating cell population in 
the initial harvested cell population. In order to quantify the percentage of 
endothelial cell contamination flow cytometry was undertaken for vWF (Figure 
2.3 A & B). The gated M2 region in the non-specific TgG control was set to 
overlap with 5% of the non specific binding profile. (Figure 2.3 A) The M2 gated 
region in for the vWF FACS profile counted 10% of cells positive for vWF. 
(Figure 2.3 B) Therefore after substraction of the 5% background of the non-
specific IgG control resulted in a 5% contamination of the cardiac fibroblast with 
endothelial cells. However with passaging due to the numerically larger 
population of cardiac fibroblasts and their potential for vigorous growth they 
outgrow the contaminating endothelial cells (Table 2.3). 
As no working antibody towards DDR2 was available for FACS this 
prevented the positive identification of the number of cardiac fibroblast in the 
initial cell isolation. Nevertheless an antibody against the surface antigen 
Cluster of Differentiation 90 (CD90) was available. In the heart this antigen is 
only expressed on fibroblasts. However the level of expression of CD90 varies 
between fibroblasts of different origin.  Approximately 60-80% of orbital 
fibroblasts express CD90 (Tang et al., 2006). In contrast only 28%  of fibroblasts 
from the lung of F344 rats and 15% in LEW rats are CD90 positive (McIntosh et 
al., 1994). Therefore it was anticipated that CD90 would not identify all the 
cardiac fibroblasts. (Figure 2.3 C)  Quantification was performed as previously 
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with the M2 gate set at 5% for non-specific antibody binding. This was 
subtracted from the CD90 FACS value to give an average of 52%. Thus it appears 
in primary cardiac fibroblasts 52% of cells express CD90 and can be positively 





Figure 2-3  FACS profile of WT PCFs 
FACS profile showing fluorescence (X axis: log scale) against counts (Y axis: cell 
number). (A) shows the IgG control with gates M1 set to catch 95% of the counts and 
gate M2 set to catch 5% of the counts. (B) illustrates an increase in the count in gated 
region M2 (black arrow). This was a 5% increase in the cell count  for vWF expression. 
(C) illustrates a similar set up with M1 and M2 gated regions. The control non-specific 
IgG (purple) and CD90 (green) FACS profile are shown. There was a 52% increase in 




Table 2-4 Percentage of endothelial contamination assessed by FACS 
 The percentage of endothelial cell contamination decreases with passaging  





















2.3.2 HOMOGENATE: STIMULATION OF PCF WITH ANGII DID NOT INDUCE A 
ROS RESPONSE  
The aim of the method was to measure the ROS production in 
homogenized PCFs after they had been stimulated with physiological 
concentrations of agonists. However, the intracellular ROS concentration of 
superoxide rarely exceeds 10 nM (Tarpey et al., 1999). As a result 10μg of 
protein was required to enable the measurement of basal levels of superoxide 
production.  
No significant change in ROS production was observed with either 
aldosterone or AngII stimulation in both WT or Nox2-/- PCF. (Figure 2.4) 
Similarly no increase in ROS was observed following TGFβ1 stimulation in 
WT PCF. The change in ROS production following stimulation with a range 
of different agonist has been quantified and tabulated in Table 2.4. Only AA 
stimulation resulted in a highly significant increase (p=0.002) in the ROS 
production in WT PCF (mean 3.901;95%CI 1.5-6.3 units) which was inhibited 
with DPI. This demonstrated that the WT homogenate was able to increase 
ROS production following  agonist stimulation of a Nox isoform in a 
homogenate set up.  
Under basal conditions, Tiron, the superoxide scavenger, significantly 
decreased ROS measurement in WT PCFs. (Figure 2.5) Similarly DPI, the 
flavoprotein inhibitor, caused a significant reduction in ROS production in 
both WT and Nox2-/- PCFs (Nox2-/- graph not shown). (Table 2.5) Together 
this suggests that our lucigenin assay was measuring superoxide and that 
NADPH oxidase was the main source of the basal ROS production in the WT 
PCFs. However the inhibition of ROS in the Nox2-/- PCFs by DPI would 
suggested the possible presence of another Nox isoform as a contributing 
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source for the basal ROS levels. In contrast  Rotanone and TTFA the 
mitochondrial site inhibitors, L-NAME the NOS inhibitor and allopurinal the 
xanthine oxidase inhibitor all caused a non significant reduction in the level 
of basal ROS production.  
The main disadvantage of the homogenate technique was the large 
number of cells (300,000/60 cm2 gave 3-4 triplicates of 10μg of protein) and 
therefore animals required for each experiment. As a result of this the 
adherent whole cell method was established with the aim of reducing the 
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Figure 2-4 ROS production in WT and Nox2-/- homogenates following stimulation 
with agonist 
There was no difference in the baseline ROS production between WT and Nox2 -/- PCFs.  
Stimulation with arachidonic acid demonstrated a significant increase in ROS 
production.  No significant increase was seen following stimulation with the other 
agonists. 
 
Table 2-5 Change in ROS production in WT and Nox2-/- homogenates following 
agonist stimulation 
Stimulation 
Difference in AUC 
from WT controls p-value 95% Conf.Interval 
Aldo (10μM) WT n=7 0.259 0.457 -0.436 0.953 
Ang (10μM) WT n=4 0.968 0.109 -0.226 2.162 
AA (30μM) WT n=2 3.901 0.002 1.508 6.294 
TGF (10ng/ml) WT n=2 0.757 0.637 -2.419 3.932 
 
Difference in AUC 
from Nox2-/- controls    
Aldo (10μM) NoxKO n=7 0.551 0.598 -1.540 2.642 
Ang (10μM) NoxKO n=3 -0.926 0.470 -3.488 2.642 
Control: WT n=8  NoxKO n=7  
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Figure 2-5 Average pharmacological inhibitor profile of ROS production in WT 
PCF homogenate. 
 All the inhibitors resulted in a reduction in basal ROS production. Statistically 
significant inhibition was seen only with DPI and Tiron. Similar profile was observed 
with Nox2-/- PCFs.  
 
Table 2-6 Reduction in ROS production following pharmacological inhibition in 
WT and Nox2-/-  homogenate 
Inhibitors 
Difference in AUC from 
control in WT p-value 95% Conf.Interval 
DPI n=4 -1.682 0.003 -2.782 -0.582 
Rotenone n=7 -0.486 0.120 -1.101 0.129 
TTFA n=6 -0.318 0.204 -0.811 0.175 
L-Name n=6 -0.250 0.305 -0.732 0.231 
Allopurinol n=5 -0.059 0.818 -0.570 0.451 
Tiron n=3 -1.465 <0.001 -1.951 -0.980 
 
Difference in AUC from 
control in Nox2
-/- 
   
DPI n=2 -1.47 <0.001 -2.15 -0.80 





2.3.3 ADHERENT WHOLE-CELL ROS MEASUREMENT  
A significant disadvantage of the homogenate based method was that 
large numbers of cells were required to provide sufficient protein to assess 
baseline and stimulated ROS production. Since the adherent cell method 
allows the assessment of ROS in a whole-cell format, this ROS production 
may more truely reflect the balance between oxidation and antioxidative 
pathways and be more representative of the in vivo situation. Furthermore 
homogenising the cells may obscure a small stimulatory effect of aldosterone 
or angiotensin II by disrupting ROS localisation and cellular signalling 
pathways.  
There is no known mechanism to transport NADPH into intact cells. 
Additionally, lucigenin, which is a large molecule of 510.1 daltons in size, has 
been reported to react exclusively with extracellular ROS production in intact 
neutrophils (Dahlgren et al., 1985). Consequently, to ensure the unrestricted 
access of NADPH to the inside of the cells saponin, a mild detergent that 
creates pores in cholesterol containing membranes, was used to permeablise 
the cells (Francis et al., 2002). A previous study has reported that cells 
permeabilised with 0.05% saponin showed no loss of cell viability (Endo and 
Iino, 1980).  
2.3.3.1 Surface coating influenced basal ROS production 
Extracellular matrix (ECM) has been shown to stimulate ROS 
production. Fibronectin and laminin stimulated  ROS production by 
activation of Nox4 through products of the phospholipaseA2 
(PLA2)/lipoxygenase (LOX) pathway (Edderkaoui et al., 2005).  Therefore 
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the change in basal ROS production in WT PCF was investigated. Cells were 
added to 96 well plates which were pre-coated with  fibronectin, laminin, 
collagen and gelatin for 16 hrs. Laminin, fibronectin and collagen are 
commonly used in our laboratory for coating cell culture plates to encourage 
cell adherence. 
PCF seeded onto any of the coated surfaces had a significantly higher 
basal ROS production as compared to cells on an uncoated surface. (Figure 
2.6) However this increase may simply be the result of increased number of 
cell adherence to the plate.  Since the basal ROS levels were not significantly 
different between the different coated surfaces (Table 2.6) and as gelatin was 




Figure 2-6 Basal ROS production in WT PCF in response to different surface 
coatings.  
The wells were pre coated for 16hrs with either 25ng/ml of fibronectin, 25ng/ml 
laminin or 10ng/ml of gelatin or collagen. Excess coating was removed and the PCFs 











gelatin coating p-value 95% Conf.Interval 
Gelatin (n=3) 17.487 - - - - 
un-coated (n=3) 6.044 -9.457 <0.001 -11.426 -7.489 
Fibronectin (n=3) 15.086 -2.059 0.143 -4.880 0.763 
Laminin (n=3) 20.303 1.054 0.328 -1.145 3.253 






2.3.3.2 Assessment of the effect of washing on ROS production 
After permeabilisation of the adherent cells with saponin constituents 
present in the medium can enter the cell and scavenge the ROS such as BSA. 
Also pyruvate is present in the cell culture media, which can bolster the 
endogenous glutathione antioxidant system and thus reduces ROS (Mallet, 
2000). Similarly it has been reported that the pyruvate in myocardial 
homogenates, dose dependently, reduced ROS production. However 
incorporation of a wash step to remove all traces of the culture media could 
lead to cellular detachment. To assess the effect of these factors, baseline 
ROS production of WT and Nox2-/- cells seeded onto gelatine coated 96 well 
plates was assessed in media, after removal and replacement of medium with 
75μL IC solution and after the removal of media, washing with PBS and 
replacement with 75μL IC solution.  
 The results demonstrate that ROS levels both in WT and   Nox2-/- 
were significantly (p<0.001) lower when measured in medium as compared 
to IC solution. (Figure 2.7 & Table 2.7) Inclusion of a further PBS wash step 
had no significant effect on the basal ROS measurements. In order to 
eliminate the possible quenching effect of medium on ROS production in all 
future experiments media was removed, cells washed with PBS and IC 






Figure 2-7 ROS levels in WT and Nox2-/- cells with different wash protocols. 
Basal ROS levels were measured in WT and Nox2-/- in media or media replaced with IC 
solution or media removed, 96 well washed with PBS and replaced with IC solution. 
ROS measurement was significantly lower in medium as compared to IC solution. The 
additional wash step did not significantly alter the basal ROS measurement.   
    














PBS wash 30.519 2.329 - - - - 
no PBS wash 34.835 3.199 4.316 0.280 -3.588 12.219 
media 13.206 3.200 -17.312 <0.001 -25.216 -9.409 
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2.3.4 WHOLE CELL ADHERENT: STIMULATION OF PCF WITH ANGII DID NOT 
INDUCE A ROS RESPONSE   
Baseline ROS levels in whole adherent Nox2-/- PCFs were significantly 
higher than that measured in WT. (Table 2.8 & 2.9) The effect of aldosterone 
and AngII at a range of different concentrations was examined in both WT 
and Nox2-/- PCFs. The dose response curves were performed at 
concentrations of 10-9 M to 10-6 M for both aldosterone and AngII. No 
stimulatory ROS effect of either aldosterone or AngII was seen at any of the 
concentrations used. (Table 2.8) Arachidonic acid was used as a positive 
control and the response to the classical profibrotic agonist TGF was also 
assessed. AA significantly increased the ROS levels in both WT and Nox2-/- 
PCF by a similar amount. (Table 2.8 & 2.9) However TGFβ only induced a 












SEM N Average 
ROS levels 
SEM N 
Unstimulated  30.787 1.512 8 48.115 3.181 4 
AA (30μM ) 57.033 3.747 7 75.303 4.521 3 
TGFβ (10ng/ml ) 35.388 1.272 7 50.550 3.606 3 
Aldosterone 10
-9
M  34.008 2.104 3 - - - 
Aldosterone 10
-8
M  28.253 2.767 3 - - - 
Aldosterone 10
-7
M  29.160 2.258 3 - - - 
Aldosterone 10
-6
M  30.250 1.939 8 48.048 4.352 4 
Angiotensin II 10
-9
M  30.840 3.337 3 - - - 
Angiotensin II 10
-8
M  29.148 2.140 3 - - - 
Angiotensin II 10
-7
M  34.701 1.609 8 49.048 3.587 4 
Angiotensin II 10
-6





Table 2-10 Summary of  ROS production in WT and Nox2-/- following stimulation 
with AA or TGFβ 
Comparisons Difference p-value 95% Conf.Interval 
Baseline ROS levels WT vs NoxKO 17.329 <0.001 9.017 25.640 
ROS stimulation by AA in WT 26.246 <0.001 18.338 34.154 
ROS stimulation by AA in NoxKO 27.188 <0.001 20.381 33.995 
ROS stimulation by TGF in WT 4.601 0.003 1.600 7.602 




2.3.4.1 Inhibition of ROS production in adherent WT and Nox2 -/ - PCF 
showed a similar source of basal ROS production 
A range of pharmacological inhibitors were used to investigate the 
source of ROS. NADPH is a substrate for a number of different enzymes and 
the use of pharmacological inhibitors helps to define the percentage of ROS 
production attributable to NADPH oxidase. As there was no stimulatory 
increase in ROS production with aldosterone or angiotensin II only the 
difference in basal ROS production between WT and Nox2-/- PCFs was 
investigated.  
The inhibition profiles looked similar in both WT and Nox2-/- PCFs in 
that DPI and Tiron completely eliminated the ROS production whereas 
rotenone only partially decreased it. (Figure 2.8) This partial reduction in 
ROS production by rotenone was not observed in the homogenate method. 
Statistical analysis demonstrated that DPI, rotenone and Tiron all decreased 
the basal ROS level significantly (p<0.001). However further comparison 
between DPI and rotenone demonstrated that DPI decreased the basal ROS 
level significantly more than rotenone (p<0.001) This suggests that 
mitochondrial ROS contributed 51% of the measured ROS production and 







Figure 2-8 Inhibitor profile of baseline ROS production in adherent WT and  
Nox2-/- PCFs 
PCFs (5000 cells/well) were incubated for 24hrs. Inhibitors were added 5 minutes 
prior to measurement. DPI (10μM) and Tiron (5mM) abolished all ROS production. 
Rotenone (10 μM) demonstrated a partial reduction in the ROS level. This pattern was 






AngII stimulation of rat cardiac fibroblasts has been shown to increase 
collagen production which is required for the development of fibrosis  (Lijnen 
et al., 2001). The lack of fibrosis following AngII stimulation in Nox2-/- mice 
suggested that the process was redox sensitive and in particular Nox2 
dependent. Therefore the ROS response in cardiac fibroblasts, and in 
particular that from Nox2, to AngII stimulation was investigated in this 
chapter. 
2.4.1 CELL CULTURE AND ROS MEASUREMENT 
A cell culture model for adult mouse cardiac fibroblasts was developed 
to investigate the ROS response to AngII stimulation.  Although the use of a 
cell culture approach isolates the PCFs from their local environment in the 
heart it does enable the investigation of the response in that particular cell in 
isolation. Most studies in the literature have been carried out in neonatal or 
adult rat cardiac fibroblasts. The isolation of PCFs from adult mouse heart by 
collagenase digestion is a very sensitive process. Initial isolation attempts 
were unsuccessful with Worthington’s collagenase type 2 despite using 
identical protocols. A change to Liberase Blendzyme IV Roche, which is a 
mixture of collagenase type 1 and 2, proved successful.  
Fibroblasts were identified by their spindle shaped morphology and 
DDR2 staining. Cardiomyocytes are destroyed by the digestion process and 
therefore endothelial cells are the main contaminating cells. Approximately 
5% of cells were positively identified by FACS analysis as endothelial cells 
using vWF as an endothelial cell marker. This percentage of cells decreased 
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after first passage to approximately 1% resulting in a relatively pure cell 
population for experimentation. 
 The ROS measurement was undertaken by two methods namely 
homogenate and whole cell adherent methods. The homogenate method is a 
well established method used by a number of research groups, including our 
own laboratory, to detect ROS production from whole heart or aortic 
homogenates (Belaiba et al., 2007; Byrne et al., 2003; Johar et al., 2006). In 
the homogenate method the intracellular signaling pathways and negative 
feedback loops are disturbed and hence the NADPH oxidase complex is 
unopposed by any restraining factors, such as SOD,  and can produce 
superoxide freely. Also the lucigenin and NADPH substrate have uninhibited 
access to the superoxide and superoxide producing components. However 
the significant disadvantage of this process was the large number of cells, 
approximately 250000 cells, required to achieve 10 μg of protein. 
The whole cell adherent method was less demanding on cell numbers 
(5000cells/well) and would therefore enable more replication of experiments 
and investigations with agonists and inhibitors. The whole cell adherent 
method may be more representative of the in-vivo situation where the whole 
cell has its oxidative and antioxidative pathways present and in spatial 
proximity. Hence the measured activity in the whole cell adherent method is 
more likely to reflect the balance between the oxidative and antioxidant 
pathways. Adherence of the PCFs to collagen, laminin or fibronectin 
increased baseline ROS production in each by a similar amount. ROS 
production following cell receptor and ECM protein interaction is well known 
and is probably the cause for this increase in ROS (Borgquist et al., 2002). 
Whilst the presence of constituents in cell culture media such as pyruvate 
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and BSA, which scavange ROS, significantly reduced the ROS measurement. 
Hence the whole cell adherent method was standardized by all experiments  
being undertaken on gelatin coated plates and the ROS measured after the 
culture medium was removed, cells washed and placed in IC solution. 
2.4.2 ROS REPONSE 
MAIN  FINDING: 
 Basal ROS production in PCFs originates from NADPH and the 
mitochondria. 
 Higher expression of Nox4 results in higher basal ROS levels in 
Nox2-/- in PCFs. 
 TGFβ stimulation of ROS production in PCFs is Nox2 
dependent.  
 
Despite the different protocols the results from both the homogenate 
and whole-cell adherent approaches were consistent. Arachidonic acid in 
both methods induced a significant ROS response which was not Nox2 
dependent. Both WT and Nox2-/- responded robustly suggesting the 
fibroblasts were able to increase their ROS production in response to an 
agonist and that the adherent methodology could detect such increases in 
ROS. It is known that AA stimulates Nox4 by activating the p22phox subunit 
and also that the ROS production by AA stimulation is significantly reduced 
in cardiac fibroblasts transfected with Nox4 siRNA. Taken together these 
findings would suggest that the ROS production from AA resulted from the 
stimulation of Nox4 following the activation of the p22phox  subunit (Colston 
et al., 2005).  
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The basal ROS levels were significantly higher in Nox2-/- PCFs. This is 
consistent with higher levels of expression of  Nox4 in Nox2-/- hearts (Byrne 
et al., 2003). Indeed the expression of Nox4 in Nox2-/-  PCFs was also 
investigated (by fellow colleague) and reliably found to be higher.  The Nox4 
isoform is constitutively active and therefore their higher expression levels 
would explain the higher basal levels of ROS production in Nox2-/- PCFs.    
Inhibitor experiments suggested that most of the basal ROS is NADPH 
oxidase dependent though a significant proportion is generated from the 
mitochondria. Rotenone did not inhibit ROS in the homogenate method 
whereas in the adherent method rotenone inhibited ROS production by 50%. 
This would suggest that the mitochondrion plays a role in the ROS 
production in the whole cell which is not observed after homogenizing thus 
demonstrating the advantage of the adherent technique. 
TGFβ1 stimulation did not result in any significant increase in ROS 
production in either WT or Nox2-/- PCFs in the homogenate method. 
However the numbers of repeats which were possible with this method were 
small making the interpretation of this result difficult. In the whole cell 
adherent method a significant stimulatory ROS effect was seen in WT PCFs 
following TGFβ1 stimulation. Interestingly this was not seen in Nox2-/- PCFs 
suggesting that the actions of TGFβ1 in cardiac fibroblasts could be Nox2 
dependent. Evidence in the literature supports NADPH oxidase mediated 
effects of  TGFβ1. For example TGFβ1 stimulation of rat kidney fibroblasts 
resulted in the rapid production of ROS along with increased expressions of 
Nox4 and importantly Nox2  (Bondi et al., 2010).  
 In both the homogenate and whole cell adherent methods no ROS 
stimulation was seen in either WT or Nox2-/- PCF following AngII or 
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aldosterone stimulation. This is in contrast to findings in other published 
papers. Pagano et al (Pagano et al., 1998) reported an increase in ROS in 
adventitial aortic fibroblasts following 3 hrs of AngII(10-9M) stimulation. 
Similarly Griendling et al (Griendling et al., 1994) reported an increase in 
ROS following AngII(10-8M) stimulation in vascular smooth muscle cells 
using a homogenate based method. The lack of response here would question 
whether the resident cardiac fibroblasts used in our experiments are the 
principle site of the Nox2 dependent redox signal modulation resulting in the 
loss of cardiac fibrosis seen in the Nox2-/- mice following AngII stimulation.  
2.4.3 CELLULAR SOURCE OF NOX2AND TGFΒ  SIGNALLING  
The cell source of the Nox2-dependent reduction in cardiac fibrosis 
following AngII stimulation would require an alternative hypothesis. The 
possibility exists that the experimental methods undertaken were not 
sensitive to detect a small ROS response. Nevertheless an alternative 
explanation could be that the fibroblasts involved in the development of 
cardiac fibrosis are recruited from epithelial and endothelial cells in 
processes termed epithelial-mesenchymal transformation (EMT) or 
endothelial-mesenchymal transformation (EndoMT). Zeisberg et al (Zeisberg 
et al., 2007a) demonstrated in mouse models of pressure overload following 
aortic banding that cardiac fibrosis was associated with fibroblasts of 
endothelial origin. Thus the paper suggests that the endothelial cells, and in 
particular those that undergo EndoMT to fibroblasts, are important in the 
development of cardiac fibrosis and thus could be the crucial resident cell 
source for Nox2.  EndoMT has been shown to be induced by TGF- and 
Smad signalling pathway (Zeisberg et al., 2007a).  As yet, neither NADPH 
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oxidase nor ROS have been implicated in EndoMT in the heart.  However, 
TGF-/Smad induced epithelial-mesenchymal transition in the kidney has 
been shown to be inhibited by antioxidants (Rhyu et al., 2005).  In addition, 
Smad3 may be particularly relevant to AngII induced cardiac fibrosis and 
inflammation, as a recent study demonstrated that AngII was unable to 
induce cardiac fibrosis in Smad3 deficient mice (Lan et al., 2008).  
Alternatively the fibroblast could be recruited from circulating fibroblast-like 
cells called fibrocytes that are derived from bone-marrow stem cells (Brittan 
et al., 2002; Bucala et al., 1994; Direkze et al., 2003; Ebihara et al., 2006). 
Thus the Nox2 in the fibroblast cells from these alternative sources could be a 
critical cell source for the Nox2 in the development of AngII induced cardiac 
fibrosis. 
It is known that adult cardiac fibroblasts do contribute to cardiac 
fibrosis by transforming to myofibroblasts and increasing the deposition of 
ECM (Sun et al., 2002a). In a hallmark paper, Schultz et al (Schultz et al., 
2002) tested whether AngII would be able to induce cardiac hypertrophy and 
fibrosis in vivo in the absence of TGFβ1 gene. The lack of the TGFβ1 gene fully 
prevented the development of cardiac hypertrophy and dysfunction induced 
by subpressor doses of AngII that was observed in wild type mice. Thus, this 
study provided the first direct evidence that AngII induced cardiac 
hypertrophy is mediated by TGFβ1 and indicate that TGFβ1 acts downstream 
of AngII and promotes myocyte growth and fibrosis in the heart.  
TGFβ1 signalling via Smad2/3 is important in the transformation of 
fibroblasts to myofibroblasts and Nox4 has been shown to be important in 
this signalling process (Cucoranu et al., 2005). On stimulation of human 
cardiac fibroblasts with TGFβ1 Nox4 mRNA expression was significantly 
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increased and ROS production significantly decreased by siRNA against 
Nox4. Also investigation into the profibrotic role of TGFβ1  on rat fibroblasts 
has shown significant increases in NADPH oxidase activity with increased 
expression of Nox2 and Nox4 (Bondi et al., 2010). The downstream 
activation of Nox2 by TGFβ1 is in keeping with the Nox2 dependant ROS 
response found following TGFβ1 in the current experiments. Thus as TGFβ1 
acts downstream from AngII this indicated that the fibroblasts could still be 
an important cell source for Nox2 in the development of cardiac fibrosis in 
mice following AngII stimulation. 
2.4.4 ALTERNATIVE CELLULAR SOURCE OF NOX2 
Another possibility is that macrophages are known key players and 
that their activation and migration into cardiac tissue and production of 
TGFβ are significant events in the development of AngII induced cardiac 
fibrosis (Tokuda et al., 2004). In keeping with this, the ACE activity in 
monocyte-derived macrophages from pre-hypertensive patients has been 
shown to be increased (Keidar et al., 2007). Also, in hypertensive rats, 
macrophages accumulate in the perivascular area, co-localising with 
fibroblasts, and promote the increased production of collagen (Sun et al., 
2002b). Thus monocytes/macrophages could be another possible critical 
cellular source for Nox2 in AngII induced cardiac fibrosis. In the next chapter 
bone marrow-derived macrophages (BMM) are used to investigate the role of 
Nox2 in the ability of BMM to migrate as a measure of the cell’s ability to 
chemotax and infiltrate tissue. The dependence on Nox2 in this process, and 
the lack of it in Nox2-/- mice, could explain the elimination of fibrosis in vivo 
in Nox2-/- mice to angiotensin II or aldosterone stimulation.   
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3 ROLE OF NOX2 IN THE CELLULAR MIGRATION OF 
BONE MARROW DERIVED MACROPHAGE 
3.1 INTRODUCTION 
 Fibrosis involves the infiltration of a dense inflammatory infiltrate 
including importantly macrophages (Swynghedauw, 1999). Adhesion of 
circulating monocytes  to the endothelium of the vessel wall and the 
extravasation of the cell into the heart tissue is an essential step in the 
development of cardiac fibrosis (Kuwahara et al., 2003). In keeping with this, 
the blockade of monocytes chemoattractive protein -1 (MCP-1) early in this 
process prevents myocardial fibrosis, suggesting that the migration of 
macrophages into the perivascular space during inflammation is a key event 
in triggering fibrosis (Kuwahara et al., 2004). This migration requires the cell 
to make changes in their shape which is mediated by cytoskeletal dynamics. 
Several of the steps in the migratory process have been found to be redox 
sensitive. However the role of redox signaling and more specifically ROS 
generation by Nox2, in macrophage migration is not well established. 
However NADPH oxidase is recognised to have specific subcellular 
localisation and it is thought that this localization enables NADPH to 
produce ROS in a localised space and modulate specific signalling pathways 
that mediate various cell functions, including cellular migration (Ikeda et al., 
2005b). In this chapter, we investigate the role of Nox2 in the migration of 
primary bone marrow derived macrophages. 
3.1.1 MACROPHAGE MIGRATION 
Our knowledge of the molecular mechanism regulating macrophage 
migration has developed from studies in various cell types. The initial 
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response of a cell to a migration-promoting agent is to polarize and extend 
protrusions in the direction of migration (Allen et al., 1998). These 
protrusions can be large, broad lamellipodia or spike-like filopodia, 
supported by actin filaments . (Figure 3.1) These adhesions serve as traction 
sites for migration as the cell moves forward over them, and they are 











Leading edge Cdc42 & Rac:




Figure 3-1 Migrating monocyte 
The actin has a dendritic organization in la mellipodia. In contrast, filopodia, with their 
parallel bundle organization are particularly well designed to serve as sensors and to 
explore the local environment.  
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The  Rho family of small GTPases(20-25kDa)  are pivotal regulators of 
actin and adhesion organization.(Figure 3.2) Of the Rho family GTPases, Rac 
and Cdc42 are required for protrusion of lamellipodia and filopodia. Rac 
stimulates lamellipodial extension by activating WAVE proteins (Cory and 
Ridley, 2002). Cdc42  binds to WASP proteins, and in vitro this stimulates 
the Arp2/3 complex to induce dendritic actin polymerization and 
lamellipodial protrusion (Welch and Mullins, 2002).  Another downstream 
signalling pathway for Rac and Cdc42 is their activation of the Ser/Thr 
kinase PAKs (p21-activated kinases). Upon activation PAK phosphorylates 
LIM kinase (LIMK) which phosphorylates and therefore inhibits cofilin.  
Cofilin is an actin binding protein involved in the assembly and disassembly 
of actin filaments. Hence its phosphorylation downstream from Rac and/or 
Cdc42 mediated activation is also involved in the regulation of lamellipodia 
formation.   
Following directed stimulation, e.g in response to an inflammatory 
stimulus, for the cell to migrate it must become polarized. In order to do this 
the molecular processes at the front and the back of a moving cell are 
different. Again the small GTPases are important.  Cdc42 is important in 
regulating cell polarity being active towards the front of migrating cells (Itoh 
et al., 2002). Its importance is confirmed by both inhibition and global 
activation of Cdc42 which disrupts the directionality of migration (Etienne-
Manneville and Hall, 2002). Cdc42 can influence polarity by restricting 
where lamellipodia forms (Srinivasan et al., 2003).  
Tail retraction is an active process involving RhoA. In several cell 
types inhibition of RhoA leads to the formation of an extended tail. This is 
possibly due to a decrease in the force generated by the interaction of actin 
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and myosin filaments, which is commonly termed the actomyosin based 
contractility (Worthylake et al., 2001). One model for how migrating cells 
maintain polarity is based on the fact that Rho and Rac are mutually 
antagonistic, each suppressing the other’s activity (Evers et al., 2000).  
The formation and turnover of cell-substratum adhesions is important 
to stabilise lamellopodia and for migration to occur. The integrins play an 
important part in such cell-substratum adhesions. The integrins are an 
important family of migration promoting receptors which connect the ECM 
to the intracellular cytoskeleton (Cox et al., 2001). Integrins can serve as both 
traction sites over which the cell moves and as mechanosensors, transmitting 
information about the physical state of the ECM into the cell and altering 
cytoskeletal dynamics (Geiger et al., 2001; Lauffenburger and Horwitz, 
1996).  
Activation of integrins results in them clustering and recruiting actin 
filaments.  Actin is recruited to integrins by its cytoplasmic association via 
effector proteins such as talin, vinculin, α-actinin, filamin and paxillin.  Both 
protein kinases and phosphatases appear to be central to the regulation of 
adhesion turnover and stability (Larsen et al., 2003). The focal adhesions 
organise the actomyosin apparatus and attract molecules such as focal 
adhesion kinases(FAK). Adhesion turnover in migrating cells is also 
regulated by the mitogen-activated protein kinase ERK (Brahmbhatt and 
Klemke, 2003; Turner et al., 2001). The emerging evidence favours a model 
for adhesion turnover in which activation of the protein tyrosine kinases FAK 
and Src accompanies the formation of an adhesion signaling complex that in 
turn mediates the localized activation of Rac and ERK. These signals then 
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contribute to the turnover of adhesions at the leading edge (Brahmbhatt and 
































Figure 3-2 Regulation of actin polymerisation.  
Rho, Rac and Cdc42 are activated by the exchange of Guanosine diphosphate (GDP) for 
Guanosine triphosphate (GTP) , catalysed by Guanine nucleotide exchange factors 
(GEFs). They are inactivated by the GTP hydrolysis, catalysed by GTPase activating 
proteins (GAPs). Cdc42 induces actin polymerisation by binding to WASP to induce 
branched actin filaments using ARP2/3 complex. Rac activates the ARP2/3 complex 
through the WAVE complex. Rac mediated or Cdc42 mediated activation of PAK (PAK1, 
PAK2 and PAK3) which phosphorylates LIMK (LIMK1 and LIMK2). Rho mediated 
activation of ROCK (ROCK1 and ROCK2) can also activate LIMK (LIMK1 and LIMK2).  
LIMK phosphorylates and therefore inhibits cofilin, thereby regulating actin filament 
turn over. Cofilin is dephosphorylated by the phosphatase Slingshot. Unphosphorylated 
cofilin stimulates severing and depolymerisation of filamentous actin. Redox sensitive 
pathways are indicated in as ROS.  
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In summary, a cell must sense a gradient and establish polarity. The 
plasma membrane is then extended in the direction of movement in the form 
of lamellipodia. Nascent adhesions are established in the front of the cell 
under the protrusion by restructuring of the actin cytoskeleton and changing 
its shape and size. Then a mechanical contraction force is induced by 
phosphorylation of myosin and the body of the cell contracts moving 
forward. Subsequently focal adhesions in the rear of the cell are detached and 
the trailing tail retracts. Finally the adhesion receptors are recycled by 
endocytosis and vesicular transport (Sheetz et al., 1998). These individual 
events are directed by activation of specific signals in the relevant subcellular 
compartment.  Successful migration is thus dependent on many molecules, 
the activation and actions of which are carefully timed in pertinent 
subcellular compartments and this will determine the direction, speed and 
persistence of the migration.  The remainder of this introduction discusses 
the role of ROS in regulating these steps in migration.  
3.1.2 REDOX MODULATION IN CELLULAR MIGRATION 
Several steps in the migratory process have been found to be redox 
sensitive.  Signalling cascades activated by growth factors, such as PDGF, 
through their tyrosine kinase receptor  require ROS to help propagate the 
signal further downstream  (Lassegue et al., 1995; Lee et al., 2009).  ROS can 
mediate integrin activation (Chiarugi and Fiaschi, 2007; Svineng et al., 
2008) while focal adhesion sites have been reported to activate downstream 
ROS sensitive signal transduction pathways (Koller, 2002). These ROS can 
not only mediate cytoskeletal associated signal transduction by the oxidation 
of redox sensitive proteins such as protein tyrosine phosphatase (PTPs) but 
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also induce other pro-migratory growth factors (Black et al., 2008; Marmur 
et al., 1992; Pintucci et al., 2005).     
Actin filament reorganisation is essential for cell size and shape 
changes, polarity formation and all phases of cell migration. Lamellipodia 
formation in moving cells requires cycles of actin polymerisation and 
depolymerisation.  As shown in Figure 3.2. ROS can influence actin dynamics 
both directly and indirectly through alteration of intracellular signalling 
pathways.  Treatment of actin with high concentrations of H2O2 has been 
shown to directly decrease the rate of polymerisation, elongation, increase 
monomer concentration and inhibit binding of actin capping protein, filamin 
(DalleDonne et al., 1995; DalleDonne et al., 1999; Milzani et al., 1997). The 
treatment of rabbit psoas muscle fibres with H2O2 results in decreased fibre 
contractility by the indirect impairment of the actomyosin enzyme activity 
(Price et al., 1998).  However these studies used a high concentration of H2O2 
which did not mimic the physiological state. In contrast lower concentrations 
of H2O2 seemed to promote actin polymerisation and the formation of stress 
fibres (Moldovan et al., 2000).  However the effect of the oxidant on the actin 
cytoskeleton may be cell type specific. As such,  Huot et al (Huot et al., 1997) 
showed that the same concentration of H2O2 induced fragmentation of F-
actin in fibroblasts but reorganisation in endothelial cells leading to stress 
fibre formation. Figure 3.2 summarises the ROS dependent pathways leading 
to lamellipodium formation. 
An important mechanism that regulates the contractile apparatus is 
the Rho/ROCK pathway which in VSMC has been shown to be activated by 
ROS (Jernigan et al., 2008; Jin et al., 2004). Several major downstream 
regulators of contractility from RhoA are ROS sensitive. For example the 
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regulation of Ca2+ release in VSMC is redox sensitive (Lounsbury et al., 2000; 
Roveri et al., 1992; Scherberich et al., 2000; Tabet et al., 2004)  with Ca2+ 
dependent activation of MLCK being the major mechanism initiating cell 
contraction.  
3.1.3 NOX MODULATION OF CELLULAR MIGRATION 
There is now growing evidence in the literature that the Nox family 
proteins can also be a major source of ROS and thus have a modulatory effect 
on processes involved in cellular migration. For example, Rac stimulates 
actin polymerisation by several mechanisms including NADPH oxidase 
mediated ROS production (Moldovan et al., 2000). The dephosphorylation of 
the cytoskeletal regulator cofilin following PDGF stimulation has also been 
shown to be Nox1 dependent (Lee et al., 2009; San et al., 2008). During 
fibronectin/integrin mediated cell adhesion, ROS is dramatically increased 
by Rac-1 dependent activation of NADPH oxidase (Umanskiy et al., 2003). 
Other sources of integrin induced ROS include mitochondria(Werner and 
Werb, 2002) and lipoxygenase (Taddei et al., 2007). Recently Nox4 has also 
been shown to be a key player in the regulation of stress fiber formation and 
focal adhesion turnover in VSMC (Clempus et al., 2007). 
Most of our understanding of the role of Nox2 in modulating cellular 
migration has come from studies in endothelial cells. Nox2 modulates 
cellular migration at various sites by means of  specific subcellular 
localisation. (Figure 3.3) In endothelial cell migration, as seen during tissue 
repair in response to injury, angiogenesis, and wound healing, Rac1- and 
Nox2-dependent NADPH oxidase play an important role (Colavitti et al., 
2002; Ikeda et al., 2005a; Ushio-Fukai et al., 2002).  The Rac pathway is 
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involved in the production of ROS that accumulate at the membrane ruffles 
(Park et al., 2004), which is required for cytoskeletal reorganization and 
directed cell migration (Ikeda et al., 2005b; Moldovan et al., 2000). Nox2 
and its regulatory subunits, p47phox  and p67phox  are also targeted to the focal 
complexes or membrane ruffles in lamellipodia (Ikeda et al., 2005a; Wu et 
al., 2003; Wu et al., 2005)  thus enabling local activation of NADPH oxidase 


















































Figure 3-3 Localised ROS signalling.  
ROS signalling at lamellipodial focal complexes is mediated through formation of 
p47phox-TRAF4-Hic5 complexes and oxidative inactivation of PTP_PEST by ROS, which 
is required for activation of Rac1 and its effector PAK1, which phosphorylate p47phox 
through formation of TRAF4-Rac1-PAK1 complexes. Localised ROS at membrane 
ruffles and lamellipodial leading edges are mediated through p47phox-WAVE1-Rac1-
PAK1  and Rac1-IQGAP1-Nox2 complexes respectively,  which phosphorylate p47phox. 




The mechanism for targeting NADPH oxidase to the lamellipodial 
leading edge and membrane ruffles is through the interaction of p47phox  with 
WAVE1 (Wientjes et al., 2001; Wu et al., 2003). The p47phox-WAVE1 
complexes contain Rac1 and Rac1 effector PAK1, which phosphorylates 
p47phox . Antioxidants and inhibition of p47phox-WAVE1 interaction block 
ROS production and ruffle formation (Wu et al., 2003).  Another important 
targeting protein is IQGAP1 which  functions as a scaffold protein to target 
Nox2 and Rac1 to the specific membrane compartments to localize ROS 
production, thereby achieving specificity of redox signaling, which may 
contribute to EC migration (Ikeda et al., 2005a). 
3.1.4  SUMMARY 
Cellular migration is a complex process which is tightly regulated. 
Many of these steps can be modulated by ROS. Compartmentalisation of 
NADPH oxidase, in particular Nox2, as a source of ROS allows for the 
modulation of specific signalling pathways. Most is known of the role of 
redox modulation in the migration of endothelial, fibroblast and VSM cells. 
The aim of the following studies was to specifically explore the role of Nox2 
in the migration of BMM which have been identified as being important in 




3.2.1 ANIMAL HUSBANDRY AND MAINTENANCE  
All the mice used in these experiments were maintained in a 
designated facility in accordance with the Code of Practice for the Housing 
and Care of Animals Used in Scientific Procedures.  Mice were housed up to a 
maximum of 5 per cage and had free access to water and normal food chow.  
All experimental procedures in this thesis involving animals were 
carried out under the authority of a Home Office Personal Licence and 
Project Licence.  All procedures were performed in strict accordance with the 
Home Office “Guidance on the operation of Animals (Scientific Procedures) 
Act 1986”, Her Majesty’s Stationary Office (London, UK).   
3.2.2 ISOLATION AND CULTURE OF MOUSE PRIMARY BMMS   
The murine femoral bones were harvested from 6-8 week old WT and 
Nox2-/- mice after they were culled using terminal anaesthesia (2.5% 
isoflurane (Abbott, UK)//97.5% oxygen). All the surrounding tissue on the 
bone was meticulously removed using forceps in a tissue culture hood for 
sterility. Once the bone was cleaned a 21-gauge needle was used to pierce 
both ends of the bone. Using a 5-mL syringe the bone marrow was flushed 
out of the bone with 5 mL of macrophage starve medium (Table 3.1) into a 
15-mL Falcon tube. An additional 5 mL of macrophage starve medium was 
added and the flush resuspended vigorously using a pipet. The cells were 
then centrifuged for 5mins at 1000rpm and the pellet resuspended in 5 mL of 
macrophage starve medium. The cells were then counted and 2X105 
cells/cm2 were seeded onto 10cm tissue culture plastic petri dishes for 3 days 
in macrophage growth media. (Table 3.1) Cells were thus harvested from 
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three WT and three Nox2-/- mice with which all the experiments were 
conducted  in chapter 3 and 4. 
 









RPMI 1640 with L-glutamine 
ADD 
1% Essential amino acids 
1% sodium pyruvate 
1% P+S 




This comprises of the starve media 




After 3 days the non-adherent population of cells containing the 
haematopoietic precursor cells were removed. The cells which attach to the 
bottom of the flask are a mixed population of differentiated hematopoietic 
cells and fibroblasts. The non adherent cells are centrifuged, resuspended 
and counted. The cells can then be cryogenically frozen in growth medium 
containing 10% DMSO at a cell density of 5 x105 cells in each vial.  To recover 
frozen cells the vials were rapidly thawed and 1 mL of warm growth medium 
was added dropwise. Then 4 further mLs of growth media was added and the 
cells centrifuged for 5 min at 1000g. The cells were seeded onto 6-cm 
bacterial culture plates in 5 mL of growth medium at a density of 10 cells/mL  
(i.e. a vial containing 5 x 105 cells seeded one 6-cm dish). The cells were 
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incubated for a further 5 days without refeeding. The cells in general 
remained in suspension for approximately 4 days at which point the 
differentiated BMMs became adherent and could be harvested on day 5 for 
experimentation. 
 To harvest the cells the medium was removed carefully and 2.5 mL of 
lysis solution such as Versene (Gibco) is added. The cells were incubated for 
approximately 20 min and then the cell suspension was collected by vigorous 
pipetting across the dish into a 15ml falcon tube. A further 2.5 mL of 
macrophage starve medium was added and the cells centrifuged for 5 min at 
1000g. The cells were then resuspended in macrophage growth medium for 
seeding coverslips for staining or for Dunn chambers. 
3.2.3 MIGRATION EXPERIMENTS  
3.2.3.1 Random motion analysis 
To study random cell motion, cells were seeded onto 6 well plastic 
petri dishes at a density of 2x104 cells/ml in macrophage growth medium and 
incubated overnight. Following incubation, cells were starved of CSF-1 in 
macrophage starve medium for 8 hours. The cells were then stimulated with 
CSF-1 by the re-introduction of CSF-1 (30 ng/ml) containing growth media. 
Cell images were collected using a Pulnix CCCD camera, taking a frame every 
5 min for 18h using AQM acquisition software (Andor, UK). 
3.2.3.2 Directed migration: Dunn Chemotaxis Chamber Preparation 
The Dunn Chemotaxis Chambers (DCC) (Figure 3.4) were placed on 
tissue paper until the storage ethanol had evaporated. Initially the chamber 
was washed to remove any residual traces of ethanol; 100-150 μL of starve 
medium was placed over the centre of the chamber, without overflow, and 
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then removed. This was repeated six times to wash the chambers.  Then     
150μL of starve medium was placed over the chamber until it filled both 
wells. The medium had been gassed by placing it in a bijoux tube in an 
incubator overnight in 5% CO2, which was important as once the chamber is 
sealed by wax there is no opportunity for further gas exchange. Care was 
taken to invert the coverslip with the seeded cells attached onto the chamber 
without incorporating any bubbles into the chamber. The coverslip was 
placed slightly off centre so that a small gap remained in the outer well. 
However, the coverslip must completely cover the inner well so that the outer 
well could be drained without any loss of medium from the inner well. Once 
the coverslip was in place, the chamber was sealed on three sides with wax. 
The fourth side remained unsealed and the medium was removed from the 
outer well with Whatman paper.  100 μL of growth media (with added 
chemoattractant) was added into the outer well  through the gap, ensuring 
that it was bubble-free, until the well was full. The final edge was quickly 
waxed to completely seal the gap. The DCC was immediately placed onto the 
microscope stage and filming started. 
3.2.3.3 Time-Lapse Microscopy and Migration Analysis 
The assembled Dunn chamber was placed on the heated stage of a 
microscope. The live image from the microscope was then viewed on the 
computer monitor using the Acquisition manager (AQM) software (Kinetic 
Imaging; Liverpool, UK) and  a region of the bridge was selected for 
recording and the image orientated such that the source of chemoattractant 
(outer well) was at the top of the screen. (Figure 3.4) This is extremely useful 
for subsequent tracking and mathematical analysis of chemotactic behaviour. 
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Ideally there should be 15-25 cells in the field of view and the cells should be 
evenly spaced. For analyzing the chemotactic behaviour of BMMs in a 
gradient of recombinant CSF-1, a time-lapse interval of 10 min was used and 
the cells filmed for 18h. CSF-1 is a known chemotactic factor which has been 
used in our laboratory before (Wells et al., 2004).  
Once the random motion or directed motion assay were finished, the 
recorded sequence of images were analyzed using the same AQM software 
(Kinetic Imaging). Each cell was individually tracked (Figure 3.4) using the 
AQM software throughout the time-lapse sequence. In our laboratory the 
following tracking criteria has been adopted:  
 Only cells present in the first frame were tracked.  
 If any cell present in the first frame divided within the first 60 
frames it was excluded. 
 If a cell present in the first frame divided at a later stage in the 
film it was tracked until it ceased to be migratory. For BMMs 
this is normally one to two frames or 20 min before mitosis 
occurs. 








Figure 3-4 Dunn Chamber assembly, microscopy and tracking 
A: The Dunn chemotaxis chamber with coverslip in place. The chamber consists of two 
concentric circles ground into one face of a glass slide (inner and outer wells). An 
annular ridge (bridge) separates the two wells. Insert, the bridge is 20μm lower than 
the surrounding glass slide resulting in a gap between the coverslip and the bridge.  
B: BMMs in the DCC as imaged by AQM Software. A region of the bridge is selected for 
recording and the image orientated such that the source of chemoattractant (outer 
well) is at the top of the screen.  
 C: Cell trajectories starting points are shifted to co-ordinate point (0,0) and plotted 
using an analysis program written in the laboratory on Mathematica software. (Zicha et 
al., 1997; Zicha et al., 1991) 
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Once all the appropriate cells in the field of view had been tracked the 
marked positions of each cell in each frame are saved. The files recorded the 
cell number, frame number, x-coordinate and y-coordinate of every tracked 
cell in every frame.  Finally, trajectory analysis was conducted using a range 
of software designed by Dr. Graham Dunn and Dr. Daniel Zicha at the 
Randall centre, Kings College London (Zicha et al., 1991; Zicha et al., 1997) 
(software is not commercially available). This datasheet was transferred to 
Mathematica for statistical analysis. Chemotaxis analysis required the cells to 
reach a horizon defined in the analysis software package. Over the period of 
observation cells migrated towards this horizon up the positive CSF-1 
gradient. Cells which reached the horizon were registered as having 
demonstrated positive chemotaxis. 
In this analysis the assumption for the null hypothesis was that the 
cell trajectories have uniform distribution in all direction. The underlying 
distribution is one of a Rayleigh distribution. This program returns a 
Rayleigh test for unimodal clustering of direction. If the null hypothesis is 
rejected by the Rayleigh test the cells are showing a significant directional 
response to CSF-1. 
3.2.4  STAINING  
The BMM were seeded on the coverslips at  2 x 105 cells per coverslip.  
The cells were allowed to settle for one hour and then those for starvation 
and/or restimulation were starved of CSF-1 by replacement of the growth 
media with starve media for 12 hours. Following CSF-1 starvation the cells for 
restimulation with CSF-1 were stimulated by the reintroduction of the growth 
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media for 5mins. The cells were then washed with PBS and fixed with 1% 
paraformaldehyde for staining.  
The cells on the coverslips were permeablised with methanol and 
blocked with 5% BSA. The cells were stained for actin using phalloidin-FITC 
(1:1000) in 1% BSA. The staining was visualised under fluorescent 
microscopy and images taken. The image was analysed using ImageJ where 
the cells were traced to obtain their shape and size. Five random fields were 
chosen per image. The data from the staining were analysed using regression 
analysis where any clustering in the data arising from the fact that 
experiments were undertaken on the same run/day was allowed for and 
adjusted appropriately. 
3.2.5 WESTERN BLOTTING  
3.2.5.1 Protein samples 
Cells were seeded onto 6-well plates. The media was not changed for 
growing cells while the medium of starved cells was replaced with 
macrophage starve media. Following 12 hours starvation the cells for CSF1 
stimulation were stimulated for 5, 15, 30 or 60 mins by the re-introduction of 
growth media. After stimulation the wells were washed and lysis solution 
added. The 6 well plates were kept on ice. The wells were then scraped and 
the sample removed and placed into eppendorf tubes. The eppendorf tubes 
were spun for 10mins at 12000rpm and the supernatant removed into a new 
eppendorf tube. To denature the protein, samples were heated to 100oC for 
3mins. Sample buffer was then added prior to freezing and storage.  
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3.2.5.2 Western blotting 
To prepare 7.5% polyacrylamide gel the components included in  
Table 3.2 were added to a 50ml tube. Following the addition of TEMED 
(Sigma) which catalyzes the polymerization of acrylamide, the gel was poured 
into the Novex Mini-Cell Kit (Invitrogen) and left for 30 min to polymerize. 
The stacking gel solution (Table 3.2) was then poured over the separating gel. 
The well comb was placed immediately. The gel was left for 30 min to 
polymerize. Once the gel was set, the comb was removed. The gel was placed 
in the electrophoresis apparatus (BioRad). The gel tank was filled with 1x 
Running Buffer (all buffers and solutions applied in SDS PAGE are listed in 
Table 3.3). 10μg of each protein sample was loaded on the gel. 10μl of Dual 
Color Precision Plus ProteinTM standard (Biorad) was co-electrophoresed 
with the sample. The gel was run at a constant 125V for 1.5 h. 
 






7.5% Resolving Gel 
 
 
H2O    6.12ml 
3M Tris-HCl pH 8.8  1.25ml 
30% acrylamide (Biorad) 2.5ml 
10% SDS   100μl 
10% APS   100μl 
TEMED    10μl 
 
Stacking Gel 
H2O    3.79ml 
1.5M Tris-HCl pH 6.8  0.65ml 
30% acrylamide  0.63ml 
10% SDS   50μl 
10% APS   50μl  





3.2.5.3 Western Blotting protocol 
The transfer cassettes, sponge pads, filter paper and the nitrocellulose 
membrane (Whatman) were equilibrated in 1x Gel Transfer Buffer (all 
buffers and solutions applied in Western Blotting Protocol are listed in   
Table 3.3). The Nitrocellulose membrane was placed on the gel. The transfer 
construct was assembled and placed in a transfer tank filled with 1x Gel 
Transfer Buffer. The transfer was run at 100V for 1h. Following the transfer, 
the membrane was blocked in blocking buffer for at least 1h at room 
temperature. The blocking buffer was discarded and replaced with primary 
antibody (included in Table 3.4) diluted with blocking buffer. The membrane 
was incubated with primary antibody overnight at 4°C on a rotary shaker. 
The next day, the membrane was washed three times for 20 min per wash in 
TBST, at room temperature. The membrane was then incubated with 
secondary antibody (Table 3.4) diluted with Blocking Buffer for 2h at room 
temperature. After incubation with secondary antibody, the membrane was 
washed three times for 20 min per wash, in TBST at room temperature. The 
blots were developed using Pierce® ECL Western Blotting Substrate Kit 
(Thermo Scientific) according to manufacturer’s instruction. The equal parts 
of ECL detection reagents were mixed and immediately placed over the 
membrane. The membrane was incubated with this solution for 1 min at RT. 
The membrane was placed in a film cassette with a protein side facing up. 
The X-ray film (Fujifilm) was placed on the top of the membrane in a red 
safelight appropriate for X-ray exposure. The time of exposure was from 1-10 
min depending upon the intensity of the signal. The blots were scanned and 
band densities were quantified with Kinetic Imaging software to obtain the 
ratio phosphorylated protein to total protein.  
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The data from the western blot analysis were analysed using 
regression analysis where any clustering in the data arising from the fact that 
experiments were undertaken on the same run/day or on the same gel was 
allowed for and adjusted appropriately.  
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30g Tris                                                 up to 1l H 2O 
10g SDS  
 
 








Membrane Wash Buffer 
(TBST) 
 
1M Tris-HCl pH 7.6 25ml  
5M NaCl                 10ml               up to 1l H2O 
Tween20   1ml 
 
 






100mM Tris/HCl pH 6.8 
4% SDS 
20 % Glycerol 
0.2% Bromophenol Blue 




5% (wt/v) Skim Milk powder (Marvel) in 1x TBST 
 
5% (wt/v) BSA powder (BDH) in  
1x TBST(for experiment with phosphor-antibodies) 
 
































1% (wt/v) BSA 





3.3.1 MODULATION OF NOX2-/-  BMM CELL SHAPE  
Many of the signalling pathways that regulate cellular migration are 
the same as those controlling cellular morphology. Therefore the WT and 
Nox2-/- BMM cell morphology was analysed under basal growing conditions. 
Growing Nox2-/- BMM had on average a larger spread area and were more 
elongated in their shape as compared to growing WT BMM. (Figure 3.5 & 
3.6) On average growing Nox2-/- BMM were 4% (0.03AU; p=0.048) more 
elongated with on average a 9% (0.022AU; p=0.05) increased spread area. 
Therefore these data suggests that Nox2 plays a significant role in regulating 
the shape and size of BMMs. 
3.3.2 ROCK INHIBITION DID NOT EMULATE THE NOX2-/- PHENOTYPE 
 Rho Kinase (ROCK) has an important regulatory role in actin 
cytoskeletal dynamics (Bhadriraju et al., 2007). Furthermore ROCK is 
important for tail retraction (Smith et al., 2003; Worthylake et al., 2001), the 
inhibition of which can result in an elongated phenotype, as observed in 
Nox2-/- BMM. Thus the influence of ROCK inhibition on WT shape changes 
was investigated.  
 The addition of a ROCK inhibitor significantly increased WT BMM 
spread area by 0.045AU (p=0.029). (Figure 3.5 & 3.6) (+19% compared with 
growing WT BMM).  However inhibition of ROCK in WT BMM did not 
induce any significant elongation. Thus the complete phenotype seen in 











Figure 3-5 Differences in phenotype between WT, WT+ROCK inhibitor  and  
Nox2-/- BMM 
 The loss of Nox2 results in the BMM having on average a larger spread area and a  
more elongated shape. The addition of a ROCK inhibitor resulted in an increase in the 
spread area of the WT BMM. No change was seen in the elongation of WT BMM with 
















































Figure 3-6 Area and shape changes in WT and Nox2-/- BMM with and without 
ROCK inhibiton 
Spread area and shape were quantified in arbitrary units (AU) using Image J. Loss of 
Nox2 resulted in an increase in the spread area and a significant increase in the 
elongation of the BMM.   The addition of a ROCK inhibitor resulted in an increase in the 
spread area of WT BMM but no change was seen in cellular elongation.(   : p< 0.05, 
N=150 WT or Nox2-/- cells) 
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3.3.3 CSF-1 STIMULATION IN WT AND NOX2-/- BMM 
BMM show a morphological response to CSF-1 stimulation (Wells et 
al., 2004) where deprivation of CSF-1 induces cell elongation and re-
stimulation leads to centrifugal spreading.  However the role of Nox2 in this 
response has not been investigated.  
Following CSF-1 starvation both WT and Nox2-/- macrophages 
reduced their spread area to a similar size which was not significantly 
different. (Figure 3.7)  The re-introduction of CSF-1 allowed the assessment 
of the influence of Nox2 on the dynamic changes occurring in the cell’s 
spread area and shape.  Following the re-introduction of CSF-1 for 5mins the 
WT macrophages significantly increased their spread area by 79% (0.115 AU; 
p<0.001)  from its starting starved spread area. The Nox2-/- macrophages 
also showed a significant increase in their spread area by 55% (0.087 AU; 
p<0.001) from their starved spread area. This reduced response was not 
significantly (p=0.06) different from the response seen in WT BMM.  
After starvation WT and Nox2-/- BMM had a similar degree of 
elongation. On stimulation with CSF-1 both cell types showed a similar 
reduction in their elongation as they spread out and became more rounded in 
shape. (Figure 3.7) The WT cells reduced their elongation by 11% (0.08AU; 
p<0.001) similar to the 13% (0.095AU; p<0.001) seen in Nox2-/- BMM. 
Therefore both WT and Nox2-/- BMM displayed a similar morphological 
response to CSF-1.   
Although the difference in spread area was not statistically significant, 
taken together with the reduced cell area for growing WT cells, these data do 
suggest that Nox2 expression is in part required for normal BMM behaviour. 
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Interestingly, both populations were able to centrifugally spread in response 
to CSF-1, suggesting that CSF-1 responses are not completely dependent on 
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Figure 3-7 Shape and size changes to CSF1 stimulation in WT and Nox2-/-  
 The increase in spread area is reduced in Nox2-/- BMM however the decrease in 
elongation following CSF-1 stimulation is similar between WT and Nox2-/- BMM. Taken 
together with the larger growing spread area of Nox2-/- the data suggest a role for Nox2 




3.3.4 NOX2-/- BMM SHOWED REDUCED RANDOM MOTION FOLLOWING CSF-1 
STIMULATIONDO NOT MIGRATE TOWARDS CSF-1. 
Given changes in growing cell spread area and a reduction in the 
spread area in response to CSF-1, defect in CSF-1 stimulated random 
migration in Nox2-/- BMMs was investigated.  
A significant reduction (p=0.02), in cell displacement was observed 
(Figure 3.8) following CSF-1 stimulation in Nox2-/- BMM where a reduced 
number of the Nox2-/- BMMs population were able to reach the set horizon as 
compared to WT BMMs. 
The reduction in cell displacement could be the result of a reduction in 
cell speed or persistence in direction of motion. Interestingly the persistence 
in direction of Nox2-/- BMM was higher than in WT. (Figure 3.8) However 
neither the persistence nor the speed were significantly different. On 
stimulation with CSF-1 a similar trend was observed. The speed and 
persistence increased in WT and Nox2-/- BMM with a similar higher 
persistence in direction remaining in Nox2-/- BMM, however no significant 
difference was observed.   
Thus taken together the data suggests an important role for Nox2 in 
the random migration of BMM following CSF-1 stimulation.  Despite similar 
speed of migration and a higher persistence in direction of motion the     
Nox2-/- BMM were unable to randomly travel for longer distances to reach 
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Figure 3-8  Nox2-/- BMM have reduced cell displacement 
WT and NOX2-/- BMMs were seeded on plastic, CSF-1 deprived, then stimulated with 
CSF-1 and imaged (N=20 WT or Nox2-/- tracks).  
A & B: Cell tracks of WT and Nox2-/- BMM respectively. The tracks have been re-set to 
co-ordinate (0,0).  
C & D: The number of cells reaching a set circular horizon was monitored and found to 
be significantly (p=0.02) more in the WT than Nox2-/- BMM following CSF-1 
stimulation.  
E & F: Mean cell migration speed and mean persistence of direction were calculated 
from cell tracks above. Persistence of direction was higher in Nox2-/- BMM following 
CSF-1 stimulation. However no significant difference was observed.  
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3.3.5 NOX2-/- BMM DO NOT MIGRATE TOWARDS CSF-1 
BMM are known to have a chemotactic response to CSF-1 (Wells et al., 
2004), and in a physiological context are likely to be responding to a gradient 
of chemoattractant rather than global stimulation.  Thus the WT and Nox2-/- 
BMMs where challenged to chemotax towards a source of CSF-1 using the 
Dunn Chemotaxis Chamber.  
WT BMM demonstrated positive chemotaxis towards a CSF-1 
gradient. (Figure 3.9) However the loss of Nox2 resulted in the loss of this 
positive chemotaxis towards the CSF-1 gradient, suggesting that Nox2 
modulation of downstream signaling following CSF-1 stimulation is crucial in 
establishing directed migration. 
 
3.3.6 NOX2-/- BMMS HAVE  REDUCED SPEED AND PERSISTENCE IN A CSF-1 
GRADIENT 
The loss of chemotaxis observed in Nox2-/- populations could be 
accounted for by a reduction in cellular speed and/or reduction in the 
persistence of movement.  Therefore the speed and persistence of the cellular 
motion was analysed. 
 The speed of migration of WT BMM towards a CSF-1 gradient was 
significantly greater than that seen in Nox2-/- BMM (p<0.001) (Figure 3.9). 
The persistence in the cellular migration towards the CSF-1 gradient was also 
significantly (p<0.001) reduced in Nox2-/- BMM as compared to WT  
(Figure 3.9). This suggests Nox2 plays an important role in the regulation of 
speed and the persistence in directed cellular migration of the BMM towards 














































Figure 3-9 Loss of chemotaxis and reduction in speed and persistence of cellular 
motility following loss of Nox2 
A: The loss of Nox2 resulted in a loss of chemotaxis towards a CSF-1 gradient. The WT 
cells showed an average upward movement (red arrow). This was significantly 
directed upwards as illustrated by the green wedged 95% confidence interval. 
Interestingly the average migration of the Nox2-/- BMM was away from the CSF-1 
gradient. 
B & C:  A significant reduction in speed and persistence of motion was seen in the 
Nox2-/- BMM towards a CSF-1 gradient as compared to WT BMM.(       : p<0.001)  
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3.3.7 NOX2-/- BMM SHOW REDUCED LEVEL OF ERK1/2 PHOSPHORYLATION 
FOLLOWING CSF-1 STIMULATION AS COMPARED TO WT BMM 
Given the differences detected in both cellular morphology, cell 
spreading and directed cell migration, altered signalling downstream of   
CSF-1 in Nox2-/- cells could explain this. In particular CSF-1 is well known to 
stimulate both ERK (Smith et al., 2008) and Akt phosphorylation (Sester et 
al., 2005)  in BMMs and levels of ERK phosphorylation have been linked to 
cell spreading (Smith et al., 2008) and both ERK1/2 and Akt have an 
established role in cellular motility (Brahmbhatt and Klemke, 2003; Turner 
et al., 2001). Thus, this set of experiments investigated whether these 
signaling moieties are downstream of Nox2.    
In response to CSF-1 stimulation both WT and Nox2-/- macrophages 
showed a increased levels of ERK1 and ERK2 phosporylation. (Figure 3.10) 
However the intensity of this response following 15mins of stimulation was 
significantly higher in the WT BMM for both ERK1 (p<0.001) and ERK2 
(p=0.01) suggesting a role for Nox2 in ERK1 and ERK2 phosphorylation 
following CSF-1 stimulation.  The duration of ERK1 and ERK2 
phosphorylation was not significantly different between WT and Nox2-/- 
BMM.  
Akt phosphorylation, following CSF-1 stimulation, also increased in 
both WT and Nox2-/- BMM by 15 minutes (Figure 3.10). However the level of 
phosphorylation at 15 mins and over the ensuing hour was not significantly 
higher in the WT BMM as compared to Nox2-/- BMM (p=0.28). Hence no 
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Figure 3-10  ERK1/2 and Akt  phosphorylation in following CSF-1 stimulation 
 WT BMM had in general higher levels of phosphorylation than Nox2-/- BMM following 
CSF-1 stimulation. This was significantly higher at time point 15mins (   :p<0.05) for 
ERK1 and ERK2. No significant difference was seen at any time point between WT and 
Nox2-/- in their levels of Akt phosphorylation. (The phosphorylation blots were on the 
same gel and normalized against their total protein blots. Phosphorylation and Total 




The coordination and synergy between the cytoskeletal dynamics at 
the leading edge, the strengthening of adhesion to the ECM and cellular 
contractility play a key role in the dynamics of cellular morphology and 
migration (Ridley, 2001b; Ridley, 2001a; Ridley, 2004; Ridley, 2008). Redox 
signaling has been shown to be influential in this process at many different 
stages. In this chapter Nox2 has been shown to be important in regulating 
cellular morphology and to be critical in modulating cellular migration, speed 
and persistence.  
 
3.4.1 DUNN CHAMBERS  
Dunn chemotaxis chamber (DCC) slides were used to investigate the 
cellular motility. Chemotaxis can be studied using a Boyden chamber or 
transwell assay. However both these methods are based on scoring cells that 
have migrated into or through a filter membrane toward a source of putative 
chemotactic factor. In these assays, the local concentration gradients of 
chemotactic factor in and around the pores of the filter membrane are 
variable and unknown. Furthermore, the migratory behavior of the cells is 
unobservable and can only be deduced from the final distribution of the cell 
population. In contrast in the DCC, the migratory behavior of cells can be 
directly observed in a gradient of known direction and magnitude. The DCC 
allows the direct observation of slowly moving cells in a concentration 
gradient that is stable over  longer periods of time (Dunn and Zicha, 1993; 
Zicha et al., 1991). The DCC chamber has been successfully used to 
characterize the migratory response of human macrophages to CSF-1 (Jones 
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et al., 2002), fibroblasts to platelet-derived growth factor (Zicha et al., 1991) 
and thrombospondin-1 (Orr et al., 2003), neutrophils to interleukin-8 (Zicha 
et al., 1998) and microglia to adenosine triphosphate/adenosine diphosphate 
(Honda et al., 2001). Hence the DCC in conjunction with time-lapse 
microscopy is a powerful tool that enables the user to observe directly the 
morphological response of cells to a chemoattractant in real time from which 
detailed information on the chemotaxis, speed and persistence of the cell 
migration can be obtained. 
3.4.2 MIGRATION- DIRECTIONALITY 
 
MAIN  FINDING: 
 Nox2 is crucial for chemotaxis towards a CSF-1 gradient. 
 
A key finding was that the loss of Nox2 in BMM resulted in the 
complete loss of chemotaxis towards CSF-1. This indicated an important role 
of Nox2 in the ability of a cell to sense an external signal and/or in cellular 
polarisation. 
Cells can respond directionally to very shallow chemoattractant 
gradients with a difference of less than 10% in the concentration of the 
chemoattractant between the front and rear of the cell (Devreotes and 
Janetopoulos, 2003). Such a small difference in signaling between the front 
and rear needs to be amplified into steeper intracellular signaling gradients 
in order to generate a cellular response. The phosphoinositides 
PtdIns(3,4,5)P3  (PIP3) and PtdIns(3,4)P2[PI(3,4)P2] along with PI3K and 
PTENS are key signaling molecules in this process (Merlot and Firtel, 2003; 
 135 
Ward, 2004). This amplification process involves both localized 
accumulation and activation of PI3Ks, which generate PIP3/PI(3,4)P2, and 
the phosphatase PTEN, which removes them (Leslie et al., 2007). Cells with 
altered PI3K or PTEN activity can usually show chemokinesis but exhibit a 
significantly reduced chemotaxis (Procko and McColl, 2005; Ward, 2004). 
Many of these signaling molecules have been shown to be redox sensitive. 
Leslie et al (Leslie et al., 2003) demonstrated that oxidative stress with H2O2 
resulted in the inactivation of PTEN. PTEN is a member of the Protein 
Tyrosine Phosphatase family which can be physiologically regulated through 
reversible oxidation resulting in their inactivation (Denu and Tanner, 1998; 
Lee et al., 1998). The inactivation of PTEN results in an increase in cellular 
phosphoinositides and thus the loss of any gradient established by the 
phosphoinositides to a chemoattractant signal. Moreover phosphoinositides, 
PtdIns(3,4,5)P3  (PIP3) and PtdIns(3,4)P2[PI(3,4)P2], have been shown, by 
way of their Phox domains for subunits p40phox  and p47phox  , to be involved in 
the recruitment and activation of these regulatory proteins,(Ellson et al., 
2001; Ponting, 1996) thus establishing another means of redox modulation of 
the downstream signaling.  
Following directed stimulation in order for the cell to migrate, it must 
become polarized. The small GTPases are important in this process and in 
particular Cdc42. Cdc42 is a master regulator of cell polarity by being active 
towards the front of migrating cells (Itoh et al., 2002) and by restricting 
where lamellipodia form (Srinivasan et al., 2003). Its importance is 
confirmed in experiments where both the inhibition and global activation of 
Cdc42 disrupts the directionality of migration (Allen et al., 1998; Etienne-
Manneville and Hall, 2002).   In contrast to this the loss of Rac did not affect 
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chemotaxis in BMM to CSF-1 (Wells et al., 2004). How Cdc42 and Nox2 are 
associated is not entirely clear however evidence from the literature suggest 
that in an in-vitro cell free experiment Cdc42 can act as a competitive 
inhibitor of ROS production by Rac-1 and Rac-2 activation of cytochrome 
b558. The cyt-b558-binding domain of Cdc42 resulted in competitive binding 
with Rac2 (Diebold et al., 2004).  
The formation of filopodia enables cells to sense their environment in 
a particular direction. Cells can then form lamelopodia fronts, with a gradual 
shift in the dominance between these fronts towards a single frontal region in 
the direction of movement. Cdc42 has been shown to be important in the 
formation of lamelopodia by restricting where lamelopodia form (Srinivasan 
et al., 2003).   The ability to shift fronts is important for cells to enable them 
to turn and migrate in the desired direction. The persistence measure reflects 
the ability of the cells to turn and achieve directionality. Thus it was in 
keeping with their lack of chemotaxis that Nox2-/- BMM demonstrated more 
convoluted migratory paths. 
Thus the results established an important role for the ROS from Nox2 
in the establishing directionality in BMM migration towards CSF-1. 
 
3.4.3 MIGRATION- SPEED AND PERSISTENCE 
 
MAIN  FINDING: 
 The innate persistence in the direction of random 
motion in BMM is increased in the absence of Nox2. 
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 Speed and persistence of directed motion is reduced in 
the absence of Nox2. 
 Downstream Nox2 signalling is mediated by ERK1/2.  
 
The experiments assessing the random motion of the BMM showed a 
significant reduction in the numbers of Nox2-/- BMM reaching the set 
horizon and an increased intrinsic persistence in direction of motion. 
Random motion allows cells to explore their environment. The increased 
intrinsic persistence observed in Nox2-/- BMM under random migration 
suggested that the loss of Nox2 could result in a reduction in the cells ability 
to turn and explore their environment. Indeed Pankov et al (Pankov et al., 
2005) had demonstrated that total Rac1 activity was important in 
determining whether random cell migration followed a more intrinsic 
random or directionally persistent pattern of motion.   The data here suggests 
that, at least in part, some of these regulatory functions of Rac1 could be 
through Nox2.   Moreover the loss of Nox2 had also significantly reduced the 
distance the BMM randomly migrate to explore their immediate 
environment, following CSF-1 stimulation.   Taken together the data 
demonstrated an important role of for Nox2 in BMM migration. 
In contrast to random motion, directional migration moves cells 
rapidly between points. An important result was the significant reduction in 
the cellular speed of migration in Nox2-/- BMM under directed motion.  The 
speed reflects an integrated measure of the rate of actin turnover in the 
cytoskeleton, actin-myosin contractility and integrin adhesion, detachment 
and their recycling by endocytosis and vesicular transport. 
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The molecular mechanism for the Nox2 dependency in the speed of 
BMM migration is not established.  Indeed many of the proteins involved in 
the control of actin cytoskeleton reorganisation are redox sensitive such as 
PTENS and PI3K (Kim et al., 2008). (Figure 3.2) Lamellipodia in moving 
cells require cycles of actin polymerization and depolymerisation. Rac 
stimulates actin polymerization by several mechanisms, including NADPH 
oxidase mediated ROS production (Moldovan et al., 2000). The relation 
between the actin cytoskeleton and ROS seems to work both ways.  Cortactin, 
an actin-binding protein that has traditionally been found to regulate 
polymerization of the actin cortex, has also been shown to mediate p47phox 
translocation to the membrane during angiotensinII induced activation of 
NADPH oxidase (Touyz et al., 2005). Moreover, actin activates Nox2 in 
neutrophils in a cell-free system, implying a direct effect on NADPH oxidase 
enzyme activity, and destabilization of the actin cytoskeleton robustly 
enhances the neutrophil respiratory burst activity (Bengtsson et al., 2006; 
Morimatsu et al., 1997). A more complete understanding of this bidirectional 
relation between NADPH oxidases and the actin cytoskeleton may shed 
further light on how it mediates migration.  
The significantly reduced phosphorylation of ERK1/2 was in line with 
its important role in cellular migration and that of Nox2 in the activation of 
Ras/Raf/MEK/ERK signalling cascade downstream from the tyrosine 
receptors. ERK1/2 localise to the cell membrane (Glading et al., 2001) and to 
focal adhesions (Fincham et al., 2000)  and promote lamellipodium 
formation and spreading in epithelial cells (Ishibe et al., 2004). Adhesion 
turnover is important for cellular migration (Chiarugi et al., 1998; Rigacci et 
al., 2002) and ERK has been shown to be important in its regulation 
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(Brahmbhatt and Klemke, 2003; Turner et al., 2001). Smith et al found that 
ERK1/2 activity was reduced in PAK1–/– BMMs which displayed spreading 
defects compared with WT BMMs thus suggesting that optimal activation of 
ERK1/2 is required during BMM spreading (Smith et al., 2008). The 
observed reduced activation of ERK1/2 in the Nox2-/- BMM following CSF-1 
stimulation suggesting a possible mechanism whereby Nox2 generated ROS 
is able to modulate the downstream response via activation of ERK.  
3.4.4 MIGRATION: ALTERNATIVE NADPH OXIDASE 
Nox4 has also recently been found to be a key player in the regulation 
of stress fiber formation and focal adhesion turnover in VSMCs (Clempus et 
al., 2007).  Poldip2 is a recently reported new regulator of Nox4 (Lyle et al., 
2009). Poldip2 is an activator of Nox4 mediated ROS production in VSMCs 
which can negatively affect focal adhesion turnover and inhibit VSMC 
migration. These findings suggest a potentially novel mechanism of local 
ROS production by which focal adhesion turnover is coordinated. Certainly a 
role of Nox2 in the regulation of such adhesion formation in BMM could 
explain the difference observed in their shape and then in their speed and 
persistence. Further studies of difference in the expression of integrins would 
increase the understanding of the exact underlying mechanism whereby the 
loss of Nox2 results in a reduction in the speed of migration in BMM. 
Schroder et al (Schroder et al., 2007) demonstrated in rat SMC that 
inhibition of Nox4 with siRNA did not affect migration to βFGF agonist 
stimulation. However the inhibition of Nox1 significantly blocked migration. 
The migration in these experiments was assessed by a scratch wound assay 
which gives a measure of cellular migration but not of the individual 
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components such as the speed, persistence or chemotaxis, unlike in the Dunn 
chamber. Nevertheless the experiment demonstrated an important role of 
Nox1 in the migration of VSMC to βFGF agonist stimulation. Similarly 
Haurani et al (Haurani et al., 2008) in a transwell set-up showed that Nox4 
promotes AngII induced myofibroblast migration. Again, the transwell set-up 
did not enable the migration to be investigated in any more detail.  
3.4.5  SUMMARY 
In summary, in order to initiate cardiac fibrosis and hypertrophy the 
migration of macrophages into tissue is an important initial step. However 
the loss of Nox2 results in significant reduction in the random migration of 
BMM. On interrogating the BMM towards a directed target the loss of Nox2 
proved crucial as its loss resulted in the complete loss of chemotaxis. Nox2 
was also important in the BMM speed and persistence towards a CSF-1 
gradient with significant reductions in both. This loss of Nox2 also 
manifested itself in a reduced ERK1/2 phosphorylation and spreading 
responses to CSF-1 stimulation.  As macrophage infiltration is an important 
first step in initiating cardiac fibrosis and hypertrophy the defect in the 
migration of Nox2-/- BMM could explain the reduction in cardiac 
hypertrophy and fibrosis observed in Nox2-/- mice following AngII 
stimulation. Thus the Nox2 in the infiltrating cells, namely the BMM, could 
be a critical cell source for the Nox2. Thus in the next chapter the effects of 
AngII exposure on WT and Nox2-/- BMM chemotaxis and migration was 
investigated.   
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4 EFFECT OF NOX2 ON BMM SHAPE, SIZE AND 
MIGRATION TO CSF-1 STIMULATION FOLLOWING 




4.1.1 ROLE OF ANGII IN THE PATHOGENESIS OF CARDIAC FIBROSIS  
Pathological AngII signalling in vascular, endothelial and cardiac cells 
promotes inflammation and altered vasoreactivity, migration and fibrosis. 
These effects ultimately contribute, at least in part, in causing hypertension, 
atherosclerosis, and heart failure. Improved clinical outcomes after 
treatment with ACE inhibitors and ARBs confirm the importance of AngII in 
the pathogenesis of these disease (Garg and Yusuf, 1995; Igarashi et al., 
2001; Yusuf et al., 2000).  
 The development of cardiac fibrosis, as part of hypertensive heart 
disease, results from the cellular deposition of extracellular matrix and the 
infiltration of macrophages, as described in the introduction [section 1.3.3].  
A number of studies and experimental models of atherosclerosis and 
hypertension have shown that RAS blockade ameliorates 
monocytes/macrophage infiltration (Capers et al., 1997; Dol et al., 2001). In 
keeping with the role of AngII in cardiac fibrosis, AngII has also been 
implicated in ECM formation and regulation (Matsubara et al., 2000; Touyz 
et al., 2001b), in regulation of collagen (Kato et al., 1991; Mifune et al., 2000) 
and proteoglycan synthesis (Evanko et al., 1998; Iozzo, 1998; Sasamura et al., 
2001). Furthermore the production of matrix metalloproteinases and 
breakdown of collagen IV is also modulated by AngII (Libby and Lee, 2000). 
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These effects of AngII are humoral and occur independently of the physical 
blood pressure effects. Hence cardiac fibrosis has been found to develop in 
both the left and right ventricles, on biopsies of myocardial tissue, despite the 
right heart pumping blood against a reduced afterload and not developing 
cardiac hypertrophy(Amanuma et al., 1994). Studies have shown that the 
blockade of AngII or its action results in  reduced fibrosis. As such Tokuda et 
al (Tokuda et al., 2004) demonstrated that a sub-depressor dose of 
candersartan (an angiotensin II receptor blocker), in mice who had had 
supra-renal aortic banding, markedly ameliorated perivascular fibrosis. Also, 
AngII infusion increased aortic atherosclerosis and aneurysm formation 
again independent of blood pressure.   Hence the pathophysiological 
importance of AngII in hypertensive heart disease cannot be overstated.  
4.1.2 ROLE OF ANGII IN CELLULAR MIGRATION 
The infiltration of macrophages is an important early event in the 
development of AngII induced cardiac fibrosis. This was demonstrated by the 
blockade of MCP-1 or ICAM-1, by way of neutralising antibodies (Kuwahara 
et al., 2003; Kuwahara et al., 2004). This inhibition of macrophage 
recruitment and tissue infiltration prevented the onset of cardiac fibrosis.  
AngII has been shown in a number of studies to induce cellular 
migration via MAPK activation (Kyaw et al., 2004; Ohtsu et al., 2005; Xi et 
al., 1999). In keeping  with this  Yoshizumi et al (Kyotani et al., 2010) 
demonstrated that olmesartan inhibited AngII induced VSMC migration.  
However, the downstream signalling and subsequent cellular migration 
induced by AngII has been shown to be more complex. Thus aldosterone has 
been shown to act synergistically with AngII to stimulate VSMC migration. 
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This cross talk between aldosterone and AngII is complex, involving 
downstream c-Src regulated NADPH oxidase activation, resulting in 
Rho/Rho kinase activation controlling cellular migration (Montezano et al., 
2008). This synergistic effect on cellular migration could explain, at least in 
part, the several lines of evidence suggesting a complex interaction between 
AngII and aldosterone in-vivo  from our laboratory and others (Iglarz et al., 
2004; Johar et al., 2006). Along with inducing migration AngII has also been 
demonstrated to augment cellular migration towards other 
chemoattractants. Thus VSMC pre-treated for 48 or 72 hours with AngII 
demonstrated significantly more migration towards PDGF.  This effect was 
ERK1/2 dependent and was inhibited by the AT1 receptor blockade (Blaschke 
et al., 2002).   Thus AngII has an important role in inducing cellular 
migration which is an essential cellular event in the development of cardiac 
fibrosis.  
4.1.3 ROLE OF NOX2 IN THE PATHOGENESIS OF ANGII INDUCED CARDIAC 
FIBROSIS 
Many studies, in particular animal studies of AngII induced 
hypertensive heart disease causing cardiac hypertrophy and fibrosis, have 
shown an important role for Nox2 (Bendall et al., 2002a; Byrne et al., 2003; 
Johar et al., 2006), as summarised in the introduction  [section 1.9]. Thus in 
mouse models of hypertensive heart disease simulated with AngII infusion, 
our laboratory has shown that Nox2-/- mice had markedly reduced fibrosis 
(Bendall et al., 2002a; Byrne et al., 2003; Johar et al., 2006). Furthermore 
Johar et al (Johar et al., 2006)  showed that the profibrotic effects of AngII  
were inhibited by the antioxidant N-acetyl-cysteine, consistent with the role 
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of ROS in this process. Nox2 has also been implicated in aldosterone induced 
myocardial fibrosis (Johar et al., 2006). Also previous studies using global 
Nox2 knockout mice have shown Nox2 to be important in the development of 
cardiac hypertrophy in response to a low sub-pressor dose of AngII (Bendall 
et al., 2002a) and also at pressor doses (Byrne et al., 2003).  Thus these 
studies established an important association between AngII stimulation, 
NADPH oxidase and the development of cardiac fibrosis and hypertrophy. 
However these studies were not able to ascertain the cell source where the 
effect of the Nox2 was crucial for the development AngII induced 
hypertensive heart disease. In chapter 3 Nox2 was shown to be crucial in 
BMM migration towards CSF-1 thus establishing BMM as a possible 
important cell source for Nox2 in the development of AngII induced cardiac 
fibrosis and hypertrophy.  
4.1.4 DOWNSTREAM ANGII SIGNALLING AND NOX ACTIVATION    
Once AngII binds to its receptor it activates a series of signaling 
cascades. Most of the known physiological effects of AngII are mediated by 
its receptor angiotensin type 1 receptor (AT1R) (Matsusaka and Ichikawa, 
1997). This receptor is widely distributed in all organs, including liver, 
adrenals, brain, lung, kidney, heart and vasculature. Once AngII binds to the 
AT1R, it activates a series of signaling cascades, which in turn regulates the 
various physiological effects of AngII.  
One well-established mechanism by which AngII signaling occurs 
involves the classic G protein-mediated pathways (Ushio-Fukai et al., 1998). 
These proteins activate further downstream effectors such as phospholipase 
C (PLC), phospholipase A2 (PLA2)and phospholipase D (PLD) (Ushio-Fukai 
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et al., 1999).  Activation of PLC produces inositol-1,4,5-triphosphate (IP3) 
and diacyglycerol (DAG). IP3 binds to its repector on sarcoplasmic reticulum 
opening channels to allow efflux of calcium into the cytoplasm causing 
eventual cellular contraction.  DAG activates PKC which participates in the 
activation of Ras/Raf/MEK/ERK pathway. PLD activation results in 
hydrolysis of phosphatidylcholine (PC) to choline and phospatidic acid (PA). 
PA is rapidly converted to DAG leading to sustained PKC activation. PLA2 
activation leads to the production of arachidonic acid (AA)  and its 
metabolites. These derivatives of AA not only contribute to cellular 
contraction but AA itself can also act by activating NADPH oxidase (Block et 
al., 2006).  Thus G protein mediated pathways contribute to cellular 
contraction and activate downstream proteins that enhance migration 
related signalling.  
In addition to signaling through heterotrimeric G proteins, AT1 
receptors have also been shown to activate monomeric small G proteins.  The 
small G proteins were introduced in chapter 3  comprising of RhoA, Rac1 and 
Cdc42 amongst others, that act as molecular switches to regulate cellular 
responses (Laufs and Liao, 2000). AngII stimulated Rac1 participates in 
cytoskeletal organization, cell growth, inflammation and regulation of 
NADPH oxidase. In VSMC AngII stimulated Rac1 acts upstream of p21-
activated kinase and JNK. 
 An alternate mechanism by which AngII signals further downstream 
is by activating MAPKs, including ERK1/2, JNK and p38MAPK.  AngII can 
differentially activate the three major members of the MAPK family (Touyz et 
al., 1999; Touyz et al., 2001a) and the events further downstream are 
numerous and heterogeneous.  AngII stimulates phosphorylation of many 
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non-receptor tyrosine kinases including c-Src family kinases , Ca2+-
dependent tyrosine kinases (e.g Pyk2) , focal adhesion kinase (FAK) and 
Janus kinases (JAK). In addition, AngII can cross-talk with several  receptor 
tyrosine kinases, via AT1R activation, including EGFR (Ushio-Fukai et al., 
1998), PDGF (Heeneman et al., 2000) and insulin receptor.  The induction of 
the above mentioned pathways is tightly regulated. In patients with 
overstimulated RAAS or enhanced responsiveness to AngII these pathways 
may initiate and propagate pathological events. The role of tyrosine kinases 
in AngII-mediated signaling has been extensively reviewed elsewhere (Berk 
and Corson, 1997; Kim and Iwao, 2000; Matsusaka and Ichikawa, 1997).  
Interestingly many of the effects of AngII are mediated by ROS 
(Griendling et al., 2000). These have been demonstrated by the use of 
antioxidants, where the use of SOD or tempol corrected the AngII induced 
elevation in blood pressure with a decrease in superoxide production 
(Laursen et al., 1997; Nishiyama et al., 2001).  ROS are also known to directly 
affect important regulators of cell migration such as PTEN, FAK or Src 
(Chiarugi et al., 2003; Kwon et al., 2004; Li et al., 2008). A growing body of 
data point to the key role of ROS production by NADPH oxidase in the 
control of cell migration and cytoskeletal reorganization (Moldovan et al., 
2000; Ushio-Fukai, 2006). NADPH oxidase has been shown to be an 
important source of ROS formation following AngII stimulation in cultured 
VSMC (Griendling et al., 1994).  Infusion of AngII  has been shown  to induce 
hypertension associated with an increase in the  NADPH oxidase derived 
superoxide production (Rajagopalan et al., 1996a). This increased acitivity of 
NADPH oxidase was associated with an increase in the expression of p22phox, 
levels of which decreased following the use of SOD.  
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The signalling pathways in VSMC have been the most extensively 
studied, where it has been shown that AngII regulates NADPH oxidase 
activity in a biphasic manner.  The initial phase occurs rapidly, within 30-
seconds, and involves the activation of PKC and the mobilization of calcium 
to initiate p47phox phosphorylation. The second plateau phase which occurs 
over approximately 6-hours acts through c-Src and PI3-K to activate Rac1 
and other NADPH oxidase subunits (Seshiah et al., 2002).  AngII can also 
regulate NADPH oxidase by increasing the expressions of its subunits and 
influencing the rate of their association. As such in human VSMCs increased 
levels of of p47hox mRNA has been shown along with increased levels of 
phosphorylation and translocation of p47phox  to the membrane following 
AngII stimulation (Touyz et al., 2003; Touyz et al., 2004).  In isolated rat 
VSMCs, interfering with p22phox antisense transfection resulted in a 
reduction in AngII induced superoxide production (Ushio-Fukai et al., 1996). 
The overexpression of p22phox  targeted specifically to VSMC potentiated 
AngII-induced vascular hypertrophy the effect of which was prevented by the 
treatment with ebselen an antioxidant, thus verifying ROS as a direct 
activator (Weber et al., 2005). In other cell types AngII has been found to 
regulate NADPH oxidase activity by again regulating the expression of its 
subunits. Thus in CMEC, p22phox  expression and subsequent ROS production 
(Xie et al., 2001), the expression of Nox2 and Nox4 in human umbilical vein 
and the expression of Nox1, 2 and 4 and p22phox in endothelial cell from rat 
aorta have been shown to be increased following treatment with Ang II 
(Higashi et al., 2003; Yamagishi et al., 2005). 
In summary, following AngII stimulation the downstream signalling 
pathways are extensive and complex. This enables the downstream signalling 
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of AngII to be modulated, for example by NADPH oxidase, and also allows 
for AngII to modulate the downstream signaling of other agonists such as 
CSF-1.  
4.1.5 SUMMARY 
Taken together the evidence suggests macrophage migration and 
infiltration into the heart is crucial for the development of hypertensive heart 
disease secondary to AngII stimulation. Evidence from our laboratory 
amongst others has shown Nox2 to play an important role in AngII induced 
cardiac fibrosis. In chapter 3 Nox2 was shown to be crucial in the migration 
of BMM towards a CSF-1 gradient thus establishing the Nox2 in BMM as an 
important cell source. However the exact effect that the presence of AngII 
may have on this BMM migration, especially in the absence of Nox2, is not 
established. The current chapter aims to investigate the differences the 
presence of AngII may have on the cellular migration of BMM, especially in 





The methods in this chapter are similar to those in chapter 3. 
Consequently the methods are only described here in summary with details 
given of the differences in the methodology where they arise.  
4.2.1 ISOLATION AND CULTURE OF MOUSE PRIMARY BMMS  
The murine femoral bone were harvested and the marrow flushed 
using a 21-gauge needle with 5 mL of macrophage starve medium (section 
8.2.2). After centrifugation  the pellet was resuspend in 5 mL of macrophage 
starve medium, counted and seeded at 2x105 cells/cm2 density onto a 10cm 
tissue culture petri dishes for 3 days in macrophage growth media. 
After 3 days the non-adherent population of cells containing the 
monocytes were removed.  The cells were centrifuged, resuspended and 
counted and then cryogenically frozen in growth medium. When required the 
cells were defrosted and seeded onto 6-cm bacterial culture plates in 5 mL of 
growth medium at a density of 10 cells/mL. The cells were then incubated for 
a further 5 days without refeeding. AngII was added to the appropriate cells 
at  a concentration of 10-7M as previously used in our laboratory. This was 
replenished after 2 days to maintain the concentration of AngII. The cells in 
general remained in suspension for approximately 4 days. The differentiated 
BMMs then became adherent and were harvested on day 5 for 
experimentation. The cells were harvested off the dish with the dissociation 





4.2.2 DUNN CHEMOTAXIS CHAMBER EXPERIMENTS  
4.2.2.1 Preparation 
The Dunn Chemotaxis Chambers (DCC) were washed and prepared 
from storage as before (section 3.2.3.2). Care was taken to invert the 
coverslip with the AngII incubated cells attached onto the chamber, such that 
the inner well was completely covered with a gap left in the outer well. The 
inner well contained macrophage starve media with AngII. (Figure 4.1 B) 
Once the coverslip was in place, the chamber was sealed on three sides with 
wax and the outer well was drained from the fourth side (gap) with Whatman 
paper.  100 μL of macrophage growth media with AngII was then added into 
the outer well through the gap. Thus there was a CSF-1 gradient and no AngII 
gradient across the bridge in the Dunn chamber. (Figure 4.1 B & C) The final 
edge was quickly waxed to ensure that the gap was completely sealed. The 
DCC was immediately placed onto the microscope stage and filming started. 
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Figure 4-1 Preparation of the Dunn Chamber  
A: Cover slip with AngII conditioned BMM was placed onto the Dunn chamber. B: The 
outer chamber contained growth media (+CSF) with AngII while the inner chamber 
was filled with starve media (no CSF) with AngII. C: Thus there was no AngII gradient 
across the bridge. The cells are exposed only to the CSF-1 gradient. D: Positive 
chemotaxis of the AngII conditioned BMM towards the CSF-1 gradient  was recorded 






4.2.2.2 Time-Lapse Microscopy and Migration Analysis 
The assembled chamber was placed on the heated stage and a region 
of the bridge was selected for recording and the image orientated such that 
the source of chemoattractant, namely the CSF-1, in the outer well was at the 
top of the screen. (Figure 4.1 D) The cells were filmed for 18hrs and 
subsequently tracked and analysed using Mathematica. (also see section 
3.2.3.3) 
4.2.3 STAINING  
The AngII incubated BMM were seeded onto the coverslips at  2X105 
cells per coverslip.  The cells were allowed to settle and then those for 
starvation and/or restimulation were starved of CSF-1 by overnight 
replacement of AngII-containing growth medium with AngII containing 
starve media. Following CSF-1 starvation the cells for restimulation were 
stimulated with CSF-1 by the reintroduction of growth media containing 
AngII for 5mins. Thus the response of the cells to CSF-1 was assessed in the 
presence of AngII. The cells were then washed with PBS and fixed with 1% 
paraformaldehyde for staining.  
The cells on the coverslips were permeabalised with methanol and 
blocked with 5% BSA. The cells were stained for actin using phalloidin-FITC 
(1:1000) made in 1%BSA. The staining was visualised under fluorescent 
microscopy and images taken. The images were analysed using Image-J 
where the cells were outlined to obtain their shape and size. Five random 




4.2.4 WESTERN BLOTTING  
The cells were seeded onto 6 well plates in macrophage growth 
medium containing AngII. The growing cells did not have their media 
changed. Those for starvation had their media changed to macrophage starve 
media containing AngII. After overnight starvation of CSF-1, macrophage 
growth medium containing AngII was added to cells for restimulation for  5, 
10 15, 30 or 60mins following which the wells were washed and lysis solution 
added. The 6 well plates were kept on ice, the wells scraped, samples 
removed and placed into eppendorf tubes. The samples were spun at 
12000rpm for 30 mins and the supernatant removed to a new eppendorf. To 
denature the protein, samples were heated to 100oC for 3mins, sample buffer 
was added and the sample frozen and stored. Protein expression was then 





4.3.1 NOX2-/- BMM IN THE PRESENCE OF ANGIOTENSIN II HAVE A 
SIGNIFICANTLY INCREASED SPREAD AREA. 
The average spread area of growing WT BMM in the presence of AngII 
was smaller.(Figure 4.2) In complete contrast, in the presence of AngII, 
Nox2-/- BMM showed a significant increase in their growing spread area by 
22% (0.057AU; p=0.04). As a result growing BMM spread area, in the 
presence of AngII, was significantly (p<0.001) greater in Nox2-/- BMM 
compared with WT BMM.  
In the presence of AngII cell elongation decreased by a similar amount 
in both WT and Nox2-/- BMM. Thus growing cellular shape, in the presence 
of AngII, was not affected by the absence of Nox2.  
AngII incubation of growing WT and Nox2-/- BMM resulted in an 
altered phenotype. The presence of AngII had resulted in both WT and  
Nox2-/- BMM becoming more rounded in shape. However, while growing WT 
BMM showed a decrease in their cellular spread area, Nox2-/- BMM showed a 
significant increase. Thus, the data suggest that BMM can differentially 
regulate their cellular shape and size.  Also that AngII signalling via Nox2 
reduces cellular size which in the absence of Nox2 results in stimulation of 

















































Figure 4-2  Difference in the spread area and elongation between growing WT 
and Nox2-/- BMM following AngII incubation. 
Growing BMM showed an important role for Nox2 in the regulation of their spread area 
following AngII incubation. WT BMM decreased their spread area in contrast to Nox2 -/- 
BMM which showed a significant increase in their spread area in the presence of AngII.  
This opposing response in cellular size is in contrast to the regulation of cellular shape 
in which the more elongated phenotype of Nox2-/- BMM was rescued such that both 
groups of cells had a similar, more rounded, shape in the presence of AngII. (   = p<0.05, 










4.3.2 NOX2-/- BMM SHOW LESS  CSF-1 INDUCED CELLULAR SPREADING IN 
THE PRESENCE OF ANGII 
In chapter 3 CSF-1 starvation had resulted in a 37% reduction in WT 
BMM spread area and a 38% reduction in Nox2-/- BMM spread area (p=ns). 
It should be noted that the Nox2-/- BMM had a larger absolute growing 
spread area than WT BMM. The spread area, in the presence of AngII, 
showed a similar reduction in both WT and Nox2-/- BMM of 23% and 36% 
respectively. Thus the ability of WT and Nox2-/- BMM to relatively change 
their spread area, following CSF-1 starvation, was unaffected by the presence 
of AngII. However it is noteworthy that the AngII incubated Nox2-/- BMM 
had a significantly (p=0.048) larger absolute starved spread area from that 
observed in WT, Nox2-/-, and AngII incubated WT BMM. (Figure 4.3). Taken 
together the data demonstrated that, though WT and Nox2-/- BMM showed a 
relatively similar response to CSF-1 starvation, in the presence of AngII, the 
initial larger growing spread area observed in AngII incubated Nox2-/- BMM 
(Figure 4.2), was not completely reversed following CSF-1 starvation, as was 
observed in Nox2-/- BMM without AngII. (Figure 3.7)  
The re-introduction of CSF-1 to AngII incubated WT BMM showed a 
significant increase in their spread area. The area increased by 54% (0.088 
AU; p<0.001) which was less than the 79% response seen in WT BMM in the 
absence of AngII. However this reduced response, by 25%, was not 
statistically significant (p=0.09).  
In contrast, the re-introduction of CSF-1 to AngII incubated Nox2-/- 
BMM showed only a borderline significant increase in their spread area. The 
area increased by only 14% (0.03 AU; p=0.05) as compared to the 55% 
response seen in Nox2-/- BMM in the absence of AngII. This reduced 
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response, by 41%, was statistically significant (p<0.001). Thus in Nox2-/- 
BMM the presence of AngII had further reduced the spreading effect by    
CSF-1.    
Thus in summary the data showed that, in the presence of AngII, Nox2 
is important in CSF-1 induced cellular spreading. In the presence of AngII, 
WT BMM had a reduced cellular spreading response to CSF-1 stimulation. 
However the loss of Nox2 not only resulted in a reduced ability to contract 



















Difference in increase in spread area following 5mins CSF-1 









Figure 4-3  Difference in the increase in spread area following 5mins CSF-1 
stimulation in WT and Nox2ko BMM with and without ANG incubation.  
Incubation of WT BMM with AngII resulted in a non-significant reduction in the cellular 
spreading in response to CSF-1 stimulation. (WT:79% vs WT AngII:54%) In contrast 
the response in the Nox2-/- BMM, following AngII incubation, of just 14% was only 
borderline significant (p=0.05). The cellular spreading response, following incubation 
with AngII, was a significantly reduced (Nox2-/-: 55% vs Nox2-/- AngII: 14%).                    
(   = p<0.05) Thus Nox2-/- BMM appear to loose their CSF-1 induced cellular spreading 
response following incubation with AngII.  
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4.3.3 CSF-1 STIMULATION IN NOX2-/-  BMM INDUCEED A LARGER REDUCTION 
IN CELLULAR ELONGATION ONLY IN THE PRESENCE OF ANGII  
The presence of AngII did not affect the ability of WT and Nox2-/- 
BMM to elongate following CSF-1 starvation, similar to their response in the 
absence of AngII. (see section 3.3.3)   
The presence of AngII did not significantly affect the ability of WT 
BMM to change shape following restimulation with CSF-1. (Figure 4.4) 
However, in the presence of AngII, the Nox2-/- BMM shortened significantly 
more [0.06AU (p=0.01)] than WT BMM. Thus the data suggests that AngII 
does not affect the cellular shape changes induced by CSF-1 stimulation and 
that the response elicited by AngII in Nox2-/- BMM is non-Nox2 dependent 






















Difference in the decrease in elongation following 5mins CSF-1 














Figure 4-4 Increased reduction in the elongation of Nox2-/- BMM incubated with 
AngII following 5mins CSF-1 stimulation 
The decrease in elongation in WT BMM following CSF-1 stimulation is unchanged in 
WT BMM incubated with AngII or with the loss of Nox2. However the absence of Nox2 
in BMM incubated with AngII resulted in a larger decrease in their elongation following 
CSF-1 stimulation. This is suggestive of a more complicated downstream inte rplay 
between Nox2 and AngII signalling.  
 
In summary the smaller and more rounded phenotype observed in WT 
BMM in the presence of AngII is significantly changed in the absence of Nox2 
resulting in a larger growing spread area. Reduction in BMM’s ability to 
reduce and increase cellular spread area following CSF-1 starvation and 
stimulation in the presence of AngII is significantly enhanced in the absence 
of Nox2. The presence of AngII or the absence of Nox2 did not significantly 
influence cellular shape changes following CSF-1 stimulation.  However in 
combination the presence of AngII and the absence of Nox2 demonstrated a 
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hitherto unobserved cellular shape change following CSF-1 stimulation due 
to AngII singnalling via non-Nox2 downstream signalling pathways.  
4.3.4 NOX2-/- BMM MAINTAINED A LACK OF CHEMOTAXIS TOWARDS A  CSF-1 
GRADIENT IN THE PRESENCE OF ANGII 
In chapter 3 Nox2-/- BMM showed a loss of chemotaxis towards a   
CSF-1 gradient. The presence of AngII did not change this response in WT 
and Nox2-/- BMM. Thus WT BMM, in the presence of AngII, continued to 
demonstrate significant positive chemotaxis towards a CSF-1 gradient 
whereas the Nox2-/- BMM showed a similar lack of chemotaxis. (Figure 4.5) 
The data would therefore suggest that any stimulation of the 
downstream signalling in the presence of AngII is redundant with regards to 
influencing the positive chemotaxis as observed in WT BMM. More 
importantly any such changes were not able to rescue the lack of chemotaxis 
observed in the absence of Nox2.  
 
4.3.5 ABSENCE OF NOX2 REVERSED THE EFFECT OF ANGII ON  SPEED  OF 
MIGRATION 
In the presence of AngII WT BMM showed a significant (p<0.001) 
decrease in their speed of migration towards a CSF-1 gradient. (Figure 4.5) 
The speed was reduced to the level observed in Nox2-/- BMM without AngII 
stimulation (p=0.2). In contrast, with the absence of Nox2 a significant 
(p<0.001) increase was observed in the speed of migration. (Figure 4.5)  The 
speed increased to a value similar to that observed in WT BMM without 
AngII stimulation (p=0.1).  
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These data suggests that following AngII stimulation, the downstream 
Nox2 dependent signaling resulted in a reduction in cellular speed of 
migration, towards a CSF-1 gradient. In the absence of Nox2 AngII 
stimulation increased the speed of migration towards a CSF-1 gradient. 
Hence this implicated the signalling pathways stimulated, independent of 
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Figure 4-5 The chemotaxis speed and persistence in the motion of WT and Nox2 -/- 
BMM 
WT BMM incubated with AngII demonstrated positive chemotaxis which was not 
observed in the Nox2-/- BMM. In the presence of AngII the speed of migration decreased 
and the persistence increased in WT BMM. In the absence of Nox2, AngII stimulation 
resulted in an increase in the speed of migration and the persistence showed an even 
larger increase. Thus in the presence of AngII, Nox2 dependent signalling, reduces the 
speed and attenuates the increase in persistence towards a CSF-1 gradient. Thus both 
speed and persistence show increases in the absence of Nox2 following BMM 
incubation with AngII. (N= 20 WT or Nox2-/- tracks)     
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4.3.6 PRESENCE OF NOX2 ATTENUATES ANGII INDUCED INCREASE IN 
PERSISTENCE OF THE MIGRATION IN BMM TOWARDS A CSF-1 GRADIENT. 
The presence of AngII significantly (p=0.006) increased the 
persistence in the migration of WT BMM.  (Figure 9.5) In chapter 3 the loss 
of Nox2 had resulted in a significantly (p<0.001) decreased persistence. 
However in the presence of AngII, Nox2-/- BMM showed a significant 
(p<0.001) and substantial increase in persistence to a value which was 
significantly greater than that observed in AngII incubated WT BMM 
(p<0.001). (Figure 4.5) The data  imply that downstream signaling of AngII 
via Nox2 could possibly be inhibiting the increase in persistence, thus the 
absence of Nox2 resulted in a larger increase in cellular persistence. 
Alternatively, other non-Nox2-dependent signalling pathways may be 
stimulated underlying the increase.   
Taken together the data suggests that the effect of AngII appears to be 
one where the cells migrate more slowly with more directionality towards the 
CSF-1 gradient.  The response in Nox2-/- BMM was considerably different. 
Given their lack of chemotaxis towards the CSF-1 gradient, the increased 
speed and persistence manifested itself as rapid forward and backward 
movements on the Dunn chamber.   
 
4.3.7 IN THE PRESENCE OF ANG II CSF-1 STIMULATION RESULTED IN MORE 
ERK1 PHOSPHORYLATION IN NOX2-/-  BMM    
WT and Nox2-/- BMM in the presence of AngII showed a similar 
ERK1/2 and Akt phosphorylation profile to that observed in the absence of 
AngII. Namely the increase in phosphorylation peaked in intensity by 15mins 
after which it declined to baseline.  
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As such with AngII incubation both WT and Nox2-/- BMM showed an 
increased level of ERK1 and ERK2 phosphorylation by 15 mins.   ERK1 
phosphorylation in WT BMM at 15mins was higher though this did not reach 
statistical significance (p=0.25). (Figure 4.6) However in Nox2-/- BMM ERK1 
phosphorylation increased significantly (p=0.023).    
The phosphorylation of ERK2 following AngII incubation in both WT 
and Nox2-/- BMM showed a similar significant (WT: p=0.02 and Nox2-/-: 
p=0.05) increase by 15 mins.  (Figure 4.6) 
 Following AngII incubation the levels of Akt phosphorylation did not 
show any significant difference from the levels of phosphorylation observed 
in WT or Nox2-/- BMM in the absence of AngII.  (Figure 4.6) 
Thus, following CSF-1 stimulation, AngII incubation had resulted in a 
significantly larger increase in ERK2 phosphorylation, independent of Nox2. 
However with the loss of Nox2 a larger increase in the level of ERK1 
phosphorylation was seen in the presence of AngII. Therefore this differential 
response could, in part, explain the exaggerated responses observed in   
Nox2-/- BMM, in the presence of AngII, following CSF-1 stimulation in 
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Figure 4-6 Change in phosphorylation profile following AngII incubation to CSF-1 
stimulation  
 A significant increase in the levels of ERK1 phosphorylation at time point 15mins was 
seen in Nox2-/- BMM following AngII incubation. The increase in ERK1 phosphorylation 
in WT BMM did not reach statistical significance. Significant increases in the levels of 
ERK2 phosphorylation was seen in both WT and Nox2-/- BMM. No significant change 
was seen in the Akt phosphorylation. Thus following in the presence of AngII, ERK1 





4.4 DISCUSSION  
In hypertensive heart disease, the RAAS has been shown to be 
upregulated (Egido, 1996) and this increased exposure of cells and tissue to 
AngII is thought to play an important pathophysiological role. Thus AngII 
has been demonstrated to affect cell adhesion (Kim et al., 1996; Pastore et al., 
1999; Prasad et al., 2001) and chemotaxis (Blaschke et al., 2002; Fukuhara et 
al., 2000; Liu et al., 2003; Montezano et al., 2008), responses important in 
the development of cardiac fibrosis and hypertrophy.   In chapter 3 Nox2 was 
demonstrated to be crucial in BMM chemotaxis towards a CSF-1 gradient. In 
this chapter the effect of AngII exposure on this migratory response of BMM 
towards  CSF-1 stimulation was investigated. Thus  differences in the 
response between WT and Nox2-/- BMM could explain, at least in part, in-
vivo differences observed in the development of cardiac fibrosis and 
hypertrophy.  
4.4.1 EFFECT OF ANGII ON BASELINE GROWING BMM SHAPE AND SIZE 
 
MAIN  FINDING: 
 AngII effects mediated by Nox2 reduces the size of growing WT 
BMM. 
 
One of the major functions of AngII is vasoconstriction which is 
mediated by G-protein dependent signaling pathways.  Activation of AT1 
receptors leads to downstream effectors such as PLC which produces IP3 and 
DAG. IP3 binds to its receptor on the sarcoplasmic reticulum allowing a 
calcium efflux which results in cellular contraction by myosin light chain 
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kinase (MLCK). The contracted smaller, rounded phenotype of the growing 
WT BMM in the presence of AngII was understandable. Interestingly, this 
AngII mediated effect was dependent on Nox2 as the   Nox2-/- BMM failed to 
develop a similar rounded contracted phenotype. In contrast, the Nox2-/- 
BMM showed a larger growing cellular size. This may simply reflect the 
effects of AngII in the absence of any downstream Nox2 modulation thus 
implying a crucial role for Nox2 in AngII induced cellular contraction 
regulating cellular size. Alternatively, it could be the result of AngII 
stimulation of other pathways in the altered cellular physiology observed in 
Nox2-/- BMM. In chapter 2 Nox2-/- fibroblasts were found to have a higher 
baseline ROS production probably due to the increased levels of Nox4 
subunits (Byrne et al., 2003). This requires further study to elucidate 
whether the differential stimulation of downstream Nox subunits by AngII 
can result in contrasting cellular responses, namely cellular contraction or 
spreading.  
4.4.2 EFFECT OF NOX2 ON THE INTERPLAY BETWEEN ANGII AND CSF-1 
INDUCED CELLULAR SPREADING  
 
MAIN  FINDINGS: 
 AngII incubation reduces CSF-1 induced spreading in BMM. 
 Nox2 is important in determining the spreading response to 
CSF-1 stimulation, following AngII incubation. 
 
Most in vitro studies of cellular migration use a single agent to 
stimulate migration. Cellular migration in vivo is probably a result of the 
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exposure to multiple promigratory and antimigratory molecules. Therefore 
receptor crosstalk is likely to occur and have a significant effect on migration. 
The experiments involving CSF-1 stimulation investigating cellular spreading 
or migration, allowed for a simple experiment to observe the interplay 
between AngII and CSF-1. As the cellular processes controlling cellular shape 
and size and that in cellular migration are similar, both were investigated in 
response to CSF-1 stimulation.   
Stimulation of BMM by AngII reduced the spreading response 
induced by CSF-1. This interplay is in keeping with the effects of AngII 
observed elsewhere whereby it influences the signalling transduction 
mechanism induced by other agonists. A prime example of this is insulin 
signalling. In vivo studies in rats show that infusion of AngII induces insulin 
resistance (Ogihara et al., 2002; Patiag et al., 2000) and that patients with an 
imbalance in RAS homeostasis exhibit decreased insulin sensitivity (Kurtz 
and Pravenec, 2004; Nosadini and Tonolo, 2004). In the current experiment 
AngII stimulation decreased the CSF-1 induced cellular spreading response. 
Interestingly Nox2 was found to be important in this process. Thus the 
decreased response following CSF-1 stimulation, in the presence of AngII, 
was larger in Nox2-/- BMM. The exact mechanism for this would require 
further study however the transactivation of receptor tyrosine kinases is a 
major mechanism by which AngII influences other signalling pathways and 
could therefore be a possibility. Both the receptor tyrosine kinase pathways 
and AngII activated G protein signalling pathways activate several common 
downstream pathways, of which some are redox sensitive. Hence 
nonreceptor activation of downstream receptor kinase signalling pathways by 
AngII can occur, with the possibility of Nox2 modulation. In recent years       
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c-Src, a tyrosine kinase, has surfaced as a key player and has been shown to 
be activated by AngII in a ROS dependent manner. Src kinase and its 
substrate such as FAK and Pyk2 have been shown to be regulated by AngII. 
Thus AngII can phosphorylate FAK to allow for cell adhesion and activation 
of cytoskeletal proteins including Pyk2 (Eguchi et al., 1999), paxillin (Leduc 
and Meloche, 1995) and talin (Sabe et al., 1997) all of which interact to 
regulate cell shape and size.  
 
 
4.4.3 EFFECT OF NOX2 ON THE INTERPLAY BETWEEN ANGII AND CSF-1 
INDUCED BMM MIGRATION- SPEED OF CELLULAR MIGRATION 
 
MAIN  FINDINGS: 
 AngII incubation reduced the directed speed of motion 
towards a CSF-1 gradient in BMM. 
 Nox2 is crucial for chemotaxis as AngII incubation could not 
rescue the loss in chemotaxis in Nox2-/- BMM. 
 Nox2 is not crucial for cellular speed towards a CSF-1 gradient 
as AngII incubation can rescue the reduction in speed.  
 
BMM exposed to AngII had reduced speed of migration towards a 
CSF-1 gradient. This was in contrast to  Blaschke et al (Blaschke et al., 2002) 
who had shown that pre-incubation of rat VSMC with 48 or 72 hours of AngII 
significantly increased PDGF directed migration. This effect was inhibited by 
AT1 receptor blockade confirming it to be an AngII effect.  Inhibition of 
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ERK1/2 also abolished the AngII effect on PDGF directed VSMC migration. 
In keeping with this, 48 hrs of incubation had resulted in an increase in 
expression and phosphorlylation of ERK1/2 and proline rich tyrosine kinase 
2 (Pyk2) and focal adhesion kinase (FAK) suggesting that changes in their 
levels could be responsible for the changes in migration. Taking both 
observations together the data would imply that the integrated effect of AngII 
on a tyrosine kinase receptor based chemoattractant could be cell-specific.   
It is probable that in-vivo AngII production by local RAS at sites such 
as an atheromatous plaque could promote PDGF directed migration of 
VSMC.  In contrast, a slower speed of migration in BMM may aid the 
migration of the macrophages across the endothelium into tissue thus 
explaining the observed reduction in the speed of migration in BMM towards 
CSF-1. Studies have shown that in normal rat and human hearts, ACE 
expression is confined almost exclusively to the endothelial cells of coronary 
arteries, arterioles and capillaries (Falkenhahn et al., 1995). Thus circulating 
monocytes attracted by tissue CSF-1, on exposure to endothelial AngII could 
slow down their motility, facilitating their diapedesis across the endothelium. 
Myocardial expression of ACE is upregulated in pressure overloaded rat 
ventricles and in viable myocardium following experimental myocardial 
infarction, resulting in more conversion of AngI to AngII (Challah et al., 
1995; Hirsch et al., 1991; Schunkert et al., 1990; Wollert et al., 1994). Thus 
high AngII production at sites of inflammation, as in hypertensive heart 
disease, could slow and retain infiltrating macrophages to the site of interest.  
The increased exposure of resident cells, such as cardiac fibroblast, to these 
infiltrating macrophages would enable macrophages, by the paracrine 
production of TGFβ, to transform the fibroblasts to myofibroblasts.  
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The Nox2-/- BMM, despite an increased speed of migration in the 
presence of AngII, failed to reach the set horizon even after 18 hours of 
observations, thus failing to register a positive chemotactic response towards 
the CSF-1 gradient. The data would suggest that Nox2 remains crucial in 
establishing a chemotactic response towards the CSF-1 gradient as discussed 
in chapter 3 and that stimulation with AngII and further downstream 
signalling pathways, independent of any Nox2, is not able to rescue this. The 
data also suggests that the role of Nox2 in the regulation of cellular 
chemotaxis and speed of migration is different. Thus Nox2 is crucial for 
chemotaxis towards CSF-1 and though Nox2 is also important in the 
regulation of cellular speed, it is not essential. Stimulation by AngII can 
rescue the speed of migration, independent of Nox2.   This has also been 
demonstrated in the literature by Sadok et al in HT29-D4 colonic 
adenocarcinoma cells. Nox1 down regulation inhibited cellular migration but 
did not affect total distance nor mean velocity of migration (Sadok et al., 
2008) again demonstrating a differential effect of a Nox subunit in these 
processes. 
The dynamic assembly and disassembly of integrin mediated adhesion 
and cytoskeletal reorganization are necessary for efficient cellular spreading 
and migration (Moissoglu and Schwartz, 2006). It was interesting that on 
acute stimulation with CSF-1 a smaller spreading response was observed in 
Nox2-/- BMM, in the presence of AngII. However in the presence of AngII the 
migratory speed of Nox2-/- BMM, towards the CSF-1 gradient, showed a 
marked increase.  A possible explanation for this contrasting response could 
be due to the different Nox subunits. Thus Nox2 by its structure can rapidly 
produce more ROS than the other Nox subunits. Thus it is more suited to 
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elicit an acute response and could therefore be more important in the acute 
CSF-1 response, an effect which was increased in the presence of AngII. 
However, Nox4 functions constitutively and requires an upregulation in its 
expression to increase its effect. Haurani et al have demonstrated in rat 
adventitial myofibroblasts that AngII acting as an chemoattractant can 
increase migration in a concentration dependent manner and that this effect 
was Nox4 dependent (Haurani et al., 2008).  The pre-incubation with AngII 
and stimulation of increased levels of Nox4 in Nox2-/- BMM (Byrne et al., 
2003) could explain the observed increase in speed of migration which was 
not seen in WT BMM, probably due to lower levels of Nox4. Thus exposure to 
endothelial AngII, Nox4 mediated  increase in the migratory speed may 
hinder the need for macrophage adherence and transmigration. Further 
experiments would be required to verify this hypothesis, however, if true this 
effect of Nox4 in the Nox2-/- mice would not be physiological and will be 
peculiar to the Nox2-/- mice. A basal level of ROS may be required to keep 
proteins in their normal redox state. Thus some of the changes in the 
signaling cascades may not reflect the physiological state. Nevertheless the 
data suggests that the regulation of migratory speed is complicated, involving 
multiple pathways where different Nox subunits could function in 






4.4.4 EFFECT OF NOX2 ON THE INTERPLAY BETWEEN ANGII AND CSF-1 
INDUCED BMM MIGRATION -PERSISTENCE IN CELLULAR MOTION 
 
MAIN  FINDING: 
 AngII incubation can rescue the loss in persistence in directed 
motion towards a CSF-1 gradient.  
 
In chapter 3 Nox2 was shown to be important in determining the 
persistence in the random migration of BMM and also in directed migration 
towards a CSF-1 gradient. AngII stimulation increased this persistence in the 
directed migration of WT BMM. The intrinsic propensity of cells to continue 
migrating in the same direction without turning is closely related to 
integrin/cytoskeletal interaction resulting in modulation of directionality of 
cellular migration (Pankov et al., 2005). A switch in the integrin subtype has 
been described as underlying the changes in cellular motility from a random 
motion to a more directional one. Thus in epithelial cells an integrin switch 
between αvβ3 to α5β1 can result in a different behaviour in motility (Danen 
et al., 2005; White et al., 2007).  Nox1 was demonstrated to be important in 
this process wherein the knockdown of Nox1 lead to a loss of directional 
migration suggesting that Nox1 could be a switch between random and 
directional migration.  
Interestingly the persistence in the Nox2-/-  BMM also increased 
following AngII stimulation. The data would imply that downstream 
signaling of AngII via Nox2 could possibly be inhibiting the increase in 
persistence, thus the absence of Nox2 had resulted in a larger increase in 
cellular persistence. Alternatively, other non-Nox2 dependent signalling 
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pathways, such Nox4, may be stimulated underlying the increase similar to 
the increase in speed of migration. Further experiments would be required to 
determine this however if this explanation is established then it would 
demonstrate that AngII stimulation of Nox4, or other non-Nox2 signalling 
pathway,  is an alternative means by which BMM can increase their 
persistence of migration towards CSF-1 stimulation. 
  
4.4.5 SUMMARY 
Taken together the data suggests that AngII has a slowing effect on the 
CSF-1 induced chemotaxis in BMM. The influence of AngII on the acute 
responses of CSF-1 is Nox2 dependent. The possibility exists that some of the 
AngII effect occur via Nox4. These aberrations in cellular migration towards 
a chemotactic stimulation in Nox2-/- BMM could, in part, play a role in the 
reduced fibrosis and hypertrophy observed.   
However, these experiments have been conducted in vitro. The 
combined influence will greatly differ in vivo where the cells are exposed to 
AngII for a longer duration and the cells attracted by different chemotactic 
and risk factors. As such  oleic acid and AngII both increased VSMC 
migration but co-incubation had an additive effect (Greene et al., 2001).  In 
the next chapter we investigate in-vivo the cell specific role of Nox2 in 
circulating inflammatory and resident cardiac cells in AngII induced cardiac 
fibrosis.    
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5 CELL SPECIFIC ROLE OF NOX2 IN ANGII INDUCED 
CARDIAC HYPERTROPHY AND FIBROSIS 
 
5.1 INTRODUCTION 
5.1.1 INVOLVEMENT OF NOX2 IN CARDIAC FIBROSIS AND HYPERTROPHY 
The role of Nox2 in cardiac hypertrophy and cardiac fibrosis has been 
demonstrated in many studies in the literature. Bendall et al (Bendall et al., 
2002a) have shown that left ventricular hypertrophy (LVH) induced by a 
subpressor dose of AngII infusion (0.3mg/kg/day) was inhibited in Nox2-/- 
mice. As Nox2-/- mice have a lower baseline blood pressure than WT mice it 
was theoretically possible that the reduced hypertrophy could be a result of 
this. In order to exclude this possibility Byrne et al (Byrne et al., 2003) 
investigated the effect of a pressor dose of AngII (1.1 mg/kg/day) on cardiac 
hypertrophy. This research demonstrated that a modest pressor dose of 
AngII, which raised the blood pressure in Nox2-/- mice to a similar level to 
that in WT mice, still failed to induce significant hypertrophy in the Nox2-/- 
mice. This finding supported the conclusion that Nox2 was essential for the 
development of AngII induced cardiac hypertrophy. 
The role of Nox2 in AngII induced cardiac fibrosis has been 
investigated by Johar et al (Johar et al., 2006). In WT mice, subcutaneous 
infusion of a pressor dose (1.1mg/kg/min) of AngII for 2 weeks significantly 
increased NADPH oxidase activity. In line with this, the level of interstitial 
fibrosis as measured by the mRNA expression of fibronectin, procollagen I, 
and connective tissue growth factor was also significantly increased. These 
effects were all inhibited in Nox2-/- hearts. 
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These studies demonstrate an important role for Nox2 in the 
development of AngII dependant cardiac hypertrophy and fibrosis. However 
as these experiments had been undertaken in Nox2-/- mice in which the Nox2 
had been knocked out globally it was not possible from these studies to 
ascertain in which cell the loss of Nox2 was critical. In order to explore this 
the following experiments use chimeric mice to investigate the role of Nox2 
in peripheral circulating inflammatory cells and resident cardiac cells in the 
development of AngII induced cardiac fibrosis and hypertrophy.  
Chimeric mice are established by the replacement of bone marrow 
cells in the recipient mice of a particular genotype with the bone marrow cells 
from mice of a different genotype.  This technology is a crucial technique in 
cardiovascular and other research work which enables disease processes to 
be investigated (Herijgers et al., 1997; Schiller et al., 2001; Van et al., 1997; 
Van et al., 2000).  In the current experiments the formation of chimeric mice 
resulted in WT mice with circulating bone marrow cells which are deficient in 
Nox2. Thus this enabled the contribution of Nox2 in circulating cells, 
towards the development of cardiac fibrosis and hypertrophy following AngII 
stimulation, to be investigated. 
5.1.2 ANG II MODULATION OF HAEMATOPOIESIS  
The bone marrow RAS and in particular its effector  hormone, AngII, 
modulates the control of haematopoiesis by influencing a variety of 
differentiation and maturation factors (Haznedaroglu, 1999; Weber et al., 
1999). As such, hypertensive patients treated with losartan experienced mild 
normocytic anaemia after renal transplantation (del et al., 1998). In keeping 
with these observations, Mrug et al (Mrug et al., 1997) showed that Ang II 
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increased the growth of erythroid progenitors in vitro, an effect completely 
abolished by losartan. Further evidence for the role of AngII modulation in 
haematopoiesis comes from studies which demonstrate that AngII infusion 
increased the haematocrit in ACE knockout mice (Cole et al., 2000).  Thus 
taken together these findings support a role for AngII in the modulation of 
bone marrow hematopoiesis. 
The mature blood cells, derived from the bone marrow, undergo a 
complex series of proliferative and differention steps. During this process 
there is a changing array of adhesion molecule expression in these progenitor 
cells. These markers help to distinguish and identify both lineage and 
maturational stage of the cells and therefore reflect on their function.  
The antigenic differentiation of two monocyte subsets in mice was first 
achieved on the basis that monocytes could be subdivided according to their 
expression of chemokine receptor 2 (CCR2), L-selectin (CD62L) and CX3C-
chemokine receptor 1 (CX3CR1). One monocyte subset expressed CCR2, 
CD62L and only moderate amounts of CX3CR1 (CCR2+ CD62L+ CX3CR1-) 
whereas the second did not express CCR2 or CD62L but expressed higher 
amounts of CX3CR1 (CCR2- CD62L- CX3CR1+). The CCR2+  monocyte subset, 
as expected, migrated towards the CCR2 ligand, CC-chemokine ligand 2 
(CCL2; also known as MCP1) (Palframan et al., 2001). The expression of 
CCR2 and the capacity to migrate towards CCL2 is consistent with the 
important role of this chemokine and its receptor in the recruitment of 
monocytes to inflammatory lesions, and therefore the murine CCR2+ 
monocytes are known as the ‘inflammatory’ subset (Gu et al., 1998; Kurihara 
et al., 1997; Kuziel et al., 1997; Lu et al., 1998).  
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The receptors that are expressed by the inflammatory-monocyte 
subset are broadly considered to be chemokine and adhesion receptors, 
involved in the recruitment of leukocytes to an inflammatory lesion. In 
addition, Geissmann et al (Geissmann et al., 2003)  identified Ly6C (which is 
part of the epitope of Granulocyte Receptor 1) as an additional marker of 
CCR2+ monocytes in mice. These studies indicated that 
CCR2+CD62L+CX3CR1lowLy6C+ mouse monocytes correspond to CD14hiCD16- 
(classic) human monocytes, which are also CCR2+CX3CR1low  and that     
CCR2-CD62L-CX3CR1hiLy6C- mouse monocytes correspond to CD14+CD16+ 
human monocytes, which also express large amounts of CX3CR1. Thus this 
analogy allowed the results in mice to be correlated with humans as 





The evolving evidence from the literature would suggest that bone 
marrow-derived monocytes with the phenotype CCR2+CX3CR1lowLy6C+ are 
released into the circulation (Figure 5.1). In the presence of inflammation, 
the bone-marrow-derived monocytes can respond to pro-inflammatory cues, 
migrate into inflamed tissues and differentiate into macrophages (Geissmann 
et al., 2003; Qu et al., 2004). These Ly6C+ monocytes are immature cells and 
are thought to mature to Ly6C- cells in the circulation (Sunderkotter et al., 
2004).  In the absence of inflammation, a switch in monocyte phenotype 
occurs, to tissue-resident macrophages and dendritic cell, the mechanism of 
this regulation  is unknown. This then generates monocytes that are 
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postulated to enter the tissues and replenish the tissue population of 
macrophages and dendritic cells. These are known as the ‘resident’ monocyte 

















Figure 5-1 Maturation of monocyte subsets in mice. 
 Ly6C+ bone-marrow monocytes are released into the peripheral blood.  Ly6C+   
monocytes are thought to respond to pro-inflammatory cues  (such as CCL2), and be 
recruited to inflammatory tissue. Most ‘inflammatory’ monocytes are thought to 
differentiate into macrophages, which are important for clearance of pathogens and for 
the resolution of inflammation.  In the absence of inflammation, CX3CR1hiLy6C–  
monocytes enter the tissues and replenish the tissue-resident macrophage and 





Thus Ly6Chi and Ly6Clow expressing monocytes show differing 
functions in normal physiological processes. The  infarcted heart sequentially 
and actively recruits Ly6Chi and Ly6Clow expressing monocytes via CCR2 and 
CX3CR1, respectively. Ly6Chi expressing monocytes dominate the early phase 
of recruitment and exhibit phagocytic, proteolytic, and inflammatory 
functions. Ly6Clow expressing monocytes dominate the later phase and have 
attenuated inflammatory properties, and express vascular-endothelial 
growth factor. Consequently, Ly6Chi expressing monocytes digest damaged 
tissue, whereas Ly6Clow expressing monocytes promote healing via 
myofibroblast accumulation, angiogenesis, and deposition of collagen 
(Nahrendorf et al., 2007). However, the numbers of these different types of 
monocytes can alter in disease processes. For example in 
hypercholestrolaemia the numbers of Ly6chi expressing monocytes are 
increased (Libby et al., 2008; Swirski et al., 2007). Also myocardial 
infarction, in atherosclerotic mice with chronic  Ly6Chi monocytosis, results 
in impaired healing, underscoring the need for a balance between the 
numbers of Ly6Chi and Ly6Clow expressing monocytes (Panizzi et al., 2010). 
The change to the numbers of Ly6Chi expressing monocytes in 
hypertension has not been investigated.  One of the aims of this chapter is to 
characterise the change in the number of Ly6Chi expressing monocytes in the 
bone marrow and peripheral blood of WT and Nox2-/- mice following AngII 
induced hypertension.  
5.1.3 ADHESION AND MIGRATION OF CIRCULATING MONOCYTES  
Leukocyte recruitment to the arterial wall and the heart is a hallmark 
of the early stages of hypertension and  hypertensive heart disease in which  
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AngII is known to play a critical role (Hernandez-Presa et al., 1997; Mervaala 
et al., 1999). AngII is capable of promoting monocyte adhesion and activation 
in vitro (Hahn et al., 1994) and as such monocyte migration into the vessel 
wall, a critical event leading to the development of cardiac fibrosis, can be 
attenuated by ACE inhibition or by pretreatment with an AT1 receptor 
antagonist (Hahn et al., 1994; Hernandez-Presa et al., 1997; Mervaala et al., 
1999). Moreover, AngII superfusion of the rat mesenteric microcirculation 
induces leukocyte adhesion in venules (Piqueras et al., 2000). Therefore, 
AngII may be a key factor in the leukocyte adhesion and subsequent 
subendothelial infiltration observed in hypertension. 
The interaction between the circulating inflammatory leukocytes and 
the inflamed endothelium  is mediated by three groups of adhesion 
molecules namely the integrins, selectins and the Ig superfamily (Carlos et 
al., 1990; Carlos and Harlan, 1994). The initial low affinity interaction 
between the leukocytes and the endothelium, manifesting itself as rolling 
behavior, involves the participation of selectins. The rolling leukocyte by the 
participation of intergrins and Ig superfamily becomes firmly adherent on 
the vessel wall which allows the process of transendothelial leukocyte 
migration to occur. Additional steps in this process such as slow rolling, 
adhesion strengthening and spreading, intravascular crawling and the route 
of transmigration makes this process even more complex (Ley et al., 2007).  
The selectins, which mediate leukocyte rolling, are a family of lectin-
like molecules of which 3 types namely L-selectin, P-selectin and E-selectin 
have been described. The P-Selectins are expressed on endothelial cells and 
platelets whereas E-selectins are only expressed on endothelial cells. In 
contrast L-selectins are only expressed on leukocytes. It is widely accepted 
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that the L-selectin shedding is involved in the recruitment by leukocyte 
extravasation into inflamed tissued (Kishimoto et al., 1989). The role of 
AngII in this regulation of L-selectin shedding has been demonstated from 
different lines of evidence. Clincal studies have shown that L-selectin density 
on lymphocytes and monocytes/macrophages was significantly lower in 
hypertensive patients than in normotensives (Mills et al., 2002; Zapolska-
Downar et al., 2006). In an in vitro study, Vega et al (Vega et al., 2010) 
demonstrated that AngII, in a dose dependent manner, induced shedding of 
L-selectin in human neutrophils rapidly over the course of minutes reaching 
maximum shedding at five minutes. In keeping with this Prasad et al (Prasad 
et al., 2001) demonstrated a significant increase in L-selectin expression on 
monocytes, lymphocytes and granulocytes in patients treated with losartan, 
an AngII receptor antagonist. Thus an AngII dependent mechanism might 
lead to direct L-selectin shedding and leukocyte extravasation into local 
inflammatory sites in hypertensive cardiac disease.  
There is also evidence supporting the involvement of ROS in the initial 
adhesion process involving L-selectin. In neutrophils, H2O2 exposure 
increases their adhesion to the endothelium (Fraticelli et al., 1996). Also 
metalloprotease 17 (or ADAM 17), a sheddase of L-Selectin promoting 
shedding, has been shown to be redox sensitive (Wang et al., 2009b). 
Therefore AngII may mediate its cardiac effect on L-selectin expression by 
mediating the production of ROS, in particular from Nox2. Thus this could 
explain the lack of cardiac fibrosis and hypertrophy in Nox2-/- mice following 
AngII stimulation.      
The  leukocytes adherent to the vessel wall are required to mobilize 
themselves  to the nearest  junctional site on the endothelium before starting 
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diapedesis (Schenkel et al., 2004). Diapedesis is a rapid process in which the 
leukocytes extend themselves by the formation of pseudopods, across the 
endothelial border. This requires the rapid disassembly and reassembly of 
the cytoskeleton enabling the cell to change shape. The process of diapedesis 
has been reviewed in detail in the literature (Kamei and Carman, 2010; 
Muller, 2003) and the redox sensitive regulation of the actin cytoskeleton as 
been described in chapter8. Thus AngII, via ROS from Nox2, could influence 
the dynamics of the actin cytoskeleton and therefore the ability of the 
leukocytes to diapedese. Again this could account for the lack of cardiac 
fibrosis and hypertrophy observed in Nox2-/- mice following AngII 
stimulation. 
Thus another aim of this chapter is to investigate the expression of L-
selectin and filamentous actin in monocytes derived from the bone marrow 
and peripheral blood of WT and Nox2-/- mice following AngII stimulation. 
5.1.4 AIM  
This chapter aims to successfully establish chimeric mice which will be 
used to investigate the cell specific role of Nox2, namely that of resident 
cardiac cells versus circulation inflammatory cells, in AngII induced cardiac 
fibrosis and hypertrophy. 
In WT and Nox2-/- mice stimulated with AngII the numbers of 
inflammatory, Ly6Chi expressing bone marrow and blood monocytes and 




5.2.1 GENERATION OF CHIMERA MICE 
Mice aged 8-12wks were used as recipient mice. The mice were 
initially irradiated with whole body irradiation. The purpose of the 
irradiation is to completely deplete the haematopoietic system of the 
recipient mice to allow the repopulation of the bone marrow cells from the 
donor mice. The ionizing radiation causes lesions in cellular DNA (Duran-
Struuck and Dysko, 2009; Prise et al., 2005). Due to the large number of 
lesions, many of them are not repaired or suffer misrepair by the DNA repair 
system that can lead to apoptosis (Prise et al., 2005). The survival rates of the 
mice  tend to be lower if they are irradiated with a single high dose (9.5Gy) of 
radiation rather than two doses of 6Gy (Cui et al., 2002). At our institute the 
practice is to irradiate the mice with a single dose of 7Gy of radiation in a 
linear accelerator. The marrow from the donor mice is harvested the 
following day for injection into the recipient mice by tail vein injection.  
It is important to realize that alternative methodologies exist to BMT 
chimeric mice. In most cases it is technically feasible to carry out similar 
experiments by making use of transgenic technology. However, the setting up 
of BMT chimeric mice is usually faster and more cost effective. In BMT 
experiments the cells given to the recipient mice are histocompatible as the 
mice are genetically identical due to their inbreeding thus preventing any 
graft versus host disease. Crucially the acute replacement of bone marrow in 
the BMT chimeric mice prevents for any chronic compensatory changes to 
take effect as could happen in transgenic mice.  However, a limitation is that 
irradiation itself could unknowingly have had other effects. 
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5.2.2 PREPARATION OF MARROW FOR INJECTION 
The marrow was obtained following culling of the mice with terminal 
aneasthesia and harvesting their femurs for flushing. The mice used in the 
experiments were of similar age to the recipient mice as it has been shown 
that the age of the donor mice does not affect the repopulation efficiency of 
the bone marrow (Harrison and Astle, 1982). The murine femurs are cleaned 
of the surrounding tissue by gentle pulling using forceps to prevent 
contamination of the bone marrow cell on flushing of the marrow. The 
procedure was undertaken in a tissue culture hood so as to maintain sterility.  
Once the bone had been cleaned a 21-gauge needle was used to thread 
through both ends of the bone. Then, using a 5-mL syringe with a 21G needle, 
the bone marrow was flushed out of the bone with 5 mL of serum free DMEM 
into a petri dish.  An additional 5 mL of serum free DMEM was added to the 
petri dish, the cells collected and placed into a falcon tube and centrifuged for 
5 min at 1000g at room temperature. The supernatant was discarded and the 
pellet resuspended in serum free DMEM.  Half a milliliter of serum free 
DMEM was used to resuspend the pellet for every mouse culled and 0.25ml 
of suspension was then used to inject into each mouse. Thus the marrow 
from one mouse was sufficient to inject two recipient mice.  
5.2.3 TAIL VEIN INJECTION 
Before the tail vein injection the mice were heated in an incubator at 
30oC to dilate the tail veins. The mice were then held in a restraining device 
to immobilise them and allow access to the mouse tail.  The vein was 
identified visually, as normally the mice have a vein coursing both the lateral 
sides of the tail which can be used for injection, and 0.25mL of  marrow 
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suspension was carefully injected into the tail vein by a slow continuous 
push.   
Each run had a control mouse which did not receive marrow injection. 
These mice served as controls for the lethal irradiation dose that the mice 
received. Hence in the absence of any BMT approximately two weeks after 
the irradiation the control mice were culled due to their declining health.  
Four days after administration of the bone marrow the cellular 
repopulation starts through the homing of the cells to the bone marrow 
cavity (de Winther and Heeringa, 2003). By the seventh day after the 
transplantation, the bone marrow repopulation is completely restored (de 
Winther and Heeringa, 2003). The circulating leukocytes are replaced with 
donor derived cells between 2-4 weeks after the transplantation. Therefore a 
period of one month was allowed for the recovery of the bone marrow and 
peripheral blood cells before any experimentation. The repopulation of the 
circulating blood cells was confirmed by FACS analysis of peripheral blood 
via tail vein blood sampling and ultimately by genotyping of the marrow cells. 
5.2.4 FACS COUNTING OF CELLS IN TAIL VEIN BLOOD  
To confirm the repopulation of the marrow and the peripheral blood 
count, tail vein blood samples were taken every 4 days over 16 days. For this 
the mice were anaesthetized (2.5% isoflurane(Abbott, UK)//97.5% oxygen) 
and the tail tip excised with  scissors. Five drops of blood was allowed to drop 
into an eppendorf tube containing EDTA. The tail was cauterized to achieve 
haemostasis and the mouse returned to its cage.  
One ml of RBC lysis solution (9 parts NH4Cl (0.16M) and 1 part Tris-
HCl (0.17M;pH7.6) pH adjusted to 7.6 with HCl) was added to the eppendorf 
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containing the blood and left to stand for 10mins. The eppendorf was then 
centrifuged at 1200rpm for 5mins. The supernatant was discarded and the 
pellet resuspended in PBS and moved to a FACS tube.  The cells were 
incubated for 1hr on ice with antibody against CD45 (MACS 1:200) [Miltenyi 
Biotec], a pan-leukocyte marker. The sample was then centrifuged, 
resuspended in PBS and analysed by FACS. The machine was set to count the 
number of events over 10mins. 
5.2.5 MARROW CELLS FOR GENOTYPING  
Genotyping (undertaken with Simon Walker) was used to confirm the 
presence or absence of the Nox2 gene from the marrow cells of the chimera 
mice. The marrow was harvested and digested in a solution of Proteinase K 
((10mg/ml) Roche, UK) in an alkaline buffer (0.1 M Tris EDTA, 0.1 M 
Na2EDTA, 1% SDS and 0.15M NaCl, ph 8.0) for 2-4 hours at 550C. cDNA was 
precipitated in isopropanol, washed with 80% ethanol and resuspended in 
TE buffer (1mM EDTA, 10 mM Tris, pH 8). Amplification of resultant cDNA 
was conducted in a thermal cycler (AB Applied Biosystems, UK) involving 35 
cycles of denaturing (30 seconds at 940C), annealing (30seconds at 560C) and 
synthesis (30 seconds at 720C). A duplex reaction on 1μl of cDNA was 
achieved using primers (10μM) for Nox2 in a 25μL total reaction volume 
containing 12.5 μL Red Taq Ready Mix, 0.5 μL forward primer, 0.5μL reverse 
primer 1, 1 μL reverse primer 2 (Table 5.1) and 9.5 μL of nuclease-free H2O.  
Subsequent polymerase chain reaction (PCR) products were separated by 
electrophoresis on a 1.5% agrose gel containing ethidium bromide (400 
ng/mL) in 40 mM Tris-acetate, 1 mM EDTA and visualized under ultraviolet 
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light. A single band at ~240 basepaires (bp) confirmed WT status and a 
single band at ~195bp confirmed a Nox2-/- .   
 
















GTT CTA ATT CGA TCA GAA GCT TAT CG 
 
5.2.6 OSMOTIC PUMP INSERTION 
Osmotic pumps (Figure 10.2) were used to administer AngII (0.3mg 
or 1.1mg/kg/day) in vivo over 14 
days. Pumps were inserted into WT, 
Nox2-/- , WT chimeric and Nox2-/- 
chimeric mice   These pumps are 
designed with an inner reservoir 
(bladder) to hold the drug 
surrounded by a salt sleeve and a 
semi-permeable outer capsule.  The 
high osmolality of the salt sleeve 
causes water to flux across the 
capsule into the pump, which compresses the flexible reservoir dispensing 
the drug at a set rate via a flow moderator.  The permeability of the outer 
capsule controls the flux of water and thus the amount of drug displaced 
irrespective of the drug concentration or formulation, for example, pump 
 
Figure 5-2 Alzet Corp® Model 2001 
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model 2001 which was used in the current series of experiments, infuses at a 
constant rate of 0.25µl/h over 14-days. Equivalent control groups were 
implanted with osmotic pumps containing saline.   
To implant the osmotic pumps the mice were anaesthetized (2.5% 
isoflurane (Abbott, UK)//97.5% oxygen) and an area shaved on their upper 
back. The site was sterilized with iodine before making a subcapular incision 
(1-2cm). A subcutaneous pocket was created by blunt dissection and the 
osmotic pump was then implanted into this space with the flow moderator 
facing downwards into a posterior subcutaneous pocket created.  The 
incision was closed with 5/0 vicryl suture.  Buprenorphine (Vetergesic™, UK; 
0.05mg/kg) analgesic was administered by intramuscular injection at the 
start of the procedure and the mice were allowed to recover in a warmed 
(37°C) cage for a minimum of 30 minutes.  
Infusion of pharmacological agents such as AngII via implanting 
osmotic pumps subcutaneously is well-established. The AngII induces 
hypertension and cardiac hypertrophy (Berry et al., 2001)  as well as causing 
a proinflammatory phenotype (Chen et al., 1998)  resulting in cardiac 
fibrosis, therefore mimicking the development of LVH in humans (Berry et 
al., 2001; Weber and Brilla, 1991).  Infusing AngII at a low dose 
(0.3mg/kg/day) over a 2-week period causes a small degree of hypertrophy 
without significantly increasing blood pressure.  However, hypertension can 
be achieved with higher pressor doses of AngII (>0.7mg/kg/day) (Kawada et 
al., 2002) which is accompanied by a greater hypertrophy and increased 
cardiac fibrosis (Johnson et al., 1992; Sun et al., 1993; Sun et al., 1997). A 
criticism of this model is that plasma levels of AngII can be substantially 
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greater in some animals (up to 80 fold higher in canines) than those seen in 
humans (Kawada et al., 2002; Weiss et al., 2001).  
5.2.7 NON-INVASIVE ASSESSMENT OF BLOOD PRESSURE MEASUREMENT  
Measurement of systolic blood pressure is an essential component of 
overall haemodynamic analysis (Kurtz et al., 2005a). Non-invasive blood 
pressure measurement was conducted by tail-cuff plethysmography (Kent 
Scientific, USA).  Tail cuff plethysmography is an inexpensive, relatively 
simple method of assessing systolic blood pressure.  However, there are 
several limitations to this method the predominant one being that, in order 
to obtain measurements the mice have to be restrained which may cause 
stress thus altering blood pressure, with differences in stress levels between 
mice or within the same mouse over subsequent days will add to the 
variations in the assessment of blood pressure.  The mice are exposed to 
further stress by exposing the mice to the heated environment (ambient 
temperature of 25°C), which is required to ensure sufficient dilation of the 
tail artery to provide a clear signal.   
It is critical that the mice are trained for several days before the start 
of the experimental protocol such that they become accustomed to the 
restrainer. As such prior to the assessment of blood pressure, each mouse 
underwent a series of training sessions over a five-day period which consisted 
of introducing each mouse into a plastic tube restrainer, and positioning both 
the occlusion and plethysmography cuffs over the tail, prior to cuff inflation.  
The duration of time in the holder and number of inflations were gradually 
increased over the training sessions to acclimatise the mice to the procedure.  
Once acclimatised, an average blood pressure measurement was taken from 
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six consistent readings, per session per mouse, acquired by Chart® software 
(Adinstruments, UK) via a Powerlab® amplifier (Adinstruments, UK).   
The acclimatization should reduce some of the variation in measuring 
the blood pressure.  Nevertheless, blood pressure naturally varies even over 
short periods of time and plethysmographically derived blood pressure is 
only a snap shot (~15minutes) of a mouse’s systolic blood pressure during the 
day, when this normally nocturnal animal is less active.  Therefore, the 
limited number of measurements that can be obtained may not reflect the 
true average blood pressure.  However it is generally considered that 
although tail cuff plethysmography has its limitations it can be used to 
confidently assess the substantial changes in blood pressure expected with 
interventions such as AngII infusion (Kurtz et al., 2005b).   Thus the blood 
pressure measurements were undertaken at the same time everyday. 
5.2.8 ORGAN,  MARROW AND BLOOD HARVEST 
Following the period of AngII infusion blood and organs were 
harvested from the mice. For this mice were anaesthetised using Isoflurane 
(2-2.5% isoflurane/oxygen) and a thorocotomy performed to allow access to 
the inferior vena cava. The inferior vena cava was then pierced using a  29G 
needle and 0.5-1 mls of blood was collected into EDTA treated tubes. The 
femurs were also harvested for the later marrow harvest as described earlier 
in section 5.2.2. 
For histological analysis the heart must be harvested in diastole. To 
achieve this a KCl (5M)-PBS solution was infused into the LV, via the already 
performed thoracotomy, at an approximate pressure of 115mmHg for 15-sec. 
The  right-atrium was cut to allow the blood and solution to flow.  The heart 
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was then harvested, rinsed in cold PBS (4°C), any connective or adipose 
tissue removed, blotted dry and weighed (Sartorius, UK). The heart was then 
dissected into the LV, right ventricle (RV) and atria and the individual 
sections weighed.  For histological studies the LV was divided into three 
transverse sections, a small section of ~1mm at the base of the heart and a 
larger section (4-6mm) at the apex were frozen, whilst a middle section 
approximately between 2-3mm was preserved for histological studies in 1% 
paraformaldehyde and stored at 4°C.  Tissue for frozen sections were snap 
frozen in liquid nitrogen and stored in vapour phase of liquid nitrogen           
(-150°C) until required.   
5.2.9 HISTOLOGICAL PREPARATION 
The hearts for histological studies were arrested in diastole prior to 
harvesting.  The tissue was preserved for paraffin sectioning by fixing in 
paraformaldehyde (1% in PBS at 4°C) for up to 12 hours. Following this the 
tissue was washed in 2 changes of PBS for 30 minutes at 4°C and then 
subsequently moved into 80% ethanol (in PBS at 4°C).  Samples were set in 
paraffin blocks after a series of automated dehydration steps overnight 
(Shandon Hypercentre XP; 70% ethanol room temperature (RT), 1h; 96% 
ethanol RT, 1h; 96% Ethanol, RT, 1h; 100% ethanol, RT, 2h; 100% ethanol, 
RT, 2h; 50% Xylene+50% ethanol (100%), RT, 2 h; Xylene (100%), RT, 2h; 
Xylene(100%), RT 2h; Paraffin, 60°C, 1.5h; Paraffin, 60°C, 1.5h).  Sections 
were subsequently cut using a Microtome (Micron HMS60, Germany) 
generally at 6µm on Superfrost plus slides (VWR, UK). 
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5.2.10 PMA  STIMULATED ROS PRODUCTION IN MARROW CELLS: DHE 
The process of setting up the BMT chimeric mice could have altered 
the ROS response within the marrow cells. Thus to investigate the ROS 
response of the marrow cells from chimeric mice Phorbol 12-myristate 13-
acetate (PMA) stimulation was undertaken. PMA is a diacylglycerol analogue 
which stimulates protein kinase C (PKC) which in turn phosphorylates 
p47phox  and stimulates Rac resulting in Nox2 activation. The cells were placed 
in FACS tubes, RBC lysis solution was added and the cells left to stand for 
10mins. The tubes were centrifuged at 1200rpm for 5mins. The supernatant 
was discarded and the pellet resuspended in PBS and moved to a FACS tube.  
Dihydroethidium (DHE) (Sigma) was added to a final concentration of 10μM. 
DHE is oxidised by ROS to ethidium bromide which can intercalate with 
DNA and fluoresce enabling FACS analysis. Thus DHE assay is a means of 
measuring the intracellular ROS production. To the appropriate tubes PMA 
stimulation was added to a final concentration of 100ng/ml to stimulate ROS 
production. The tubes are left to stand at 370C for 10 minutes, centrifuged at 
1200rpm for 5 minutes following which the cells washed in cold PBS with 5% 
FBS. ROS production following PMA stimulation in the marrow cells was 
quantified by FACS.     
5.2.11 PMA  STIMULATED ROS PRODUCTION IN MARROW CELLS: 
LUCIGENIN  
Measurement of ROS response was also undertaken by lucigenin 
which is a well established method in our laboratory and has been described 
in chapter 2. To summarise the marrow cells were placed in FACS tubes, RBC 
lysis solution was added and the cells left to stand for 10mins. The tubes were 
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centrifuged at 1200rpm for 5mins. The supernatant was discarded and the 
pellet resuspended in PBS. Samples were seeded (1000cells/well) on 96-well 
all white microplate in 75μl of intracellular solution (ICS; 140mM KCl, 1mM 
EGTA, 6 mM glucose, 20 mM K-PIPS, 1 mM MgCl2, pH 7) in the presence or 
absence of PMA (10μM)  stimulation. Cells were permeabilised  with 2 μL of 
0.5% saponion to allow NADPH (300μM) and lucigenin into the cell. 
5.2.12  MONOCYTE SEPARATION FROM BONE MARROW AND BLOOD  
The bone marrow and the blood samples were made up to 5ml with 
5% PBS and then rolled down the side of 10 ml falcon tube containing 5 mls 
of warm Histopaque Ficol 1038 (Sigma) so that the sample formed a separate 
layer on top of the Ficol. The sample was then centrifuged at 2000rpm for 
30mins at room temperature to separate it into layers. The white layer, 
formed at the interface between the Ficol and the sample, comprised of 
mononuclear cells. The pellet consisted of RBC and polymorphonuclear cells. 
The mononuclear layer included monocytes and lymphocytes. This layer was 
carefully removed by suction with a pipette and placed into a new falcon tube 
containing 5mls of 5%PBS. The sample was then spun at 1200rpm for 5mins 
and the pellet resuspended in 1mls of 5% PBS and counted. The cells were 
then mixed in an eppendorf tube with CD11b Microbeads (Miltenyi Biotec) 
such that 10μl of microbead was mixed with 90μl of cells, containing a 
maximum of 107  cells. The CD11b Microbeads were developed for the 
separation of mouse cells based on the expression of the CD11b antigen 
(integrin αm chain). The CD11b antibody reacts with the 170 kDa αm subunit 
of the CD11b/CD18 heterodimer (αmβ2 integrin). This integrin functions as a 
receptor for complement (C3bi), fibrinogen or clotting factor X. The cells 
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were mixed with the microbeads in at 40C for 30mins. The monocytes have 
high expression of CD11b (Sunderkotter et al., 2004) as compared to 
lymphocytes and were therefore selectively separated out by passing the 
sample through a MACS Column where the beads were attracted to a magnet. 
The cells not attached to a CD11b-microbead were washed out the bottom of 
the column. The column was washed three times and then the cells attached 
to the beads i.e. CD11b+ cells were obtained by washing the column without 
the magnet. This last wash was collected into a new falcon tube for FACS 
analysis. 
5.2.13 FACS ANALYSIS OF MONOCYTES  
The monocytes separated from the MACS Column were centrifuged, 
resuspended in 5%PBS and counted on a haemcytometer.  One hundred 
thousand cells were added to FACS tubes and incubated with an antibody 
against Ly6c (1:10; Miltenyi Biotec), conjugated to FITC and MEL-14 (1:100; 
Santa Cruz), conjugated to PE against L-selectin was used.  After incubation 
for 30mins the cells were washed and resuspended in 1ml of 5% PBS for 
quantification by FACS.  
To quantify the levels of F-actin the cells were fixed for 10mins with 
4% paraformaldehyde, permeabilised using 1% tiron prior to the addition of 
phalloidin-FITC (1:1000, Sigma) which reacts with the filamentous actin 
inside the cells. After mixing for 10mins, the cells were washed and 




5.3.1  ESTABLISHING CHIMERIC MICE  
Following injection of donor bone marrow into irradiated mice, 
repopulation  of peripheral blood was detectable from Day 12. (Figure 5.3) 
Peripheral blood samples demonstrated that cell count [counted for CD45 
(1:10; Miltenyi Biotec), a pan leukocyte marker] was similar between all the 
mice before irradiation. After irradiation the counts decreased to almost zero. 
Introduction of donor marrow cells via tail vein injection resulted in the 
repopulation of marrow and peripheral blood which was detectable after day 
12. Control mice which received no marrow cells started to decline in health 
and two weeks after irradiation were deemed too ill and had to be culled. The 
experiment demonstrated that a injection of donor marrow cells was able to 
successfully repopulate the marrow of irradiated mice with the subsequent 
recovery of peripheral blood count and ultimately survival. 
Chimeric mice were established by the reconstitution of the bone 
marrow with donor marrow obtained from a mouse of a different genotype. 
This was confirmed by the genotyping of the marrow cells from the chimeric 
mice. (Figure 5.3) The genotyping of the marrow from Nox2-/- chimeric mice 
confirmed that it expressed Nox2 and thus was derived from the WT donor 
mice. Similarly the marrow from WT chimeric mice expressed no Nox2 and 
therefore had to originate from Nox2-/- mice. The average weight of WT mice 
pre procedural was 25.5g (range: 20.7g – 32.2g) and that of Nox2-/- mice 
26.2g (range: 23.1g – 29.5g) 
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Bone marrow genotyping of WT 
and Nox2-/- chimera mice WT cDNA for WT 
positve control
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Figure 5-3 The repopulation of peripheral blood cell and marrow genotype of 
chimeric mice  
TOP: The mice re-injected with marrow [two WT (black)and two Nox2-/-(broken blue)] 
remain healthy in line with the recovery of  their peripheral blood cell count over the 
course of the following 16 days. Mice not injected with marrow cells [one WT (red)] 
was culled due to poor health.  
BOTTOM: Representative blot demonstrating that the genotype of the marrow cells of 
a Nox 2-/- or WT recipient mouse matched those of the donor mouse.  
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A differential ROS response of the Nox2-/- and WT marrow cells to 
PMA stimulation would provide an effective functional means to 
demonstrate that a successful bone marrow repopulation with donor cells 
retained the characteristics of the donor marrow rather than that of  the 
original bone marrow (Figure 5.4: top). As such, WT marrow cells responded 
to PMA stimulation with a large ROS response as demonstrated by a shift in 
the DHE profile to a mean fluorescence value 112.4 units (Figure 5.4, top) 
However, in the absence of Nox2 this ROS response is lost  with a shift in the 
DHE profile to a mean fluorescence of only 14.7 units. In keeping with this, 
appropriate ROS response was seen following bone marrow transplantion.  
Thus a robust PMA response was seen either in Control chimeric WT mice 
(WT mice transplanted with WT marrow: WT/WT) or chimeric Nox2-/- mice 
(Nox2-/- mice transplanted with WT marrow: Nox2-/-/WT ) i.e. a mean 
fluorescence shift of 74.9 and 98.2 units respectively. Thus the characteristics 
of the donor marrow are retained in the recipient mice upon transplantation. 
The ROS response of the new repopulated marrow was also assessed 
with lucigenin (Figure 5.4: bottom). As expected PMA stimulation resulted in 
a marked increase in the ROS response in marrow cells from WT mice which 
was not seen in marrow cells from Nox2-/- mice. As such the repopulated 
marrow from a WT/WT mouse showed a marked ROS response following 
PMA stimulation. Conversely, the repopulated marrow from a WT/Nox2-/- 
mouse failed to show a significant ROS response following PMA stimulation. 
Similarly, the repopulated marrow obtained from a Nox2-/-/WT mice showed 
a significant ROS response following PMA stimulation consistent with the 
marrow being that from a WT mouse. Thus the results from both the DHE 
and lucigenin experiments were consistent suggesting that following 
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Figure 5-4 ROS response in marrow cells following transplant 
Top: ROS response as measured by DHE following PMA stimulation  
Following PMA stimulation of WT marrow cells from WT mice (112U), chimeric 









similar response was observed. PMA stimulation of Nox2-/- marrow cells (15U) from 
Nox2-/- mice showed a reduced ROS response following PMA stimulation.  
Bottom: ROS response as measured by lucigenin following PMA stimulation  
Following PMA stimulation ROS response measurement by lucigenin 
demonstrated similar results. Namely WT marrow from WT mice, chimeric WT mice 
with WT marrow and chimeric Nox2-/- mice with WT marrow demonstrated a large 
ROS response. Expectedly PMA stimulation of Nox2-/- marrow from Nox2-/- mice or 
chimeric WT mice with Nox2-/- marrow did not show any measurable ROS response.  
  Thus the results from both the DHE and lucigenin experiments were 
consistent suggesting that following transplantation the repopulated marrow 
functionally remained that of the donor mouse.  
 
Taken together these results suggest that the process of irradiation 
and subsequent repopulation of the marrow and peripheral blood cells 
successfully generated viable chimeric mice.  The marrow cell by genotype 
and PMA responsiveness remained that of the donor mouse. Hence the use of 
these mice would enable the investigation of the cell specific role of Nox2, 
namely the role of Nox2 in the circulating cells versus that in the resident 
cells, in the generation of cardiac fibrosis and hypertrophy following AngII 
stimulation.      
 
5.3.2  CELL-SPECIFIC LOSS OF NOX2 ATTENUATED THE ANGII INDUCED 
HYPERTENSION 
To induce cardiac fibrosis and hypertrophy, AngII pumps were 
inserted subcutaneously for 2 weeks. During this time, the blood pressure of 
both the control WT and Nox2-/- mice increased significantly when compared 
to vehicle infused control (Figure 5.5). The final increase in blood pressure 
was similar between the WT and Nox2-/- mice.  The WT mice blood pressure 
showed an average increase of 2.5mmHg/day (95%CI:0.58;4.36, p=0.01) 
similar to that in the Nox2-/- mice of 2.7mmHg/day (95%CI:0.97;4.43, 
p=0.002). By day 5 both groups had a mean blood pressure which was 
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significantly higher from their controls. Importantly in WT/WT mice, AngII 
induced an equivalent increase in blood pressure to that seen in control WT 
and Nox2-/- mice [not shown]. The increase was 2.2mmHg/day 
(95%CI:0.52;3.84,p=0.01) which resulted in the blood pressure reaching a 
significantly higher value by day 5. This demonstrates transplantation per se 
does not affect the response of the mice to AngII infusion. 
However different responses were seen in the WT/Nox2-/- and     
Nox2-/-/WT chimeric mice. In these chimeric mice, the increase in blood 
pressure to AngII stimulation was attenuated. The increase was 
1.5mmHg/day and 1.6mmHg/day respectively. This meant that the blood 
pressure was not significantly higher until approximately day 10.  However 










Figure 5-5 Blood pressure response following angiotensinII stimulation 
AngII infusion resulted in a significant increase in systolic blood pressure in both WT 
(N=7) and Nox2-/- (N=5) mice. However the increase in blood pressure in response to 
Ang II infusion in either WT chimeric mice with Nox2-/- marrow (N=7) or Nox2-/- 




5.3.3  NOX2 IN CIRCULATING CELLS IS IMPORTANT FOR ANGII INDUCED 
CARDIAC HYPERTROPHY  
Following AngII stimulation both WT and Nox2-/- hearts showed a 
significant increase in the left ventricular (LV)/body weight (BW) ratio 
compared to their respected unstimulated controls [1.00 
(95%CI:0.3;1.7,p=0.01 and 1.02 (95%CI:0.28;1.76,p=0.01)]. Thus adjusted 
for their body weight the increase in the LV mass was 15.6mg 
(95%CI:1.05;34.2,p=0.045) and 17mg (95%CI:0.71;33.8,p=0.041) 
respectively. In line with the pressor response to AngII, WT/WT chimeric 
mice  demonstrated a similar hypertrophic response to that in WT and   
Nox2-/- mice (16.5mg (95%CI:1.01;31.9,p=0.037)). The LV/BW ratio 
increased by 1.00 (95%CI:0.27;1.73,p=0.01) thus confirming that the bone 
marrow transplantation procedure had not altered the ability to mount a 
hypertrophic response to AngII in these mice.  
In marked contrast in WT/Nox2-/- chimeric mice the hypertrophic 
response was attenuated (3.6mg (95%CI:-13.1;20.3,p=0.66)) and no longer 
showed a significant increase compared with WT control mice.  The LV/BW 
ratio increased by 0.5 (95%CI:-0.25;1.25,p=0.16). 
In contrast Nox2-/-/WT chimeric mice demonstrated a substantial 
hypertrophic response (30mg (95%CI:12.2;47.9,p=0.002) compared to 
Nox2-/- control mice. There was an increase in the LV/BW ratio of 2.1 
(95%CI:1.35;2.85,p<0.001). This increase was larger (12.8mg (95%CI:-
3.13;28.7,p=0.11)) than that seen in WT/WT chimeric mice. It is noteworthy 
that this increased hypertrophy was observed in mice which showed a 




Figure 5-6 LV mass/Body weight ratio and fibrosis in chimeric mice following 
AngII stimulation 
A: The LV/BW ratio increased significantly following AngII stimulation in WT (p=0.01) 
and Nox2-/- (p=0.01) mice. No loss in response was observed following bone marrow 
transplantation as  AngII stimulation resulted in a similar significant increase in the 
LV/BW ratio of WT/WT chimeric mice (p=0.01) compared to WT.  However compared 
to WT, the selective loss of Nox2 in the circulating blood cells, namely in the   
WT/Nox2-/- chimeric mice, prevented a significant increase (p=0.16) in LV/BW ratio 
 206 
following AngII stimulation. Unexpectedly Nox2-/-/WT demonstrated a significant 
(p<0.001) increase in its LV/BW ratio following AngII stimulation. 
 B & C: Cardiac fibrosis was visualized following staining of histology sections with 
Picosirus Red. The level of fibrosis was quantified and summarized in the top right 
graph. Following AngII stimulation significant (p=0.002) cardiac fibrosis was only 
observed in WT mice thus confirming earlier studies where Nox2 was found to be 
important in AngII induced cardiac fibrosis. Significant cardiac fibrosis was observed in 
WT/WT chimeric mice demonstrating once more that the process of generating 
chimeric mice had no effect on the physiological/pathophysiological response to AngII. 
Levels of cardiac fibrosis were unaltered in WT/Nox2-/- (p=0.39) but remained 
significantly (p=0.003) reduced in Nox2-/-/WT  chimeric mice suggesting a crucial role 
for the Nox2 in the resident cardiac cells in AngII induced cardiac fibrosis. (N=6/7 mice 
were used in each group for experimentation)  
 
 
5.3.4  NOX2 IN CARDIAC  CELLS IS IMPORTANT FOR ANGII INDUCED CARDIAC 
FIBROSIS  
AngII stimulation resulted in a significant increase in fibrosis in both 
the WT and WT/WT chimeric mice. The increase was approximately 
0.82units (95%CI:0.34;1.3,p=0.002) greater than in vehicle infused WT 
mice. In line with earlier results no significant increase in fibrosis was seen 
following AngII infusion in Nox2-/- mice (Increase in fibrosis of +0.41units 
(95%CI:-0.13;0.94, p=0.127) compared with vehicle infused Nox2-/- mice). 
These results again support the hypothesis that AngII induced cardiac 
fibrosis is Nox2 dependent.  In addition, they demonstrate once more that 
the process of generating chimeric mice had no effect on the 
physiological/pathophysiological response to AngII (Figure 5.6). 
The selective loss of Nox2 in the circulating blood cells, namely in the 
WT/Nox2-/- chimeric mice, had no significant effect on the degree of AngII 
induced cardiac fibrosis (figure 5.6). (WT/Nox2-/- chimeric mice showed level 
of fibrosis -0.15 units (95%CI:-0.21;0.51,p=0.39)  compared with WT/WT 
chimeric mice).  In contrast, Nox2-/-/WT chimeric mice maintained a 
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significantly reduced fibrosis compared with WT/WT(level of fibrosis was -
0.53units (95%CI:0.21;0.86,p=0.003)) which was not significantly different 
from that seen in Nox2-/- mice with or without AngII stimulation. 
 Taken together these results suggest that the Nox2 in the peripheral 
blood cells is not essential for the development of AngII induced cardiac 
fibrosis while Nox2 in the resident cardiac cells appears crucial in this 
process.  
 
5.3.5 MONOCYTES WITH HIGH CD11B EXPRESSION (INFLAMMATORY 
PHENOTYPE) WERE OBTAINED FROM BLOOD AND BONE MARROW BY 
POSITIVE SELECTION 
In mice the monocyte population in the blood comprises only 3% of 
the total leukocyte population and therefore the use of positive selection by 
microbeads was necessary in order to determine the characteristics of this 
cellular population. FACS for CD11b positive cells on the total cell population 
prepared from blood, i.e. before microbead selection, showed very few cells 
with a high expression of CD11b. (Figure 5.7 A) However following positive 
selection with the microbeads a large population of high CD11b expressing 
monocytes was obtained (Figure 5.7 B ) and moreover FACS of the flow-
though from the MACS Column showed very few CD11b positive expressing 
cells were lost. (Figure 5.7 C)  Thus the process successfully captured the low 
numbers of high CD11b expressing cells with very few lost during washing 
providing a relatively pure population of monocytes. 
There was relatively more high CD11b expressing cells in the bone 
marrow (Figure 5.7 D & F). Nevertheless positive selection with CD11b-
microbeads on the bone marrow preparation resulted in a purer 
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concentration of high CD11b expressing monocytes. (Figure 5.7 E & F) As the 
bone marrow had a larger number of such cells, FACS for CD11b positive cells 
on the flow-through showed the loss of these cells. (Figure 5.7 F)      
The possible contamination of the monocyte population selected by 
the microbeads with lymphocytes which express lower levels of CD11b was 
investigated. Double staining of CD11b and CD3 (pan leukocyte marker) was 
undertaken on the purified monocytes from blood and the flow-through from 
the MACS column. The blood sample showed no low CD11b and CD3 
expressing cells. (Figure 5.7 G) However, these cells were observed in the 
flow through which suggest that they were not retained by the microbeads 
(possibly because the CD11b expression was too low) and were therefore 
subsequently lost in the washing (Figure 5.7 H-white arrow). In conclusion 
these experiments demonstrated that monocytes were successfully obtained 











Figure 5-7 FACS analysis on blood and marrow monocytes before and after 
microbead separation 
Blood:- A: Shows the scatter of blood cells before microbead separation. The y-axis 
shows the separation of mononuclear cells into those with high expression of CD11b 
(upper left quadrant). Few monocytes (CD11b high expressing) are observed. B: 
Following separation a concentration of monocytes is now observed in the left upper 
quadrant.  C: The results of the separation are summarized. Few monocytes (CD11b 
high expressing) are observed before separation (red) however following separation 
CD11b expressing cells have been successfully concentrated (green). The loss of 
monocytes in the flow through of the MACS columns (white) shows minimal loss of 
these cells.   
Bone marrow:- D: Bone marrow has a larger population of mononuclear cells with 
high CD11b expression even before MACS separation. E: However a homogenous 
population of monocytes (CD11b high expressing) cells is obtained following MACS 
separation as observed with a loss of cells in the lower left quadrant.  F: The results are 
summarized where a large number of CD11b high and low expressing cells are 
observed amongst the mononuclear cells before separation (red). Following separation 
(green) a concentration of monocytes (CD11b high expressing) are obtained. Due to the 
large numbers of monocytes some were found in the wash through from the MACS 
columns.   
Lymphocyte contamination:- G: Lymphocytes are the other common mononuclear 
cell population typically with low CD11b expression. As before the y-axis shows CD11b 
expression wheras now the x-axis is labeled to detect levels of CD3 expression (double 
staining).  No discernible lymphocyte contamination (lower right quadrant) was found 
in the monocytes separated from blood. H: However the lymphocytes (CD3 positive 
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and low CD11b expressing) were found in the wash through from the MACS Column 
(white arrow). 
 
5.3.6 ANGII STIMULATION RESULTED IN AN INCREASE IN L-SELECTIN 
EXPRESSION IN BLOOD MONOCYTES IN NOX2-/-  MICE 
Modulation of L-selectin expression by AngII was investigated as 
discussed earlier, this selectin is important for the adherence of cells to the 
endothelium and their shedding and subsequent migration into tissue(Carlos 
and Harlan, 1994). Hence Nox2 modulation of its expression may influence 
the ability of cells to infiltrate the heart and induce cardiac fibrosis. 
However, no significant differences in the baseline expression of L-
selectin on bone marrow monocytes from WT (476AU +/-  21) and Nox2-/- 
(484AU +/-13) mice could be detected. The expression of L-selectin was also 
similar between WT (547AU +/- 9) and Nox2-/- (538AU +/- 19) monocytes 
derived from blood. (Figure 5.8) This would suggest that the baseline 
expression of L-selectin in blood and bone marrow derived monocytes was 
not significantly influenced by the loss of Nox2. Interestingly, independent of 
Nox2, the expression of L-selectin was found to be significantly increased in 
monocytes derived from blood as compared to bone marrow (average mean 
fluorescence was higher by 61.9AU (95%CI: 17.6; 106.2 p=0.012). 
AngII stimulation did not induce any significant change in the 
expression of L-selectin in monocytes derived from blood or bone marrow in 
WT mice. Similarly in the Nox2-/- mice the bone marrow derived monocytes 
did not show any significant change in the L-selectin expression with AngII 
stimulation. However L-selectin expression was significantly increased in 
blood monocytes derived from Nox2-/- mice (by 83AU (95%CI: 37.8; 
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129.1,p=0.001). Therefore the data suggests a significant role of Nox2 in the 
shedding of L-selectin in peripheral blood monocytes following AngII 
stimulation. After 14 days of stimulation with AngII this manifested itself as 










































































































































































































Figure 5-8 Changes in L-selectin, F-actin and Ly6c expression in WT and Nox2-/- 
bone and blood monocytes following AngII stimulation  
L-Selectin: Expression of L-selectin was significantly more in PB than BM in both WT 
and Nox2-/- mice.  Following AngII stimulation for 14 days expression of L-selectin was 
significantly increased in peripheral blood monocytes from Nox2-/- mice.  
F-Actin: Expression of filamentous actin was significantly higher in blood monocytes 
as compared to bone marrow. The loss of Nox2 or stimulation with AngII did not 
significantly change its expression.  
Ly6c: Percentage of high Ly6c expressing monocytes was similar in the blood and bone 
marrow of WT and Nox2-/- mice. Stimulation with AngII showed a significant increase 
in the percentage of high Ly6c expressing monocytes in Nox2 -/- by day 3. The 
percentages in both WT and Nox2-/- mice were not significantly different from 
unstimulated by day 14.  
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5.3.7 F-ACTIN EXPRESSION WAS SIMILAR IN WT AND NOX2-/- BLOOD AND 
BONE MARROW MONOCYTES FOLLOWING ANGII STIMULATION 
The redox sensitive regulation of the actin cytoskeleton has been 
discussed in Chapter 3.  Alterations in monocyte shape are important to 
enable the cell to migrate(Kamei and Carman, 2010; Muller, 2003) and in 
order to achieve this filamentous actin (F-actin) is changed to globular actin 
as the actin is broken down and recycled. Hence he expression levels of F-
actin in WT and Nox2-/- monocytes from blood and bone marrow were 
investigated.  
In line with the L-selectin results, there was no significant difference 
in the baseline expression of F-actin in monocytes derived from bone in WT 
(608u +/- 11) or Nox2-/- (612u +/- 15) mice. The expression of F-actin was 
also similar between monocytes derived from blood in WT (708 +/- 12) or 
Nox2-/- (723 +/- 14). (Figure 5.8) As with L-selectin, this would suggest that 
the baseline expression of F-actin in blood and bone marrow derived 
monocytes was not significantly influenced by the loss of Nox2. Similar to  L-
selectin, independent of Nox2, the expression of F-actin was found to be 
significantly higher in monocytes derived from blood as compared to bone 
marrow. On average the mean fluorescence was higher by 105U (95%CI: 
74;137 p<0.001).  
However, in contrast to the L-selectin results, no significant change in 
the levels of F-actin in blood and bone marrow derived monocytes from 





5.3.8 LY6C EXPRESSION WAS INCREASED FOLLOWING 3 DAYS OF ANGII 
Monocytes with a high expression of Ly6c have been termed 
‘inflammatory’ monocytes due to their preferential recruitment into tissue 
with ongoing inflammation (Nahrendorf et al., 2007; Panizzi et al., 2010). 
The recruitment of monocytes into the heart is an important first step in the 
development of cardiac fibrosis (Sun et al., 2002b). As Nox2 has been shown 
to be important in AngII induced cardiac fibrosis, the role of Nox2 in 
monocytes maturation, as observed by changes in Ly6c expression, in the 
bone marrow and blood could be important in the development of fibrosis. 
(Figure 5.8) 
In WT mice the percentage (Figure 5.8 Ly6c-top) of high Ly6c 
expressing monocytes was similar in blood and bone marrow.  The loss of 
Nox2 did not result in any significant change in the percentage of high Ly6c 
expressing monocytes in blood or bone marrow. Thus the global loss of Nox2 
did not appear to influence the natural maturation process of monocytes in 
blood or bone marrow. 
 Following 3 days of AngII stimulation(Figure 5.8 Ly6c-middle) no 
significant change was observed in the percentage of high Ly6c expressing 
monocytes in WT blood or bone marrow. Similarly no significant change was 
observed in the percentage of high Ly6c expressing monocytes in the bone 
marrow of Nox2-/- mice. However, in contrast, monocytes derived from blood 
in Nox2-/- mice the percentage of high Ly6c expressing monocytes increased 
significantly by 18% (95%CI:-1.22;37.3,p=0.04). 
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Following 14 days of AngII stimulation the percentage of high Ly6c 
expressing monocytes in WT and Nox2-/- blood and bone marrow showed no 
significant change as compared to mice which were not stimulated. 
Thus any effect of the loss of Nox2 on the percentage of high Ly6c 
expressing monocytes following AngII stimulation could only be detected 
early during AngII stimulation and the differences were lost following more 




5.4.1 ROLE OF NOX2 IN CIRCULATING BLOOD CELLS AND RESIDENT CARDIAC 
CELLS IN CARDIAC HYPERTROPHY AND FIBROSIS  
 
MAIN  FINDINGS: 
 Nox2 in circulating peripheral blood cells  is important in blood 
pressure control. 
 Nox2 in circulating peripheral blood cells is crucial in AngII 
induced cardiac hypertrophy. 
 Nox2 present in resident cardiac cells is crucial for AngII 
induced cardiac fibrosis. 
 
Nox2-/- mice developed less hypertrophy and fibrosis in response to 
AngII stimulation than wild type mice which confirmed previous results 
demonstrating an important role for Nox2 in this process. In this chapter the 
mechanism of this protective effect was further explored by investigating in 
which cell type was the loss of Nox2 critical. In order to do this, the already 
established globally deficient Nox2 mouse was used to create chimeric mice 
in which Nox2-/- or WT circulating cells were combined with Nox2-/- or WT 
mice.   
AngII stimulation of WT chimeras with Nox2-/- marrow and in Nox2-/- 
chimeras with WT marrow resulted in a blunted blood pressure response. 
Nox2 is known to play an important part in AngII induced hypertension 
(Touyz, 2005) while other literature suggests that other Nox isoforms such as 
Nox1 are important (Gavazzi et al., 2006; Matsuno et al., 2005).  As such 
Nox1 deficient mice display a blunted hypertensive response to AngII 
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(Gavazzi et al., 2006; Matsuno et al., 2005), whereas, Nox1 overexpression 
specifically in VSMCs potentiated AngII pressor response (Dikalova et al., 
2005).  In addition, cell types other than endothelium have been linked to 
hypertension, including vascular smooth muscle cells, adventitia and more 
recently T-cells (Dikalova et al., 2005; Guzik et al., 2007; Pagano et al., 1997).  
Furthermore, NADPH oxidase in systems other than the cardiovascular 
system, e.g. the CNS, appear also to play a part in hypertension (Zimmerman 
et al., 2004). The results in this chapter suggest that Nox2 in the circulating 
inflammatory cells has a role in the development of AngII induced 
hypertension as the absence of Nox2 in the WT/Nox2-/- chimeric mice 
resulted in a blunted blood pressure response.  
The blunted hypertensive response in Nox2-/-/WT BM chimeric mice 
was unexpected.  Byrne et al (Byrne et al., 2003) had described how Nox2-/- 
mice have a natural lower baseline blood pressure necessitating the need to 
conduct experiments with pressor doses of AngII and thus again 
demonstrating an important role for Nox2 in the control of blood pressure. 
However, with pressor doses of AngII the global Nox2-/- mice were able to 
demonstrate a hypertensive response similar to that observed in WT mice. 
The blunted blood pressure response in Nox2-/-/WT chimeric mice, to 
pressor doses of AngII, would therefore suggest that the mechanism whereby 
AngII induces the hypertensive response in global Nox2-/- mice could be 
different from that in WT mice. Normally NADPH oxidase is present in many 
different cells and tissue important for blood pressure control (Dikalova et 
al., 2005; Gavazzi et al., 2006; Guzik et al., 2007; Matsuno et al., 2005; 
Pagano et al., 1997; Touyz, 2005) and as we observed earlier in WT/Nox2-/- 
chimeric mice that the presence of Nox2 in the peripheral circulating blood is 
 217 
particularly important.  Global Nox2-/- mice have a different adapted 
physiology (Bendall et al., 2002b) especially with respect to the expression of 
other NADPH oxidases and antioxidants in cells and tissues which are 
important for the control of blood pressure.  Thus the underlying mechanism 
by which a global Nox2-/- mice would develop hypertension with pressor 
doses of AngII could be different from WT mice such that paradoxically the 
blood pressure response is attenuated by the presence of Nox2 in the 
peripheral circulating blood cells.    
AngII induced cardiac hypertrophy was unaffected by the global loss 
of Nox2.  Previous studies using global Nox2 knockout mice have shown that 
Nox2 is important in the development of cardiac hypertrophy in response to 
a low sub-pressor dose of AngII (Bendall et al., 2002a) and also at pressor 
doses (Byrne et al., 2003).  However, the mice in these experiments (Bendall 
et al., 2002a; Byrne et al., 2003) had been stimulated for one week as 
compared to two weeks in the current experiments. With the longer duration 
of stimulation or higher doses of AngII the protective effect of Nox2 appears 
overwhelmed.  As such other studies too have found the loss of Nox2 to have 
no effect on the development of cardiac hypertrophy induced by a higher 
pressor dose of AngII following 2 weeks stimulation (Grieve et al., 2006; 
Johar et al., 2006; Maytin et al., 2004). Taken together the results would 
suggest that the loss of Nox2 slows the development of AngII induced cardiac 
hypertrophy. Thus in global knockout mice the cardiac hypertrophy response 
is slower but with time a similar level of hypertrophy can be achieved. The 
key result of the current studies was the fact that selective loss of Nox2 from 
the circulating inflammatory cells resulted in an almost complete loss of 
cardiac hypertrophy despite 2 weeks of pressor dose of AngII stimulation. 
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This suggests that Nox2 in the circulating cells plays a critical role in 
inducing cardiac hypertrophy in response to AngII.  
Transplantation of WT marrow into a Nox2-/- mouse resulted in an 
increased AngII induced cardiac hypertrophy over and above that seen in WT 
mice. It is important to note that the global Nox2-/- have a different adaptive 
physiology with respect to their redox expression (Bendall et al., 2002b). The 
redox state of a cell is important in modulating cell signaling. Evidence for 
this comes from studies on  rat cardiomyocytes in which AngII induced 
hypertrophy was abolished by adenoviral mediated expression of Cu/ZnSOD 
(Hingtgen et al., 2006b) Thus in global Nox2-/- mice, with time, a pressor 
dose of AngII can overwhelm the protective effect from the loss of Nox2. 
However in the Nox2-/-/WT model we have the acute infusion of  WT 
peripheral cells into Nox2-/- mice with an altered redox state of their resident 
cells.  The resident cardiac cells in the Nox2-/- mice with their reduced 
antioxidant reserves (Bendall et al., 2002b) are now infiltrated by WT 
peripheral cells which we have observed to have a increased ROS response 
(compared to Nox2-/- cells) following PMA (downstream signaling molecule 
for AngII) stimulation. Though the exact mechanism is not completely 
elucidated from these experiments, the net effect was an exacerbated 
hypertrophic response.  Nevertheless, both these chimeric mice provide 
further support for a critical role of Nox2 in the circulating inflammatory cell 
in the development of AngII induced hypertrophy.  
The blood pressure response in both WT/Nox2-/- and the Nox2-/-/WT 
chimeric mice was slower.  The exaggerated hypertrophic response in     
Nox2-/-/WT mice and the lack of it in WT/Nox2-/- was in contrast. The result 
was in keeping with Bendall et al (Bendall et al., 2002a) who had shown a 
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reduced level of cardiac hypertrophy in the Nox2-/- mice with sub-pressor 
doses of AngII suggesting that independent of the mechanical effect of blood 
pressure, chemical stimulation by angiotensin II induces cardiac hypertrophy 
via Nox2 oxidase. In contrast to AngII induced hypertrophy, the hypertrophic 
response to aortic banding was found to be similar between Nox2-/- and wild 
type mice by Byrne et al (Byrne et al., 2003). They also found an increased 
level of NADPH oxidase activity which they ascribed to the increased levels of 
Nox4 seen in the Nox2-/- mice. Maytin et al (Maytin et al., 2004) have also 
shown that pressor effects from aortic banding induced similar levels of 
cardiac hypertrophy in both wild type and Nox2-/- mice. These authors also 
found increased levels of p22phox  and  p47phox mRNA.  Taken together these 
data support the fact Nox2 does not play an essential role in cardiac 
hypertrophy as induced by the mechanical effect of aortic banding.  
The selective loss of Nox2 from circulating inflammatory cells resulted 
in no change in the level of AngII induced cardiac fibrosis.  This suggests that 
the inflammatory cells were not the critical cell source for the Nox2 in AngII 
induced cardiac fibrosis. However, the loss of Nox2 from the resident cardiac 
cells resulted in a loss in cardiac fibrosis demonstrating these cells as the 
critical cell source for AngII induced cardiac fibrosis. 
This result supports the observation of a dissociation of the fibrotic 
response from that of the hypertrophic response to AngII. In models of infra-
renal aortic banding with normal circulating levels of AngII and aldosterone, 
there is no evidence of increased cardiac fibrosis despite the presence of 
significant hypertrophy (Brilla et al., 1990). Similarly, chronic elevation of 
noradrenaline levels is not associated with increased cardiac fibrosis despite 
an elevation in blood pressure (Patel et al., 1989). Furthermore, in human 
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hypertension, fibrosis has been found in both the left and right ventricles in 
biopsies of myocardial tissue, despite the right heart pumping blood against a 
reduced afterload, suggesting that humoral factors are more important than 
the mechanical loading in the bringing about the fibrotic response 
(Amanuma et al., 1994). Raised levels of AngII are thought to play a key role 
in triggering the inflammatory response resulting in fibrosis. In support of 
this many studies have shown that the blockade of AngII or its action results 
in a reduction in fibrosis. For example, Tokuda et al (Tokuda et al., 2004) 
demonstrated that a sub-depressor dose of candersartan (an angiotensin II 
receptor blocker)  in mice who had had supra-renal aortic banding markedly 
ameliorated perivascular fibrosis.   The differential role of Nox2 in peripheral 
cells in promoting cardiac hypertrophy and in resident cardiac cells in 
promoting cardiac fibrosis following AngII stimulation offers a mechanism 
by which cardiac hypertrophy and fibrosis could occur independently. This 
observation therefore has the potential as  a specific therapeutic target for the 
management of cardiac hypertrophy and fibrosis separately. In hypertensive 
heart disease the unwanted fibrotic effects could potentially be targeted 
specifically.  
The critical cellular source for Nox2 in AngII induced cardiac fibrosis 
could be one or all of three possible sources. Firstly the resident fibroblasts 
were investigated and discussed in chapter 2 by way of their NADPH oxidase 
dependent ROS response. A Nox2 dependent ROS response was not observed 
following AngII stimulation. However, given that a Nox2 dependent ROS 
response observed in cardiac fibroblasts following TGFβ stimulation and the 
downstream placement of TGFβ to the effects of AngII (Schultz et al., 2002), 
could establish cardiac fibroblasts as an important cellular source for Nox2. 
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Secondly cardiac myocytes are known to express Nox2 (Bendall et al., 2002a; 
Peng et al., 2005; Xiao et al., 2002) and in cultured cells and in vivo models 
the activation of cardiomyocyte Nox2 may contribute to the development of 
AngII induced cardiac hypertrophy (Bendall et al., 2002a). A similar critical 
role for cardiomyocytes Nox2 could exist in cardiac fibrosis thus making it a 
critical cellular source for Nox2.  Finally, the endothelium could be an 
important cellular source for Nox2 in the development of cardiac fibrosis. 
The endothelium in pathologic settings, such as in the renin-angiotensin 
system activation, can become activated and promote increased interaction 
with circulating inflammatory cells (Frey et al., 2009). The infiltration of 
inflammatory cells is an important early event in the development of cardiac 
fibrosis, making this a possible important cellular source of Nox2. Another 
mechanism by which endothelial Nox2 might promote cardiac fibrosis is 
through the process of endothelium mesenchymal transition (EndoMT). 
EndoMT has been recognized as an important source of cardiac fibroblasts 
and was discussed in chapter 2.  Zeisberg et al (Zeisberg et al., 2007a) 
showed in a landmark study that EndoMT makes a significant contribution 
to pathologic cardiac fibrosis in a mouse model of transverse aortic 
constriction. Whether endothelial Nox2 activation affects EndMT and is 
therefore a critical cellular source of Nox2 in AngII induced cardiac fibrosis 




5.4.2 CHANGES IN F-ACTIN & L-SELECTIN EXPRESSION  AND IN THE NUMBERS 
OF LY6CHI EXPRESSING MONOCYTES  
 
MAIN  FINDINGS: 
 Bone marrow derived monocytes express less L-Selectin and F-
Actin but have a similar number of Ly6c expressing cells in 
comparison to blood derived monocytes. 
 Nox2 is not important in the baseline expression of L-Selectin, 
F-Actin or Ly6C. 
 
As the infiltration of monocytes/macrophages into the heart is an 
important initial step in the development of cardiac fibrosis (Kuwahara et al., 
2003) the characteristics of these cells from WT and Nox2-/- mice were 
investigated. High Ly6c expressing ‘inflammatory’ monocytes preferentially 
migrate into sites of inflammation (Geissmann et al., 2003; Qu et al., 2004).  
L-selectins are important for the homing of cells to sites of inflammation 
(Kishimoto et al., 1989) where the monocytes can adhere and change shape 
enabling them to migrate into tissue, a process that requires the shedding of 
L-selectin. Thus the numbers of high Ly6c expressing monocytes and the 
expression of L-selectin and F-actin in blood and bone marrow monocytes 





Monocytes in the bone marrow are adherent to the marrow sinusoid. 
On migrating out of the marrow their shape is spherical as they are 
suspended in the blood. In both WT and Nox2-/- mice F-actin expressions 
were higher in monocytes from blood as compared to bone marrow. The 
increase in F-actin may reflect the necessary change in the cytoskeleton as 
the monocyte changes shape from being flat to spherical. The flat monocyte 
has to migrate and hence requires relatively more of its actin to be in the 
globular, rather than in filamentous form, to enable for actin cytoskeleton 
turn over at the leading edge. The actin cytoskeleton and its regulation, along 
with the important role of ROS in its modulation, has been described in 
Chapter 2. Here, we observe that the lack of any baseline difference in F-actin 
levels between WT and Nox2-/- monocytes from blood and marrow suggests a 
lack of importance of Nox2 derived ROS in regulating the baseline levels of  
F-actin. 
 Stimulation by AngII has been shown to lead to changes in the actin 
cytoskeleton. Godin et al (Godin and Ferguson, 2010) on stimulation of 
HEK293 cells with AngII were able to induce membrane blebbing. Again in 
HEK293 cells Cotton et al (Cotton et al., 2007) were able to demonstrate 
membrane ruffling and Barnes et al (Barnes et al., 2005) showed the 
formation of stress fibres. However, stimulation with AngII in our 
experiments did not show any significant change in the F-actin levels. The 
stimulation with AngII in our experiments had been for 2 weeks unlike the 
more acute stimulation used in the above papers. Our results demonstrate 
that though there may be acute effects of AngII stimulation on the 
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cytoskeleton, no significant quantitative change in F-actin levels are observed 
following chronic exposure as in hypertensive heart disease.  
5.4.2.2 L-selectin 
The higher expression of L-selectin in the blood monocytes as 
compared to bone marrow monocytes could reflect the necessity of the 
rolling and adhering process of these cells to the vascular endothelium. 
Evidence in the literature suggests that the adherence of neutrophils to 
endothelium increases with exposure to H2O2 (Fraticelli et al., 1996). Also 
metalloproteinase 17, a sheddase of L-Selectin, has been shown to be redox 
sensitive (Wang et al., 2009b). The regulation of the expression of L-selectin 
is redox sensitive. However, the loss of ROS and in particular that from Nox2 
did not influence the baseline expression of L-selectin suggesting that a lack 
of Nox2 derived ROS not to be crucial in this process.  
The role of AngII in the regulation of L-selectin shedding has been 
demonstrated from different lines of evidence. Clincal studies have shown 
that L-selectin density on lymphocytes and monocytes/macrophages were 
significantly lower in hypertensive patients than in normotensives (Mills et 
al., 2002; Zapolska-Downar et al., 2006). In an in vitro study Vega et al 
demonstrated that AngII, in a dose dependent manner, induced shedding of 
L-selectin in human neutrophils rapidly over the course of minutes reaching 
maximum shedding at five minutes (Vega et al., 2010). Thus, an AngII 
dependent mechanism might lead to direct L-selectin shedding and leukocyte 
extravasation into local inflammatory sites in hypertensive cardiac disease. 
However, stimulation with AngII did not result in any significant change in 
the L-selectin levels of WT blood monocytes.  
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Unexpectedly a significantly increased expression of L-selectin was 
observed in Nox2-/- blood monocytes following AngII stimulation. The exact 
mechanism of this increase is difficult to explain but could involve less 
shedding. However, the effect of such an increase would be to impede the 
migration of these cells into the heart thus explaining the slower 
hypertrophic response observed in Nox2-/- mice. This would require 
corroborating by undertaking histological staining of the hearts.  
5.4.2.3 Ly6c 
The bone marrow has its own environmental niche and committed 
progenitors tend to localize to their bone marrow regions (Lo et al., 2007; Lo 
et al., 2009; Lo and Scadden, 2011). Oxidative stress and redox dysregulation 
in the bone marrow have direct consequences in signalling cascades 
involving pathways of survival, proliferation, angiogenesis and metastasis 
(Giles, 2006; Gius and Spitz, 2006; Szatrowski and Nathan, 1991a). As such 
studies in the 1950s indicated a critical role for cysteines and thiols in bone 
marrow cell proliferation (Baldini and Sacchetti, 1953). Long-term, self-
renewing haematopoietic stem cells (HSC) have low levels of intracellular 
ROS. However, high ROS may result in senescence, apoptosis and a failure to 
self renew. Mice deficient in ROS regulating genes have HSCs that cannot 
maintain quiescence or self-renewal capacities (Naka et al., 2007).  The 
specific role of the ROS from Nox2 in the regulation of numbers of high Ly6c 
expressing monocytes was investigated. 
The baseline percentage of high Ly6c expressing monocytes was not 
different between WT and Nox2-/- mice suggesting that the global loss of 
Nox2 did not affect the proportion of inflammatory monocytes found in 
 226 
blood or bone marrow. However, other data from our laboratory has shown 
that selective overexpression of Nox2 in endothelium resulted in a 
significantly higher percent (10%) of high Ly6c expressing monocytes in the 
blood with a corresponding significant lower percent (20%) in the bone 
marrow. (unpublished) This therefore suggests that Nox2 in the endothelium 
of the bone marrow may be important in regulating the release of these cells. 
The regulation of marrow cell trafficking has been reviewed by Shi (Shi, 
2012) where the high Ly6c expressing monocytes are said to be released from 
the bone marrow in  response to chemokine CCL2. The local  production of 
CCL2 in the bone marrow can be induced by circulating T-Lymphocyte 
receptor ligands. Using CCL2 reporter mice, CCL2-expressing cells are 
identified at the perivascular sites and seem to attract monocytes to the 
abluminal aspect of the endothelium where they subsequently gain access to 
the circulation. The results discussed above show that Nox2 in the 
endothelium results in more inflammatory monocytes circulating in the 
blood with resultant increase in cardiac fibrosis, in contrast to WT mice. 
Ly6Chi monocytes are generated in the bone marrow, and can be 
rapidly recruited to the peripheral tissues during infection or inflammatory 
response. Disease processes such as  MI and atherosclerosis have been shown 
to be associated with changes in high Ly6c expressing monocytes. Exposure 
to AngII underlies such changes supporting the possibility of a role for 
inflammatory monocytes in the development of hypertensive heart disease. 
However, no significant change was observed in the proportions of 
inflammatory monocytes following 3 days or 14 days of AngII stimulation in 
blood or marrow in WT mice. In Nox2-/- mice the numbers of high Ly6c 
expressing monocytes did significantly increase after 3 days of AngII 
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stimulation in the blood, an effect which was lost at day 14. The marrow did 
not show any significant change.  This unexpected finding is in keeping with 
the increased expression of L-selectin found in Nox2-/- mice following AngII 
stimulation and could reflect an impaired tissue infiltration of these cells, the 
effect of which is overwhelmed by day 14. This would again be in keeping 
with the slower hypertrophic response in Nox2-/- mice to AngII stimulation. 
Further investigation of the numbers of high Ly6c expressing monocytes in 
the blood at earlier time points and double staining and FACS analysis with 
L-selectin on high Ly6c expressing monocytes would help clarify this finding 
further.    
In conclusion these experiments demonstrate that the Nox2 in the 
peripheral blood cells has a significant role in the development of cardiac 
hypertrophy, while that in the resident cells is crucial for the development of 
cardiac fibrosis,  following AngII stimulation. The data also suggests a 
possible hypothesis explaining the delayed hypertrophic response observed 
in Nox2-/- mice hearts following AngII stimulation 
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6 GENERAL DISCUSSION  
6.1 BACKGROUND 
Hypertensive heart disease results in the development of cardiac 
hypertrophy and fibrosis. In mouse models of hypertensive heart disease, 
simulated with AngII infusion, Nox2 has been shown by our laboratory to be 
important in this pathophysiological process (Bendall et al., 2002a; Byrne et 
al., 2003; Johar et al., 2006). 
The development of cardiac fibrosis is thought to be in part the result 
of raised levels of AngII which can trigger an inflammatory response 
resulting in fibrosis. The fibrosis has been found in both the left and right 
ventricles in biopsies of myocardial tissue, despite the right heart pumping 
blood against a reduced afterload and not developing cardiac hypertrophy 
(Amanuma et al., 1994). This suggests that a humoral cause, namely AngII, 
for the development of cardiac fibrosis in the right ventricle. Also many 
studies have shown that the blockade of AngII or its action results in a 
reduction in fibrosis. As such Tokuda et al (Tokuda et al., 2004) 
demonstrated that a sub-pressor dose of candersartan (an AngII receptor 
blocker), in mice who had had supra-renal aortic banding, markedly 
ameliorated perivascular fibrosis. 
Our laboratory has shown that Nox2-/- mice had a markedly reduced 
fibrosis compared to wild type animals in response to either a subpressor or 
pressor infusion of AngII by Bendal et al, Byrne et al and Johar et al  (Bendall 
et al., 2002a; Byrne et al., 2003; Johar et al., 2006). Furthermore, Johar et al 
(Johar et al., 2006)  showed that the profibrotic effects of AngII were 
inhibited by the antioxidant N-acetyl-cysteine, consistent with the role of 
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ROS in this process. Nox2 has also been implicated in aldosterone induced 
myocardial fibrosis (Johar et al., 2006). Furthermore, Nox2 NADPH oxidase 
has been implicated in the genesis of fibrosis in several other organ systems 
(An et al., 2007; Bataller et al., 2003; Manoury et al., 2005; Rey and Pagano, 
2002). 
However, the role of Nox2 in cardiac fibrosis secondary to the pressor 
effect of aortic banding is conflicting. Matyn et al (Maytin et al., 2004) 
published evidence that Nox2 oxidase did not play an important role in 
cardiac fibrosis in this model as myocardial fibrosis was increased to a 
similar level in both wild type and Nox2-/- mice. In contrast, Greive et al 
(Grieve et al., 2006) demonstrated a reduced level of fibrosis in the Nox2-/- 
mice implicating an important role for the Nox oxidase in myocardial fibrosis 
following aortic banding.  
Previous studies using global Nox2 knockout mice have shown Nox2 
to be important in the development of cardiac hypertrophy in response to a 
low sub-pressor dose of AngII (Bendall et al., 2002a) and also at pressor 
doses (Byrne et al., 2003).  However the mice in these experiments had been 
stimulated for one week as compared to two weeks in the current 
experiments. With the longer duration of stimulation or higher doses of 
AngII the protective effect of Nox2 appears overwhelmed.  As such other 
studies too have found the loss of Nox2 to have no effect on the development 
of cardiac hypertrophy induced by a higher pressor dose of AngII following 2 
weeks stimulation (Grieve et al., 2006; Johar et al., 2006; Maytin et al., 
2004). Taken together, the results would suggest that the loss of Nox2 slows 
the development of AngII induced cardiac hypertrophy. In global knockout 
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mice the cardiac hypertrophy response is slower but with time a similar level 
of hypertrophy can be achieved.  
In contrast to AngII induced hypertrophy, the hypertrophic response 
to aortic banding was found to be similar between Nox2-/- and wild type mice 
by Byrne et al (Byrne et al., 2003). They also found an increased level of 
NADPH oxidase activity which they ascribed to the increased levels of Nox4 
seen in Nox2-/- mice. Maytin et al (Maytin et al., 2004) have also shown that 
pressor effects from aortic banding induced similar levels of cardiac 
hypertrophy in both wild type and Nox2-/- mice.  Taken together these data 
support the fact Nox2 does not play an important role in cardiac hypertrophy 
as induced by the mechanical effect of aortic banding, however, it does have a 
role in cardiac hypertrophy from the humoral effects of AngII. This alludes to 
different mechanisms in the development of cardiac hypertrophy from 
different stimulants. A key question was how Nox2 drives both AngII induced 
cardiac hypertrophy and fibrosis and in particular the critical cell source of 
the Nox2.  
6.2 NOVEL FINDINGS FOR THE CELL SPECIFIC ROLE OF NOX2  
Results from chapter 5 showed that the Nox2 in the circulating cells 
were important in the development of AngII induced cardiac hypertrophy 
and that the Nox2 in the resident cardiac cells were important in the 
development of cardiac fibrosis. This was a departure from the conventional 
understanding in hypertensive heart disease that cardiac fibrosis and 
hypertrophy are inevitably linked and developed together. The observation 
allowed for a possible underlying mechanism whereby the modulation of 
downstream signalling by ROS from Nox2 in different cell types could 
 231 
orchestrate the development of the two processes separately. Thus, following 
AngII stimulation the selective lack of redox modulation, by way of ROS from 
Nox2, in the circulating cells could lead to the development of cardiac fibrosis 
without hypertrophy. Conversely following AngII stimulation the lack of 
redox modulation, by way of ROS from Nox2, in the resident cardiac cells 
could lead to the development of cardiac hypertrophy without cardiac 
fibrosis. 
 The independent development of cardiac fibrosis and hypertrophy is 
supported in the literature. Thus in models of infra-renal aortic banding with 
normal circulating levels of AngII and aldosterone, there is no evidence of 
increased cardiac fibrosis despite the presence of significant hypertrophy 
(Brilla et al., 1990). Similarly, chronic elevation of noradrenaline levels, 
resulting in an elevation in blood pressure and cardiac hypertrophy, is not 
associated with increased cardiac fibrosis (Patel et al., 1989). Furthermore as 
stated earlier in human hypertension fibrosis has been found in both the left 
and right ventricles despite the right heart pumping blood against a reduced 
afterload and not developing cardiac hypertrophy(Amanuma et al., 1994).  
The cell-specific role of the Nox2 was an interesting aspect of the 
current study.  This has clinical relevance as some aspects of the hypertrophic 
response are considered protective or adaptive in the face of increased wall 
stress and therefore beneficial at least for a period of time (Frey and Olson, 
2003).  However, the development of cardiac fibrosis and subsequent 
diastolic dysfunction is detrimental in hypertensive heart disease and the 
ability to target an individual component of the disease may be valuable. 
The cardiac fibroblasts produce collagen during development of 
cardiac fibrosis and hence were a natural choice as an important cell source 
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for Nox2 in the development of AngII induced cardiac fibrosis. The cardiac 
fibroblasts were investigated for their ROS response to stimulation by AngII, 
aldosterone and TGFβ, in chapter 2, all stimulants having been implicated in 
the development of fibrosis. A Nox2 dependent ROS response in the cardiac 
fibroblasts to these stimulants would suggest behaviour in vitro which in vivo 
would implicate the resident adult cardiac fibroblasts as a critical cell source 
for Nox2. However, no Nox2 dependent ROS response was elicited by AngII 
or aldosterone stimulation. This suggested that, in hypertensive heart disease 
following AngII stimulation, Nox2 in the resident cardiac fibroblasts may not 
be a critical cell source. 
A recent study suggested a different mechanism whereby endothelial 
cells contribute, at least in part, to fibrosis by demonstrating endothelial to 
mesenchymal transition (EndMT) (Zeisberg et al., 2007a).  Adult fibroblasts 
are thought to be derived directly from embryonic mesenchymal cells (Maric 
et al., 1997).  Zeisburg et al (Zeisberg et al., 2007a) showed that appearance 
of fibroblasts during cardiac fibrosis was not solely a result of proliferation of 
resident fibroblasts but that there was a significant component which had an 
endothelial origin.  The paper suggests that the endothelial cells, and in 
particular those that undergo EndMT to fibroblasts, are important in the 
development of cardiac fibrosis and thus could be the crucial resident cell 
source for Nox2.   
It is known that adult cardiac fibroblasts contribute to cardiac fibrosis 
by transforming to myofibroblasts and increasing the deposition of ECM 
(Sun et al., 2002a). TGFβ1 signalling via Smad2/3 is important for this 
transformation and Nox4 has been shown to be important in this signalling 
process (Cucoranu et al., 2005). On stimulation of human cardiac fibroblasts 
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with TGFβ1, Nox4 mRNA expression was significantly increased and ROS 
production significantly decreased by siRNA against Nox4. Moreover in a 
hallmark paper, Schultz et al (Schultz et al., 2002) tested whether AngII 
would be able to induce cardiac hypertrophy and fibrosis in vivo in the 
absence of TGFβ1 gene. The lack of the TGFβ1 gene fully prevented the 
development of cardiac hypertrophy and dysfunction induced by subpressor 
doses of AngII that was observed in wild type mice. This study provided the 
first direct evidence that AngII induced cardiac hypertrophy is mediated by 
TGFβ1 and indicate that TGFβ1 acts downstream of AngII and promotes 
myocyte growth and fibrosis in the heart.  
The murine adult cardiac fibroblasts were stimulated with TGFβ1 in 
chapter 2 and demonstrated a Nox2 dependent ROS response. This finding 
placed Nox2 downstream of TGFβ1 and indicated that the fibroblasts could 
still be an important cell source of the Nox2 in the development of cardiac 
fibrosis in mice following AngII stimulation. Further in vivo and in vitro 
studies would be necessary in establish the exact role of TGFβ1 signalling via 
Nox2 in the development of cardiac fibrosis. 
Another key result of the current studies was the fact that selective 
loss of Nox2 from the circulating inflammatory cells resulted in a loss of 
cardiac hypertrophy despite 2 weeks of pressor dose of AngII stimulation. 
This suggests that Nox2 in the circulating cells plays a critical role in 
inducing cardiac hypertrophy in response to AngII. Infiltration of the heart 
by macrophage/monocytes, in the circulating blood, is important for the 
development of cardiac fibrosis and hypertrophy (Kuwahara et al., 2003; 
Kuwahara et al., 2004). The role of Nox2 has been demonstrated to be 
important in the migration of endothelial cells and VSMC. The current study 
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demonstrated Nox2 to be crucial in the migration of macrophages in chapter 
3 and thus indicated how the Nox2 in the peripheral circulating cells could be 
critical in the development of hypertensive heart disease by way of its role in 
macrophage migration.  A key finding was the loss of chemotaxis in BMM 
towards CSF-1. The lack of chemotaxis in Nox2-/- macrophages observed in-
vitro could reflect in-vivo behaviour and thus explain the reduced 
hypertrophy and fibrosis which was observed. However, the migration of 
macrophages to chemoattractants in vivo is an integrated response to many 
other chemoattractants such as  MCP1 and PDGF amongst others.  The 
downstream signalling for all of them may not be Nox2 dependant thus 
offering a mechanism for the slower development of cardiac hypertrophy in 
Nox2-/- mice observed in other studies. Further migration assays towards 
other chemoattractants would be necessary to further investigate the 
importance of Nox2 in macrophage migration.    
Dunn chamber analysis of macrophage migration in chapter 3 allowed 
for the speed and persistence of the migration to be assessed along with 
chemotaxis. The novel observation was that, along with chemotaxis, both the 
speed and persistence of the macrophages is dependent on Nox2, as both 
where significantly reduced. Cellular migration is a complex procedure and 
many of the steps downstream from receptor activation by the 
chemoattractant are redox sensitive.  Intracellular signal amplification to 
establish a gradient and direction by phosphoinositides, cdc42 in cellular 
polarisation and lamelopodia formation, cytoskeletal actin turnover, actin-
myosin contractility and integrin adhesion have been shown to be redox 
sensitive and discussed in chapter8. ROS from Nox2 by way of localised ROS 
production can theoretically modulate the migratory process at any of these 
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steps resulting in the reduction in cellular speed and persistence and the loss 
of chemotaxis. A more detailed investigation into the molecular mechanism 
whereby Nox2 modulates this process is a logical further direction for this 
research. 
6.3 THERAPY 
There are drugs currently in clinical use that are thought to exert some 
of their benefits by reducing oxidative stress by way of inhibition of Nox2 
oxidase.  Antagonism of the RAS is regularly undertaken when managing 
hypertension and hypertensive heart disease. ACE inhibitors and AngII 
receptor blockers (ARBs) are first line medication used in the control of 
hypertension. ACE inhibitors are used to reduce AngII levels in the treatment 
of cardiovascular diseases.  However, as previously described, AngII is well 
known to be able to activate NADPH oxidase (Griendling et al., 1999).  
Clinical studies have demonstrated that the blockade of the RAS via 
treatment with ARB or ACE inhibitors reduces oxidative stress and 
inflammation (Dandona et al., 2006).  In clinical studies, the selective 
inhibition of angiotensin II by ARBs can prevent end-organ damage from 
hypertension-associated diseases such as CHD, atherosclerosis, and renal 
disease, and these effects appear to be potentially independent of their BP-
lowering effects. Thus reduction in endpoints were seen in patients with 
Non–insulin dependent diabetes mellitus with the Angiotensin II Antagonist 
Losartan [RENAAL], (Brenner et al., 2001) Irbesartan in Diabetic 
Nephropathy Trial [IDNT], (Lewis et al., 2001) Losartan Intervention For 
Endpoint reduction in hypertension [LIFE] study, (Dahlof et al., 2002) 
Candesartan cilexitil in Heart failure Assessment of Reduction Mortality and 
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morbidity [CHARM] study, (Pfeffer et al., 2003b) and VALsartan In Acute 
myocardial iNfarction Trial [VALIANT] (Pfeffer et al., 2003a). This further 
benefit of ARBs and ACEs may therefore be, at least in part, due to reduction 
in NADPH oxidase activation.  
Statins have also shown to have antioxidative effects. Although the 
beneficial effects of statins have been mainly attributed to their cholesterol-
lowering properties, there is growing evidence that some of the advantageous 
effects of these agents are independent of their plasma cholesterol lowering 
effect (Shepherd et al., 1995; Werner et al., 2002). One such mechanism is 
the inhibition of Rac1 (Cordle et al., 2005) which is pivotal for Nox2 
activation. Therefore, statins may potentially exert some of their beneficial 
effects via inhibition of NADPH oxidase secondary to Rac1 inhibition (Maack 
et al., 1999). 
Nevertheless, there remains a substantial morbidity and mortality 
even in patients treated with statins and antagonists of the RAS system. 
Recent evidence points to the interplay between hypercholesterolemia and 
hypertension, acting through the RAS, to increase cardiovascular risk 
(Nickenig and Harrison, 2002a; Nickenig and Harrison, 2002b; Sander and 
Giles, 2002). Oxidative stress has been implicated in many 
pathophysiological conditions in the cardiovascular system, including 
hypercholesterolemia, hypertension, diabetes, and heart failure (Lavy et al., 
1991).  There still remains room for additional approaches such as the 
targeting of NADPH oxidase in the management of such patients. 
The current results raise the intriguing possibility that cell specific 
Nox2 and/or the pathways linked to its activation could provide a therapeutic 
target to tackle separately cardiac fibrosis and diastolic dysfunction and/or 
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hypertrophy especially regression of LVH.  A clear caveat to this idea is being 
able to achieve inhibitor selectivity at the cellular and isoform level. Such 
selective inhibition should not result in any unforseen detrimental 
effects. 
6.4 STUDY LIMITATIONS 
The studies in this thesis were performed in mice and any 
extrapolation to the clinical setting should clearly be made with caution in 
view of species differences. In humans, hypertension, and the resultant 
hypertensive heart disease, are generally diseases of middle age or beyond. 
The model that was chosen for study was AngII infusion for 2 weeks, which is 
an established experimental model associated with the development of 
significant interstitial cardiac fibrosis.  Therefore, the characteristics of the 
process may be different even allowing for the difference in species.  
The Nox2-/- mice have a different adaptive physiology with respect to 
their redox expression (Bendall et al., 2002b).  In keeping with this Byrne et 
al (Byrne et al., 2003) showed the increased levels of Nox4 expression in the 
heart of Nox2-/- mice. The altered physiology would make it difficult to 
ascribe all of the effects in the results to the absence of Nox2. The underlying 
mechanism could for some of the results be due to, for example, the raised 
levels of Nox4 or other as yet unidentified protein. This point has been 
discussed in the appropriate chapter discussion. 
In setting up the chimeric mice, the mice were irradiated to eradicate 
their marrow cells before replacement by tail vein injection. Again the use of 
chimeric mice is a well established method enabling the investigation of the 
effect a particular cell/gene of interest. However, the process of irradiation 
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could by itself induce biological responses which could have an influence in 
the development of hypertensive heart disease and is rarely observed in the 
past medical history of patients with hypertensive heart disease. The 
experiments were therefore undertaken with appropriate controls 
nevertheless the extrapolation of cell specific findings needs to be made with 
caution.  
It is important to appreciate that the findings from the chimera 
experiment are currently only interpreted as those due to peripheral or 
resident cell. The marrow infusion by tail vein injection would invariably 
have a mix of other cells such as stem cells and endothelial progenitor cells. 
Clearly the studies do not identify the specific cell but only allow 
understanding of the effect of Nox2 in cells either resident or for those in the 
peripheral blood.   
The investigation of the ROS response in cardiac fibroblast and the 
migration of BMM macrophages was undertaken in-vitro. Such a 
reductionist approach is clearly beneficial in allowing investigation of the 
response of interest to the single stimulation of interest. However, this 
environment is far removed from the in vivo experience where the cells are in 
tissue and exposed to a variety of stimulations at the same time.  Whether the 
isolated responses observed also hold true in vivo depends on the outcome 
from the integration of all the stimulatory signals. The possibility exists that 
the responses observed in vitro may be, in in vivo, exaggerated due to a 
synergistic interaction or not significant due to redundancy in the signalling 
pathways.   
 
 239 
6.5 FUTURE WORK 
 A drawback of knockout mice is that the absence of the target 
gene can lead to compensation by other genes. Therefore, a 
logical study to confirm  the findings in this thesis would be to 
make use of inducible knockout technology which could 
prevent any long-term compensatory effects induced by the 
absence of the gene, while still being able to achieve removal of 
the target gene for a specific time. 
 There were some unexpected results from the current 
experiments. In particular the cellular work undertaken in 
chapter 2, 3 and 4 would require confirmation with siRNA 
inhibition of Nox2. This would not only confirm results but will 
also be a setup in which the the Nox2 is inhibited acutely and 
will allow the effects to be ascribed more confidently to Nox2 
rather than other compensatory mechanisms which may be the 
result of chronic loss of Nox2.   
 The other option would be to generate cell specific Nox2-/- or 
overexpressing mice to assess the effects of Nox2 in specific 
cells in AngII induced LVH and/or cardiac fibrosis.  The 
specific knockdown or overexpression of Nox2 in circulating 
monocytes or in cardiac fibroblasts may be able to assess the 
extent to which endogenous Nox2 contributes to cardiac 
fibrosis and/or hypertrophy.  This could of particular help in 
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investigating the unexpected finding in the blood pressure 
control in the chimeric mice. 
 Another complementary study would be to investigate Nox2 in 
other cell types such as the cardiomyocyte or other 
inflammatory cells, therefore further dissecting cell specific 
roles in this disease setting such as pressure-overload or 
myocardial infarction.  These studies would be able to assess 
whether the cell specific loss of Nox2 similarly reduces cardiac 
fibrosis and hypertrophy or whether the effects were particular 
to the setting of AngII-induced LVH and fibrosis.  This would 
be important in determining the relevance of Nox2 in cardiac 
disease and in providing a better understanding.    
 Ideally the mechanism to explain how Nox2 modulates 
macrophage migration is required to achieve a better 
understanding of the process. This will require the analysis of 
downstream signalling molecules to investigate where Nox2 is 
influencing the signalling process. Also further Dunn chamber 
chemotaxis experiments will be important to assess the effect of 
Nox2 in the migration of the macrophages towards different 
chemoattractants.  
 TGFβ downstream of AngII stimulation is important for the 
development of cardiac fibrosis and hypertrophy. TGFβ 
demonstrated Nox2 dependent ROS production in fibroblasts. 
A more detailed investigation of the mechanism of action of 
TGFβ by way of Nox2 dependent ROS production in fibroblasts 
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and cardiomyocytes, and relating this to fibroblast proliferation 
and transformation to myofibroblasts, will help in determining 
the relevance of Nox2 and providing a better understanding of 
the process. 
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6.6 FINAL CONCLUSIONS 
In summary, the work undertaken in this thesis shows Nox2 in 
resident cardiac cells and in circulating peripheral inflammatory cells to have 
contrasting effects in AngII induced cardiac fibrosis and hypertrophy. The 
work showed Nox2 in macrophages to be important in their cellular 
migration, inflammatory phenotype and L-selectin expression, playing an 
important role in the development of cardiac hypertrophy. Whereas Nox2 in 
resident cardiac  cells was crucial for the development of cardiac fibrosis 
wherein Nox2 dependent TGFβ signalling in resident adult cardiac 
fibroblasts, at least in part, could be important. The findings demonstrate the 
widely varied effects of Nox2 modulation folllowing AngII stimulation in 
different cell types. It suggests to separate mechanisms for the development 
of cardiac fibrosis and hypertrophy and thus offers the potential for their 
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